<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001342.pub3" GROUP_ID="STROKE" ID="973299072211091355" MERGED_FROM="" MODIFIED="2013-01-14 10:43:00 +0000" MODIFIED_BY="Hazel Fraser" REVIEW_NO="00230001" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-01-14 10:43:00 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2012-01-31 20:43:59 +0000" MODIFIED_BY="[Empty name]">Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin</TITLE>
<CONTACT MODIFIED="2013-01-14 10:43:00 +0000" MODIFIED_BY="Hazel Fraser"><PERSON ID="5496" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ale</FIRST_NAME><LAST_NAME>Algra</LAST_NAME><POSITION>Professor of Clinical Epidemiology</POSITION><EMAIL_1>a.algra@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care/University Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 755 9350</PHONE_1><PHONE_2>+31 88 756 8206</PHONE_2><FAX_1>+31 88 755 5485</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-01-14 10:43:00 +0000" MODIFIED_BY="Hazel Fraser"><PERSON ID="16457" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Els</FIRST_NAME><MIDDLE_INITIALS>LLM</MIDDLE_INITIALS><LAST_NAME>De Schryver</LAST_NAME><EMAIL_1>e.d.schryver@rijnland.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Rijnland Ziekenhuis Leiderdorp</ORGANISATION><ADDRESS_1>Simon Smitweg 1</ADDRESS_1><CITY>Leiderdorp</CITY><ZIP>2353 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 71 5828282</PHONE_1><FAX_1>+31 71 5828573</FAX_1></ADDRESS></PERSON><PERSON ID="5496" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ale</FIRST_NAME><LAST_NAME>Algra</LAST_NAME><POSITION>Professor of Clinical Epidemiology</POSITION><EMAIL_1>a.algra@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care/University Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 755 9350</PHONE_1><PHONE_2>+31 88 756 8206</PHONE_2><FAX_1>+31 88 755 5485</FAX_1></ADDRESS></PERSON><PERSON ID="16494" ROLE="AUTHOR"><PREFIX>Prof Dr</PREFIX><FIRST_NAME>L Jaap</FIRST_NAME><LAST_NAME>Kappelle</LAST_NAME><EMAIL_1>l.kappelle@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2507975</PHONE_1><FAX_1>+31 30 2542100</FAX_1></ADDRESS></PERSON><PERSON ID="5646" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jan</FIRST_NAME><LAST_NAME>van Gijn</LAST_NAME><POSITION>Emeritus Professor of Neurology</POSITION><EMAIL_1>jan@vangijn.com</EMAIL_1><URL>-</URL><MOBILE_PHONE>-</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2507975</PHONE_1><FAX_1>+31 30 2542100</FAX_1></ADDRESS></PERSON><PERSON ID="5570" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter J</FIRST_NAME><LAST_NAME>Koudstaal</LAST_NAME><EMAIL_1>p.j.koudstaal@erasmusmc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Erasmus MC</ORGANISATION><ADDRESS_1>s Gravendijkwal 230</ADDRESS_1><CITY>Rotterdam</CITY><ZIP>3015 GD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-12-07 10:45:10 +0000" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="15" MONTH="9" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="9" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-14 10:41:01 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-14 10:41:01 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="14" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Minor amendment to the Abstract</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-12-07 10:48:23 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-12-07 10:48:20 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="1" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>We updated the search of the Cochrane Stroke Group Trials Register. We included three new studies (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>), bringing the total number of included studies to eight, involving 5762 participants. We have updated the text of the review throughout.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-12-07 10:48:23 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="1" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>The conclusions are now more clearly based.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-03-16 15:16:04 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="7" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Link to feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-03-16 15:16:47 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="4" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-16 15:18:26 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="21" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>The WARSS trial was published 15 November 2001. Data that could be extracted from the publication were incorporated in the review. A minor update in early 2005 revealed only one new ongoing study; the conclusions of the review did not change.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University Medical Center Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-13 13:02:33 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-05-28 14:19:47 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2012-01-31 20:45:02 +0000" MODIFIED_BY="Hazel Fraser">Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin</TITLE>
<SUMMARY_BODY MODIFIED="2012-05-28 14:19:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>People who have a stroke due to a blockage of an artery have a higher risk of having another possibly fatal stroke, or a heart attack. Treatment with antiplatelet drugs (like aspirin) definitely reduces this risk. Blood thinning treatment (anticoagulation by vitamin K antagonists) was believed to provide added protection. We reviewed eight trials involving 5762 participants that compared anticoagulants with antiplatelet agents for preventing recurrent stroke and found no benefit of low intensity anticoagulation over aspirin, and an increased risk of bleeding with high intensity anticoagulation.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-13 13:02:33 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-31 20:13:39 +0000" MODIFIED_BY="[Empty name]">
<P>People who have had a transient ischaemic attack (TIA) or non-disabling ischaemic stroke have an annual risk of major vascular events of between 4% and 11%. Aspirin reduces this risk by 20% at most. Secondary prevention trials after myocardial infarction indicate that treatment with vitamin K antagonists is associated with a risk reduction approximately twice that of treatment with antiplatelet therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-01-31 20:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy and safety of vitamin K antagonists and antiplatelet therapy in the secondary prevention of vascular events after cerebral ischaemia of presumed arterial origin.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-05-28 14:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Stroke Group Trials Register (last searched 15 September 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 3), MEDLINE (2008 to September 2011) and EMBASE (2008 to September 2011). In an effort to identify further relevant trials we searched ongoing trials registers and reference lists. We also contacted authors of published trials for further information and unpublished data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-01-31 20:35:41 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trials of oral anticoagulant therapy with vitamin K antagonists (warfarin, phenprocoumon or acenocoumarol) versus antiplatelet therapy for long-term secondary prevention after recent transient ischaemic attack or minor ischaemic stroke of presumed arterial origin.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-03-16 15:53:42 +0000" MODIFIED_BY="Hazel Fraser">
<P>Two review authors independently selected trials, assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-01-13 13:01:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>We included eight trials with a total of 5762 participants. The data showed that anticoagulants (in any intensity) are not more efficacious in the prevention of recurrent ischaemic stroke than antiplatelet therapy (medium intensity anticoagulation: relative risk (RR) 0.80, 95% confidence interval (CI) 0.56 to 1.14; high intensity anticoagulation: RR 1.02, 95% CI 0.49 to 2.13). </P>
<P>There is no evidence that treatment with low intensity anticoagulation gives a higher bleeding risk than treatment with antiplatelet agents: RR 1.27 (95% CI 0.79 to 2.03). However, it was clear that medium and high intensity anticoagulation with vitamin K antagonists, with an INR of 2.0 to 4.5, were not safe because they yielded a higher risk of major bleeding complications (medium intensity anticoagulation: RR 1.93, 95% CI 1.27 to 2.94; high intensity anticoagulation: RR 9.0, 95% CI 3.9 to 21).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-13 13:02:33 +0000" MODIFIED_BY="[Empty name]">
<P>For the secondary prevention of recurrent ischemic stroke after TIA or minor stroke of presumed arterial origin, there is sufficient evidence to conclude that vitamin K antagonists in any dose are not more efficacious than antiplatelet therapy and that medium and high intensity anticoagulation leads to a significant increase in major bleeding complications.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-05-28 14:23:28 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-05-28 14:20:17 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-03-31 12:53:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Patients who are entered in clinical trials after a transient ischaemic attack (TIA) or non-disabling ischaemic stroke have an annual risk of major vascular events (death from all vascular causes, non-fatal stroke, or non-fatal myocardial infarction) of between 4% and 11% (<LINK REF="REF-Algra-1996" TYPE="REFERENCE">Algra 1996</LINK>; <LINK REF="REF-APT-I-1994" TYPE="REFERENCE">APT I 1994</LINK>). The corresponding estimate for population-based studies is 9% per year (<LINK REF="REF-Warlow-1992" TYPE="REFERENCE">Warlow 1992</LINK>). </P>
</CONDITION>
<INTERVENTION MODIFIED="2012-05-28 14:20:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Secondary prevention trials after myocardial infarction indicate that treatment with vitamin K antagonists is associated with a risk reduction approximately twice that of treatment with aspirin or other antiplatelet drugs (<LINK REF="REF-Anand-1999" TYPE="REFERENCE">Anand 1999</LINK>; <LINK REF="REF-APT-I-1994" TYPE="REFERENCE">APT I 1994</LINK>; <LINK REF="REF-ASPECT-1994" TYPE="REFERENCE">ASPECT 1994</LINK>; <LINK REF="REF-EPSIM-1982" TYPE="REFERENCE">EPSIM 1982</LINK>; <LINK REF="REF-Sixty-Plus-1980" TYPE="REFERENCE">Sixty Plus 1980</LINK>; <LINK REF="REF-Smith-1990" TYPE="REFERENCE">Smith 1990</LINK>). Both treatment with aspirin and with vitamin K antagonists increases the risk of bleeding complications (<LINK REF="REF-Algra-1996" TYPE="REFERENCE">Algra 1996</LINK>; <LINK REF="REF-Hirsh-1991" TYPE="REFERENCE">Hirsh 1991</LINK>). Few data are available on the efficacy and safety of vitamin K antagonists in patients with cerebral ischaemia (<LINK REF="REF-Jonas-1988" TYPE="REFERENCE">Jonas 1988</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-05-28 14:20:11 +0100" MODIFIED_BY="Hazel Fraser">
<P>A Cochrane review on the efficacy of vitamin K antagonists compared with control found nine old trials, performed before 1980 and of poor methodological quality, and two newer trials conducted before 2000. The review concluded that there is no clear evidence of benefit from long-term anticoagulation, but that there is evidence of a significant bleeding hazard (<LINK REF="REF-Sandercock-2009" TYPE="REFERENCE">Sandercock 2009</LINK>). In patients with cerebral ischaemia and atrial fibrillation, however, vitamin K antagonists were found to be safe and significantly more effective than aspirin (<LINK REF="REF-EAFT-1993" TYPE="REFERENCE">EAFT 1993</LINK>; <LINK REF="REF-Koudstaal-1996" TYPE="REFERENCE">Koudstaal 1996</LINK>; <LINK REF="REF-Saxena-2004a" TYPE="REFERENCE">Saxena 2004a</LINK>; <LINK REF="REF-Saxena-2004b" TYPE="REFERENCE">Saxena 2004b</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-05-28 14:20:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>Aspirin, in a daily dose of 30 mg or more, offers only modest protection after cerebral ischaemia; it reduces the incidence of major vascular events by 20% at most (<LINK REF="REF-Algra-1996" TYPE="REFERENCE">Algra 1996</LINK>; <LINK REF="REF-Algra-1999" TYPE="REFERENCE">Algra 1999</LINK>; <LINK REF="REF-APT-I-1994" TYPE="REFERENCE">APT I 1994</LINK>). In direct comparisons no differences in efficacy were found between doses of 300 mg and 1200 mg (<LINK REF="REF-UK_x002d_TIA-Study-1991" TYPE="REFERENCE">UK-TIA Study 1991</LINK>) and 30 mg and 283 mg (<LINK REF="REF-Dutch-TIA-Trial-1991" TYPE="REFERENCE">Dutch TIA Trial 1991</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-01-31 20:29:04 +0000" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>To compare the efficacy of vitamin K antagonists and antiplatelet drugs in the secondary prevention of vascular events after cerebral ischaemia of presumed arterial origin.</LI>
<LI>To compare the safety of vitamin K antagonists and antiplatelet drugs in the secondary prevention of vascular events after cerebral ischaemia of presumed arterial origin.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2012-05-28 14:20:57 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-05-28 14:20:29 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-03-18 12:44:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trials with concealed treatment allocation examining long-term (more than six months) secondary prevention after recent (less than six months) cerebral ischaemia of presumed arterial origin.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-05-28 14:20:20 +0100" MODIFIED_BY="[Empty name]">
<P>Patients after cerebral ischaemia (TIA or minor ischaemic stroke) of presumed arterial origin, that is without demonstrable cardiac origin. The symptoms in TIAs or minor ischaemic strokes should develop within a few seconds, should not progress from one part of the body to another in an orderly march, and should last at least one minute (<LINK REF="REF-Dutch-TIA-Trial-1988" TYPE="REFERENCE">Dutch TIA Trial 1988</LINK>). We excluded acute (onset less than 48 hours ago) ischaemic events as well as those that occurred more than six months previously.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-05-28 14:20:26 +0100" MODIFIED_BY="Hazel Fraser">
<UL>
<LI>Vitamin K antagonists of specified intensity (by means of the International Normalised Ratio: INR) with warfarin, phenprocoumon or acenocoumarol.</LI>
<LI>A single antiplatelet drug in any dose or a combination of antiplatelet drugs.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-05-28 14:20:29 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="4">Efficacy outcome measures</HEADING>
<OL>
<LI>The composite event 'vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication' (primary outcome measure)</LI>
<LI>All-cause death</LI>
<LI>Vascular death</LI>
<LI>Vascular death or non-fatal stroke</LI>
<LI>Vascular death, non-fatal stroke or non-fatal myocardial infarction</LI>
<LI>Recurrent stroke (fatal or non-fatal; ischaemic or unknown pathologic type)</LI>
<LI>Recurrent ischaemic stroke or intracranial haemorrhage</LI>
<LI>Death or dependency at end of follow-up</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety outcome measures</HEADING>
<OL>
<LI>Major bleeding complication, i.e. any fatal or non-fatal intracranial or major extracranial haemorrhage</LI>
<LI>Fatal intracranial or extracranial haemorrhage</LI>
<LI>Intracranial haemorrhage, fatal or non-fatal</LI>
<LI>Major extracranial haemorrhage, according to the definition of the original investigator</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-05-17 16:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>See the 'Specialized register' section of the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module. We searched for trials in all languages and arranged translation of articles published in languages other than English.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-05-17 16:26:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Managing Editor on 15 September 2011. In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 3) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (2008 to September 2011) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and EMBASE (2008 to September 2011) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>The Cochrane Stroke Group Trials Search Co-ordinator devised the search strategies for the electronic databases and, to avoid duplication of effort, we limited the search of MEDLINE and EMBASE to 2008 onwards. We completed searches of these databases to January 2008 for all stroke trials and all relevant trials have been identified and are included in the Cochrane Stroke Group.</P>
<P>In an effort to identify further published, unpublished and ongoing trials we searched the following ongoing trials registers (last search 10 May 2012):</P>
<UL>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">http://www.clinicaltrials.gov/</A>);</LI>
<LI>EU Clinical Trials Register (<A HREF="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</A>);</LI>
<LI>Stroke Trials Registry (<A HREF="http://www.strokecenter.org/trials/">www.strokecenter.org/trials/</A>);</LI>
<LI>Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>);</LI>
<LI>WHO International Clinical Trials Registry Platform (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-03-28 16:04:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>We also:</P>
<UL>
<LI>searched the reference lists of relevant studies;</LI>
<LI>contacted the authors of published trials for further information and unpublished data;</LI>
<LI>used Science Citation Index Cited Reference Search for forward tracking of important articles.</LI>
</UL>
<P>We have had no explicit contact with manufacturers in the search for unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-05-28 14:20:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-03-28 15:51:27 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two review authors (AA, EDS) independently selected trials that met the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-05-28 14:20:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>The same two review authors extracted details of randomisation methods, blinding of treatments and assessments, whether intention-to-treat analysis was possible from the published data, whether treatment groups were comparable with regard to major prognostic risk factors for outcomes, the number of patients excluded or lost to follow-up, definitions of outcomes, and entry and exclusion criteria. The same two review authors assessed the methodological quality of each trial by using these extracted data. In addition, we recorded target INRs for anticoagulant treatment and the dose and type of antiplatelet treatment, duration of follow-up and the numbers of defined outcome events. The same two review authors independently extracted and cross-checked all data; they resolved discrepancies by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-03-28 16:34:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>We used the Cochrane tool for assessing risk of bias to assess the methodological quality of the included studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The tool covers the domains of sequence generation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessments. We classified items as 'low risk', 'high risk' or 'unclear risk' of bias. We resolved disagreements with help from a third review author.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-17 16:27:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>We used risk ratios to measure the effect.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-05-28 14:20:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>The outcome measure that occurred first was analysed from every individual randomised patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-03-28 15:55:32 +0100" MODIFIED_BY="Hazel Fraser">
<P>We contacted the authors of included trials for further information and unpublished data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-05-28 14:20:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>We used a fixed-effect model and assessed heterogeneity by means of the I<SUP>2 </SUP>statistic. We analysed post hoc subgroups between different levels of vitamin K antagonists. We chose the categories according to the anticoagulation levels used in the trials.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-04-11 08:01:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>None</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-03-28 15:56:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>We analysed the data according to the intention-to-treat principle.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-05-28 14:20:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>We planned the following subgroup analyses in advance: age (65 years of age or less versus over 65 years of age), sex, history of ischaemic heart disease and type of cerebral ischaemia (large vessel disease versus small vessel disease). We planned separate analyses on the comparison of vitamin K antagonists and aspirin only. A separate analysis also included studies in which patients with intracranial stenosis were analysed (because of a possible different pathophysiologic mechanism of stroke) and a separate analysis included concealed trials only. If outcome data on randomised patients were lacking, we planned both a best and worst case scenario: the best case scenario (with regards to treatment) assumed that none of the patients excluded from the analysis in the treatment group had the outcome of interest whilst all those excluded from the reference group did, and vice versa for the worst case analysis. We calculated risk ratios using the Cochrane Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We used a fixed-effect model and assessed heterogeneity by means of the I<SUP>2 </SUP>statistic. We analysed post hoc subgroups between different levels of vitamin K antagonists. We chose the categories according to anticoagulation levels used in the trials.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-05-17 16:32:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>None</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-05-28 14:22:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-05-28 14:21:46 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-05-28 14:21:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>We identified a total of 13 randomised controlled trials (RCTs). Six trials met all our inclusion criteria (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>; <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>). Because the number of selected trials was low, we decided to include two more RCTs which did not specify the intensity of vitamin K antagonists by means of the INR and did not specify the method of randomisation concealment (<LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK>; <LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>). We did not obtain this information from the study authors: we estimated the therapeutic INR range with the help of a conversion table which reflects the relationship between the thrombotest and INR (<LINK REF="REF-Van-den-Besselaar-1993" TYPE="REFERENCE">Van den Besselaar 1993</LINK>). This is not an exact estimation since there are differences between the thromboplastin reagents used (<LINK REF="REF-ICSH_x002f_ICTH-1985" TYPE="REFERENCE">ICSH/ICTH 1985</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-05-28 14:21:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>Of the eight included RCTs, which involved a total of 5762 patients, four were performed in Europe, three in North America and one in Europe, Australia and Asia. The mean age of the patients ranged from 60 to 68 years. All eight studies included patients with TIAs or an ischaemic stroke not fully recovered from within 24 hours. Two studies only selected patients with a proven intracranial major artery stenosis as well (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>). The baseline characteristics were comparable in all included studies. The treatments in the included trials were given in an open, non-blinded fashion except in <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK> and <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>, which were blinded.</P>
<P>One of the included studies did not distinguish between cerebral ischaemia caused by atherosclerosis or cardiac embolism, for example atrial fibrillation (<LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>). Two trials did not define exclusion of severe stroke (<LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK>; <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>). The mean duration of the follow-up varied from 12.4 months to 4.6 years. For one trial data were only available from an abstract; the abstract did not specify the duration of follow-up (<LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>). This information was not supplied after requesting it.</P>
<P>
<LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK> and <LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK> did not specify the outcome 'non-fatal myocardial infarction' and <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK> also did not specify 'vascular death' and whether bleeding complications were intra- or extracranial. We used the WHO stroke definition as a focal neurological deficit lasting for more than 24 hours. Therefore, we classified all outcome events described as reversible ischaemic neurological deficit (RIND) or TIA-incomplete recovery (TIA-IR) as 'ischaemic stroke'. Six trials gave a definition of a bleeding complication (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>), which included hospitalisation or a blood transfusion, or both. The definition was not clear in the other included studies and we tried to abstract the data on bleeding by interpretation of their descriptions. We could only analyse data on the outcome 'death or dependent at end of follow-up' in one trial (<LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>) because the authors of this review conducted that study.</P>
<P>One trial (<LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>) studied low intensity anticoagulation (INR 1.4 to 2.8) versus aspirin. However, the primary outcome event 'death from any cause or recurrent ischaemic stroke' did not fit in this meta-analysis. No further data on other vascular outcome events were published and we have not been able to obtain these data from the authors.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-05-17 16:38:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>We excluded five trials: three of these studies did not use concealed treatment allocation (<LINK REF="STD-Buren-1981" TYPE="STUDY">Buren 1981</LINK>; <LINK REF="STD-Eriksson-1985" TYPE="STUDY">Eriksson 1985</LINK>; <LINK REF="STD-Olsson-1981" TYPE="STUDY">Olsson 1981</LINK>) and in two trials the method of randomisation was not specified and we could not obtain this information (<LINK REF="STD-Norrving-1983" TYPE="STUDY">Norrving 1983</LINK>; <LINK REF="STD-Ortiz-Castellon-1992" TYPE="STUDY">Ortiz Castellon 1992</LINK>). Additionally, <LINK REF="STD-Norrving-1983" TYPE="STUDY">Norrving 1983</LINK> did not specify the intensity of anticoagulation and also did not clarify whether patients with stroke caused by cardiac emboli were excluded. The publication of <LINK REF="STD-Ortiz-Castellon-1992" TYPE="STUDY">Ortiz Castellon 1992</LINK> did not contain information about the duration of the treatment and the exact number of outcome events. We could not obtain this additional information.<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-05-28 14:22:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>In two trials the method of concealment of randomisation was not defined (<LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK>; <LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>); in the six other trials randomisation was concealed (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>). Two trials were blinded for treatment (<LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>) and four stated blinding of outcome assessment (<LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>).</P>
<P>In <LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK> two intensities of anticoagulation were used, which were assumed to be equivalent to each other: a thrombotest activity of 7% to 15% or Simplastin A test value of 10% to 25% which, however, are not the same. The reference they quoted describes a relationship between thrombotest activity 7% to 18% and Simplastin A 14% to 34% and 10% to 25% P&amp;P Human thromboplastin (<LINK REF="REF-Korsan_x002d_Bengtsen-1970" TYPE="REFERENCE">Korsan-Bengtsen 1970</LINK>).</P>
<P>Five trials specifically stated the number of lost patients and the possibility of an intention-to-treat analysis (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>); we do not have this information for one trial (<LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>). The other trials suggested that none of the patients were lost to follow-up, but there was no explicit statement about this nor about the possibility of intention-to-treat analysis. Moreover, the monitoring of compliance was not very strict if done at all.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-05-28 14:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>For the analyses we presumed that the published outcome events were based on intention-to-treat analysis if this was not stated specifically and that if no loss to follow-up was reported and no patients were lost. This assumption was based on the fact that the trials included that did not make any statements about this were relatively small trials with a short period of follow-up. The bias created by a wrong assumption will therefore not be of major influence. We present the results as risk ratios (RR) with 95% confidence intervals (CI), analysed with a fixed-effect model. We could not perform the planned subgroup analyses because we could not obtain enough data for adequate analyses. Since few participants were described as lost, we did not perform a worst or best case scenario analysis.</P>
<P>Because the <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK> trial showed that risk of bleeding complications increased sharply with the achieved INR, we decided to separate the trials with lower levels of anticoagulation intensity from those with a higher level. We chose the intensity groups pragmatically according to the levels used in the trials. We defined low intensity anticoagulation as a target INR of 1.4 to 2.8, medium intensity anticoagulation as INR 2.0 to 3.6 and high intensity anticoagulation as INR 3.0 to 4.5 INR. Hence we present the results for the three categories of trials separately.</P>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin K antagonists versus antiplatelet therapy (Analysis 1)</HEADING>
<P>The composite outcome 'vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication' was reported by two trials (<LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>). The risk of the outcome in the high intensity anticoagulation trial was more than two times higher in the anticoagulated patients than in those using aspirin (RR 2.30, 95% CI 1.58 to 3.35) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The excess was due to a higher bleeding frequency in the anticoagulated patients (see below).</P>
<P>The numbers of 'deaths from all causes' tended to be higher with the medium intensity anticoagulation trials (RR 1.33, 95% CI 0.94 to 1.88 for concealed trials plus trials with unknown concealment together) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In the low intensity trial the RR was 0.89 (95% CI 0.60 to 1.30). In the one high intensity anticoagulation trial more patients on anticoagulants died than on antiplatelet drugs (RR 2.38, 95% CI 1.31 to 4.32).</P>
<P>In all trials that analysed this outcome event the majority of patients died from a 'vascular cause of death', hence the relative risks for vascular death did not differ importantly from those for all deaths (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>For the combination of 'vascular death and stroke', there was no difference between medium intensity anticoagulation and antiplatelet therapy: RR of 0.93 (95% CI 0.71 to 1.22) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Among patients who received high intensity anticoagulation the risk of this outcome event was increased (RR 1.69, 95% CI 1.08 to 2.65).</P>
<P>Data on the outcome criterion 'vascular death, non-fatal stroke or non-fatal myocardial infarction' were available only for two trials (<LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>) for anticoagulation versus antiplatelet therapy: the RR was 0.85 (95% CI 0.65 to 1.12) in the medium intensity group and RR of 1.70 (95% CI 1.12 to 2.59) in the high intensity group (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>For the outcome 'recurrent stroke' (fatal or non-fatal; ischaemic or unknown pathologic type, that is excluding haemorrhage confirmed by autopsy or imaging) there was no evidence of a difference between the different treatments. This observation was regardless of the intensity of anticoagulation. The RR of all trials together was 0.84 (95% CI 0.61 to 1.15) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>For 'recurrent ischaemic stroke or intracranial haemorrhage' there was no important difference in the medium intensity anticoagulation trials: RR of 0.91 (95% CI 0.66 to 1.29) for the concealed plus unconcealed trials together. Treatment with anticoagulation INR 3.0 to 4.5 resulted in a higher risk of bleeding complications than with antiplatelet therapy: RR of 2.04 (CI 1.21 to 3.46) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
<P>In <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK> the RR of anticoagulation versus antiplatelet therapy for the outcome event of 'death or dependency at the end of follow-up' was 2.30 (95% CI 1.37 to 3.85) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>The RR of a 'major bleeding complication', that is any fatal or non-fatal intracranial or major extracranial haemorrhage, during treatment with low intensity anticoagulation was 1.27 (95% CI 0.79 to 2.03) and with anticoagulation INR 2.0 to 3.6 the RR was 1.93 (CI 1.27 to 2.94) as compared with antiplatelet therapy. High intensity anticoagulation increased the risk of major bleeding complications importantly compared with antiplatelet therapy: RR of 9.02 (95% CI 3.91 to 20.8) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>A large proportion of the 'intracranial haemorrhages' were fatal. The confidence interval for both fatal and intracranial bleeding was wide in the low anticoagulation trial, with a point estimate RR of 1.40; and also in the medium anticoagulation comparison, with a point estimate RR of 2.18. For anticoagulation with INR 3.0 to 4.5 the RR of a fatal haemorrhage was 17.4 (95% CI 2.32 to 130) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>) and the RR of an intracranial haemorrhage was 9.2 (95% CI 2.80 to 30.2) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
<P>For the outcome 'major extracranial haemorrhage', according to the definition of the original investigator, there was an RR of 2.77 (95% CI 1.55 to 4.96) in the medium intensity anticoagulation group and an RR of 8.85 (95% CI 2.69 to 29.1) in the high intensity anticoagulation group (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials) (Analysis 2)</HEADING>
<P>Analyses with only the concealed trials did not show major differences compared with the analyses of all trials (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin K antagonists versus aspirin only (Analysis 3)</HEADING>
<P>The analyses of studies comparing anticoagulation versus aspirin alone (<LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>; <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>) gave similar results as those of anticoagulation versus any antiplatelet therapy (aspirin combined with dipyridamole in one trial (<LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>) was omitted for this analysis) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>; <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>; <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>).</P>
<P>The additive effect of dipyridamole to aspirin has been analysed in another Cochrane review (<LINK REF="REF-De-Schryver-2007" TYPE="REFERENCE">De Schryver 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin K antagonists versus aspirin, including intracranial artery stenosis (Analysis 4)</HEADING>
<P>Two trials included patients with a TIA or minor ischaemic stroke and a major cerebral artery stenosis of 50% to 99%: <LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK> studied stenosis of the middle cerebral artery only whereas <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK> studied stenosis of any major intracranial artery. The addition of results of these analyses did not lead to substantially different results from the original ones without the two trials, except for the outcome events:</P>
<UL>
<LI>all deaths, in the medium intensity anticoagulation group there now was significantly more deaths, RR of 1.47 (95% CI 1.08 to 2.00) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>);</LI>
<LI>fatal intracranial or extracranial haemorrhage reached statistical significance now to the disadvantage of the medium intensity anticoagulation group, RR of 2.64 (95% CI 1.04 to 6.70) (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>).</LI>
</UL>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-05-28 14:23:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-05-28 14:23:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>There are two main issues that influence the interpretation of this review, the level of anticoagulation used and the quality of the trials.</P>
<SUBSECTION>
<HEADING LEVEL="2">Level of anticoagulation</HEADING>
<P>From <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK> it emerged that there was a strong relationship between the intensity of anticoagulation and bleeding risk (<LINK REF="REF-Gorter-1999" TYPE="REFERENCE">Gorter 1999</LINK>). Thus we decided to present the results of this review according to the level of anticoagulation: low intensity (INR 1.4 to 2.8), medium intensity (INR 2.0 to 3.6) and high intensity (INR 3.0 to 4.5). Analysis of all trials together was not useful since there is only one large trial (<LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>) in the high intensity anticoagulation subgroup, with many bleeding complications, outweighing all other smaller trials in the medium anticoagulation group. Because of the high bleeding risk with high intensity anticoagulation, all composite outcome events containing bleeding complications were all to the disadvantage of anticoagulation in <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>. A large proportion of the vascular deaths was also due to bleeding complications in the high intensity anticoagulation group. The intensity of anticoagulation was specified by means of the INR in six trials (<LINK REF="STD-AVASIS-2006" TYPE="STUDY">AVASIS 2006</LINK>; <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>; <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>; <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>; <LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>). To include more studies in this review we estimated the INR level for two other studies, but this is not an exact approach (<LINK REF="REF-ICSH_x002f_ICTH-1985" TYPE="REFERENCE">ICSH/ICTH 1985</LINK>). One trial (<LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK>) provided a confusing description of the level of anticoagulation by reporting two different intensity levels (see <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>). The method of monitoring treatment was also poorly reported.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Efficacy of vitamin K antagonists compared with antiplatelet treatment</HEADING>
<P>For the outcome events without bleeding complications (that is the ischaemic events) after TIA or minor stroke of presumed arterial origin in the secondary prevention of further vascular events, there were enough data to conclude that oral anticoagulation with vitamin K antagonists in low and medium intensities is not superior to antiplatelet therapy in patients without cardiac emboli.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Safety of vitamin K antagonists compared with antiplatelet treatment</HEADING>
<P>It is clear that high intensity vitamin K antagonists (INR 3.0 to 4.5) are not safe, because they yield a significantly higher risk of major bleeding complications. Treatment at low intensity (INR 1.4 to 2.8) was not associated with a clearly higher risk of bleeding than treatment with antiplatelet therapy. The WARSS trial evaluated low intensity anticoagulation (INR 1.4 to 2.8; median achieved INR 1.9) compared with aspirin. For the combined outcome of death or recurrent ischaemic stroke the hazard ratio was 1.13 (95% CI 0.92 to 1.38) (<LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>). In the same trial, the hazard ratio for major bleeding complication was 1.27 (95% CI 0.79 to 2.03). These results are consistent with the hypothesis that low intensity warfarin is likely to be of comparable safety to aspirin. At present there are no direct randomised comparisons of one intensity of vitamin K antagonists versus another. However, an observational study in Leiden, on the use of vitamin K antagonists among 356 patients observed for a total of 644 patient years, suggested that the risk of ischaemic and haemorrhagic events was lowest in this type of patient when the INR was in the range 2.5 to 3.5, with a nadir of the event rate at INR 3.0 (<LINK REF="REF-Torn-2001" TYPE="REFERENCE">Torn 2001</LINK>). This review is now updated with two randomised trials that investigated medium intensity anticoagulation (INR 2.0 to 3.6); there is no evidence that vitamin K antagonists are superior to antiplatelet therapy in preventing ischaemic events, but there is a clear increase in risk for bleeding complications.</P>
<P>Note: the WARSS trial (<LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>) is the largest trial in this review and has published tabulated numbers of outcome events by allocated treatment for death, major haemorrhages and for the combined outcomes of recurrent ischaemic stroke or death recurrent ischaemic stroke or death or major haemorrhage. The trialists have not yet published tabulations of the number of patients for the first occurrence of each individual event by allocated treatment in a way that would permit the inclusion of that outcome data in this review. Furthermore, the trialists have not provided these data to us. When such data are publicly available, we will update the review to include them.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-05-28 14:23:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>The number of patients lost to follow-up or with missing data in the included studies is very low and therefore we conclude that there is a good applicability of evidence.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-05-28 14:23:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>There were important methodological differences between the included studies. The method of concealment was not known in two trials (<LINK REF="STD-Garde-1983" TYPE="STUDY">Garde 1983</LINK>; <LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>). Analysis without these trials did not show any differences in outcome, and the number of concealed trials was low. We assumed that the authors of the trials listed analysed their data according to the intention-to-treat principle, but we were not sure about it as we did not know whether any patients were lost to follow-up. For this reason we were not able to perform worst and best case scenario analyses. CT scans of the brain were not required in some trials (<LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>; <LINK REF="STD-SWAT-1998" TYPE="STUDY">SWAT 1998</LINK>). Exclusion of atrial fibrillation as the cause of stroke was not specified in one trial (<LINK REF="STD-Olsson-1980" TYPE="STUDY">Olsson 1980</LINK>). Patients with cerebral ischaemia and atrial fibrillation have a different risk profile; for these patients evidence is available that anticoagulation is the first choice in secondary prevention (<LINK REF="REF-EAFT-1993" TYPE="REFERENCE">EAFT 1993</LINK>). Only two trials were double-blind studies (<LINK REF="STD-WARSS-2001" TYPE="STUDY">WARSS 2001</LINK>; <LINK REF="STD-WASID-2005" TYPE="STUDY">WASID 2005</LINK>); the open treatment studies could potentially give a bias, but on the other hand open treatment approaches reflect 'real life' more accurately. Moreover, in the largest two open studies outcome assessment was blind. Finally, the definition of bleeding complications was not always clear and differed between the trials. We had to rely on our own interpretation of a major bleeding complication in some cases. The data were dominated by the <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK> trial, which had a low risk of bias. The overall inclusion or exclusion of the other trials did not materially alter the conclusion of the review.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-05-18 13:08:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Since two review authors extracted the data independently and cross-checked the results, the risk of potential bias is low. The authors consider it unlikely that they have missed important trials in their search for data, because of the extensive literature searches and the fact that they have been working in this field for over 20 years.<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-04-11 08:02:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>There are no major differences between the included studies and other reviews.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-05-28 14:23:28 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-01-31 20:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>There is no evidence to support the routine use of vitamin K antagonists in any dose in the prevention of further vascular events after transient ischaemic attack or stroke of presumed arterial origin.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-05-28 14:23:28 +0100" MODIFIED_BY="[Empty name]">
<P>Further trials of vitamin K antagonist versus aspirin after transient ischaemic attack or minor stroke of presumed arterial origin are difficult to justify. Given the non-inferiority of new direct thrombin and factor Xa inhibitors as compared with vitamin K antagonists in patients with atrial fibrillation, and their tendency to result in fewer major haemorrhages, it is conceivable that trials with these new agents will be designed for patients with cerebral ischaemia of arterial origin</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-05-28 14:23:32 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Hazel Fraser for providing us with a list of relevant trials from the Cochrane Stroke Group Trials Register; Brenda Thomas for developing comprehensive search strategies in EMBASE, MEDLINE and CENTRAL; and Dr AMHP van den Besselaar for his help in determining the anticoagulation levels in terms of INRs.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-05-28 14:23:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>The authors were all members of the Executive Committee of <LINK REF="STD-ESPRIT-2007" TYPE="STUDY">ESPRIT 2007</LINK>, the European/Australian Stroke Prevention in Reversible Ischaemia Trial. All authors, except Els de Schryver, were members of the Executive Committee of <LINK REF="STD-SPIRIT-1997" TYPE="STUDY">SPIRIT 1997</LINK>, the Stroke Prevention in Reversible Ischaemia Trial.</P>
<P>Ale Algra is employed by the University Medical Center Utrecht. He has received several grants for cerebrovascular research from granting bodies such as the Netherlands Heart Foundation, Nederlandse HersenStichting, TromboseStichting Nederland, Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO, Netherlands Organisation for Scientific Research) and Nederlandse Organisatie voor Gezondheidsonderzoek en Zorginnovatie (ZonMW, Netherlands Organisation for Health Research and Development). In the last five years he has received speaker fees and travel expenses from Boehringer Ingelheim and Sanofi. He is one of the principal investigators of ESPRIT, the European/Australian Stroke Prevention in Reversible Ischaemia Trial, a trial that was run independently of any pharmaceutical company. After completion and full analysis of ESPRIT, the study group accepted financial support from Boehringer Ingelheim for post hoc exploratory analyses of the ESPRIT trial data in 2006. For this purpose a contract was signed in which we negotiated complete scientific freedom.</P>
<P>Jaap Kappelle has, in the past five years, received speaker and consulting honoraria from Boehringer Ingelheim and Bayer.</P>
<P>Jan van Gijn was principal investigator (with Ale Algra) of the SPIRIT Study (anticoagulants versus aspirin) - no commercial interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-05-28 14:23:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>Dr De Schryver and Professor Algra performed the collection of data: the screening of retrieved papers against inclusion criteria, the assessment of quality of the research, and the abstraction of the data.<BR/>Professor Algra is the guarantor of this review, and designed the review with the help of Professor van Gijn, Professor Kappelle and Professor Koudstaal.<BR/>Dr De Schryver and Professor Algra wrote to authors of the papers for additional information and unpublished data.<BR/>All authors performed the interpretation of the data.<BR/>Dr De Schryver was responsible for data management and entering the data into RevMan.<BR/>Dr De Schryver and Professor Algra analysed the data.<BR/>Professor Algra was responsible for the methodological perspective and, together with Professor van Gijn, Professor Kappelle and Professor Koudstaal, for the clinical, policy and consumer implications.<BR/>Dr De Schryver and Professor Algra wrote the review.<BR/>Professor van Gijn, Professor Kappelle and Professor Koudstaal provided general advice on the review.<BR/>Professor Algra, Professor van Gijn, Professor Kappelle and Professor Koudstaal had performed previous work which was the foundation of the current study.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-03-29 11:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-05-18 12:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>None</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-05-28 14:24:25 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2012-05-18 13:03:17 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2012-05-12 17:34:05 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-AVASIS-2006" MODIFIED="2012-03-29 11:56:33 +0100" MODIFIED_BY="Hazel Fraser" NAME="AVASIS 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-13 16:17:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marti-Fabregas J</AU>
<TI>Aspirin versus anticoagulants in symptomatic intracranial stenosis (AVASIS)</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>6</NO>
<PG>1450</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-29 11:56:33 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marti-Fabregas J; for the Stroke Project CVD Group of the Spanish Neurological Society</AU>
<TI>Aspirin or anticoagulants in stenosis of the middle cerebral artery: a randomized trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2006</YR>
<VL>22</VL>
<PG>162-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-18 11:13:08 +0000" MODIFIED_BY="Hazel Fraser"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESPRIT-2007" MODIFIED="2011-03-18 11:13:58 +0000" MODIFIED_BY="Hazel Fraser" NAME="ESPRIT 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-18 11:13:58 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The ESPRIT Study Group</AU>
<TI>Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<PG>115-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garde-1983" MODIFIED="2011-03-18 11:14:09 +0000" MODIFIED_BY="Hazel Fraser" NAME="Garde 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-03-18 11:14:09 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne L-G, stman J</AU>
<TI>Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation</TI>
<SO>Stroke</SO>
<YR>1983</YR>
<VL>14</VL>
<NO>5</NO>
<PG>677-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsson-1980" MODIFIED="2011-03-18 12:46:36 +0000" MODIFIED_BY="Hazel Fraser" NAME="Olsson 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-03-18 11:14:33 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brechter C, Bcklund H, Krook H, Mller R, Nitelius E, Olsson JE, et al</AU>
<TI>Comparison between anticoagulant treatment and anti-platelet therapy in order to prevent cerebral infarction in patients with TIA/RIND</TI>
<TO>Trombocytehmmande behandling eller antikoagulantia som profylax vid TIA/RIND</TO>
<SO>Lkartidningen</SO>
<YR>1980</YR>
<VL>77</VL>
<NO>52</NO>
<PG>4947-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-18 12:46:36 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olsson JE, Brechter C, Bcklund H, Krook H, Mller R, Nitelius E, et al</AU>
<TI>Anticoagulant versus anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks</TI>
<SO>Stroke</SO>
<YR>1980</YR>
<VL>11</VL>
<NO>1</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-SPIRIT-1997" MODIFIED="2011-03-18 11:15:03 +0000" MODIFIED_BY="Hazel Fraser" NAME="SPIRIT 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-03-18 11:15:03 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) study group</AU>
<TI>A randomised trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>6</NO>
<PG>857-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SWAT-1998" MODIFIED="2011-03-18 11:15:12 +0000" MODIFIED_BY="Hazel Fraser" NAME="SWAT 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-03-18 11:15:12 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart B, Shuaib A, Veloso F</AU>
<TI>Stroke Prevention with Warfarin or Aspirin Trial (SWAT)</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WARSS-2001" MODIFIED="2011-03-18 11:15:58 +0000" MODIFIED_BY="Hazel Fraser" NAME="WARSS 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-03-18 11:15:34 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mohr JP, for the WARSS Group</AU>
<TI>A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>1444-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-18 11:15:48 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohr JP, for the WARSS Group</AU>
<TI>Design considerations for the Warfarin-Antiplatelet Recurrent Stroke Study</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>156-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-18 11:15:58 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The WARSS, APASS, PICSS, HAS and GENESIS Study Groups</AU>
<TI>The feasibility of a collaborative double-blind study using an anticoagulant</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>100-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WASID-2005" MODIFIED="2012-03-29 11:57:55 +0100" MODIFIED_BY="Hazel Fraser" NAME="WASID 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-03-29 11:57:55 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chimowitz MI; for the WASID Trial investigators</AU>
<TI>Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<PG>1305-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-05-18 13:03:17 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-ARCH-2012" MODIFIED="2012-05-14 13:38:35 +0100" MODIFIED_BY="[Empty name]" NAME="ARCH 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-05-14 13:38:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Amarenco P</AU>
<TI>Prevention of new vascular events in patients with brain infarction or periferal embolism and thoracic aortic plaques &gt;= 4 mm in thickness in the aortic arch or descending aortic upstream to the embolized artery</TI>
<SO>ClinicalTrials.gov - ongoing trials</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buren-1981" MODIFIED="2011-03-18 11:16:46 +0000" MODIFIED_BY="Hazel Fraser" NAME="Buren 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-03-18 11:16:46 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buren A, Ygge J</AU>
<TI>Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack</TI>
<SO>Stroke</SO>
<YR>1981</YR>
<VL>12</VL>
<NO>5</NO>
<PG>578-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-1985" MODIFIED="2011-03-18 11:17:04 +0000" MODIFIED_BY="Hazel Fraser" NAME="Eriksson 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-03-18 11:17:04 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson SE</AU>
<TI>Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1985</YR>
<VL>71</VL>
<PG>485-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norrving-1983" MODIFIED="2012-03-29 11:58:24 +0100" MODIFIED_BY="Hazel Fraser" NAME="Norrving 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-03-29 11:58:24 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norrving B, Olsson JE, Nilsson B</AU>
<TI>Prophylactic treatment in patients with transient cerebral ischemia: anticoagulant versus antiplatelet drugs</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1983</YR>
<VL>50 Suppl 1</VL>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Olsson-1981" MODIFIED="2012-05-18 13:03:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="Olsson 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-05-18 13:03:17 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Olsson JE</AU>
<TI>Preliminary report from the ongoing comparison of the efficacy of anticoagulants and platelet inhibitors as prophylaxis of cerebral infarction in patients who have had TIA or RIND</TI>
<SO>rebro Regional Hospital, Lund, Sweden</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortiz-Castellon-1992" MODIFIED="2011-03-18 11:26:34 +0000" MODIFIED_BY="Hazel Fraser" NAME="Ortiz Castellon 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-03-18 11:26:34 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz Castellon N, Marti-Vilalta JLI, Marti J, Avila A</AU>
<TI>Treatment of patients with transient ischaemic attacks</TI>
<TO>Tratamiento de pacientes con accidente isqumico transitorio</TO>
<SO>Neurologia</SO>
<YR>1992</YR>
<VL>2</VL>
<NO>6</NO>
<PG>159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-06-13 16:17:46 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-05-28 14:24:25 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2012-05-28 14:24:25 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Algra-1996" MODIFIED="2011-03-18 11:26:59 +0000" MODIFIED_BY="Hazel Fraser" NAME="Algra 1996" TYPE="JOURNAL_ARTICLE">
<AU>Algra A, van Gijn J</AU>
<TI>Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1996</YR>
<VL>60</VL>
<PG>197-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Algra-1999" MODIFIED="2012-05-28 14:24:25 +0100" MODIFIED_BY="Hazel Fraser" NAME="Algra 1999" TYPE="JOURNAL_ARTICLE">
<AU>Algra A, van Gijn J</AU>
<TI>Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin (letter)</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1999</YR>
<VL>66</VL>
<PG>225</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anand-1999" MODIFIED="2012-05-28 14:24:25 +0100" MODIFIED_BY="[Empty name]" NAME="Anand 1999" TYPE="JOURNAL_ARTICLE">
<AU>Anand SS, Yusuf SY</AU>
<TI>Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>2058-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APT-I-1994" MODIFIED="2011-03-18 11:27:26 +0000" MODIFIED_BY="Hazel Fraser" NAME="APT I 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>81-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ASPECT-1994" MODIFIED="2011-03-18 12:47:27 +0000" MODIFIED_BY="Hazel Fraser" NAME="ASPECT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group</AU>
<TI>Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>499-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Schryver-2007" MODIFIED="2012-05-18 13:04:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="De Schryver 2007" TYPE="COCHRANE_REVIEW">
<AU>De Schryver ELLM, Algra A, Van Gijn J</AU>
<TI>Dipyridamole for preventing stroke and other vascular events in patients with vascular disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-03-28 16:19:45 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2012-03-28 16:19:45 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD001820.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dutch-TIA-Trial-1988" MODIFIED="2011-03-18 11:28:01 +0000" MODIFIED_BY="Hazel Fraser" NAME="Dutch TIA Trial 1988" TYPE="JOURNAL_ARTICLE">
<AU>The Dutch TIA Study Group</AU>
<TI>The Dutch TIA Trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<PG>512-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dutch-TIA-Trial-1991" MODIFIED="2012-05-18 13:04:44 +0100" MODIFIED_BY="Hazel Fraser" NAME="Dutch TIA Trial 1991" TYPE="JOURNAL_ARTICLE">
<AU>The Dutch TIA Trial Study Group</AU>
<TI>A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>1261-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EAFT-1993" NAME="EAFT 1993" TYPE="JOURNAL_ARTICLE">
<AU>EAFT (European Atrial Fibrillation Trial) Study Group</AU>
<TI>Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<PG>1255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPSIM-1982" MODIFIED="2011-03-18 11:28:38 +0000" MODIFIED_BY="Hazel Fraser" NAME="EPSIM 1982" TYPE="JOURNAL_ARTICLE">
<AU>The EPSIM Research Group</AU>
<TI>A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<PG>701-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gorter-1999" MODIFIED="2012-05-18 13:05:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gorter 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gorter JW, for the Stroke Prevention in reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) Study Groups</AU>
<TI>Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>6</NO>
<PG>1319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-28 14:24:25 +0100" MODIFIED_BY="Hazel Fraser" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-1991" MODIFIED="2011-03-18 11:29:04 +0000" MODIFIED_BY="Hazel Fraser" NAME="Hirsh 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J</AU>
<TI>Oral anticoagulant drugs</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>1865-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSH_x002f_ICTH-1985" MODIFIED="2011-03-18 11:29:21 +0000" MODIFIED_BY="Hazel Fraser" NAME="ICSH/ICTH 1985" TYPE="JOURNAL_ARTICLE">
<AU>International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis</AU>
<TI>ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1985</YR>
<VL>53</VL>
<PG>155-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jonas-1988" NAME="Jonas 1988" TYPE="JOURNAL_ARTICLE">
<AU>Jonas S</AU>
<TI>Anticoagulant therapy in cerebrovascular disease: review and meta-analysis</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<PG>1043-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korsan_x002d_Bengtsen-1970" MODIFIED="2011-03-18 11:30:40 +0000" MODIFIED_BY="Hazel Fraser" NAME="Korsan-Bengtsen 1970" TYPE="JOURNAL_ARTICLE">
<AU>Korsan-Bengtsen K</AU>
<TI>Comparison between various methods used to control dicumarol therapy</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1970</YR>
<VL>188</VL>
<PG>327-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koudstaal-1996" MODIFIED="2012-03-28 16:20:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Koudstaal 1996" TYPE="COCHRANE_REVIEW">
<AU>Koudstaal P</AU>
<TI>Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1996</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-03-28 16:20:18 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2012-03-28 16:20:18 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000186.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-03-28 16:22:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-2009" MODIFIED="2012-03-28 16:20:46 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sandercock 2009" TYPE="COCHRANE_REVIEW">
<AU>Sandercock PAG, Gibson LM, Liu M</AU>
<TI>Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-03-28 16:20:46 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2012-03-28 16:20:46 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000248.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saxena-2004a" MODIFIED="2012-03-28 16:20:06 +0100" MODIFIED_BY="Hazel Fraser" NAME="Saxena 2004a" TYPE="COCHRANE_REVIEW">
<AU>Saxena R, Koudstaal PJ</AU>
<TI>Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-03-28 16:20:06 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2012-03-28 16:20:06 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000185.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saxena-2004b" MODIFIED="2012-03-28 16:20:30 +0100" MODIFIED_BY="Hazel Fraser" NAME="Saxena 2004b" TYPE="COCHRANE_REVIEW">
<AU>Saxena R, Koudstaal PJ</AU>
<TI>Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-03-28 16:20:30 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2012-03-28 16:20:30 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000187.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sixty-Plus-1980" NAME="Sixty Plus 1980" TYPE="JOURNAL_ARTICLE">
<AU>The Sixty Plus Reinfarction Study Research Group</AU>
<TI>A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>ii</VL>
<PG>989-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1990" MODIFIED="2011-03-18 12:12:14 +0000" MODIFIED_BY="Hazel Fraser" NAME="Smith 1990" TYPE="JOURNAL_ARTICLE">
<AU>Smith P, Arnesen H, Holme I</AU>
<TI>The effect of warfarin on mortality and reinfarction after myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>323</VL>
<PG>147-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torn-2001" MODIFIED="2011-03-18 12:12:24 +0000" MODIFIED_BY="Hazel Fraser" NAME="Torn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Torn M, Algra A, Rosendaal FR</AU>
<TI>Oral anticoagulation for cerebral ischemia of arterial origin. High initial bleeding risk</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<PG>1993-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UK_x002d_TIA-Study-1991" MODIFIED="2012-05-18 13:06:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="UK-TIA Study 1991" TYPE="JOURNAL_ARTICLE">
<AU>UK-TIA Study Group</AU>
<TI>The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1991</YR>
<VL>54</VL>
<PG>1044-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Besselaar-1993" MODIFIED="2012-05-18 13:04:15 +0100" MODIFIED_BY="Hazel Fraser" NAME="Van den Besselaar 1993" TYPE="JOURNAL_ARTICLE">
<AU>Van den Besselaar AMPH, Yli-Myry S, Huikuri HV</AU>
<TI>Control of oral anticoagulant therapy</TI>
<SO>European Heart Journal</SO>
<YR>1993</YR>
<VL>14</VL>
<PG>723-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warlow-1992" NAME="Warlow 1992" TYPE="JOURNAL_ARTICLE">
<AU>Warlow C</AU>
<TI>Secondary prevention of stroke</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>724-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-05-28 14:23:45 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-05-28 14:23:45 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-05-28 14:23:40 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-AVASIS-2006">
<CHAR_METHODS MODIFIED="2011-03-18 12:45:25 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment: computer randomised<BR/>Blinding: open label, outcome assessment not described<BR/>Results available for all patients.<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-17 16:39:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Spain<BR/>28 patients<BR/>Mean age 67 years<BR/>68% male<BR/>Patients with TIA or mild stroke in the MCA territory presenting within 90 days, who either have no history of cerebral ischaemia, a history of ischaemia exclusively in the region of the qualifying event, or a history of cerebral ischaemia in any region with indeterminate aetiology, who were angiographically diagnosed with 50% to 99% MCA stenosis within 7 days of the qualifying event, who have 50% or less stenosis of the ipsilateral extracranial or intracranial internal carotid artery, and who have a modified Rankin scale score of 3 or less<BR/>Conventional angiography or TCD + MRA/TCD + CTA in all patients<BR/>Time since stroke: mean 24.3 days<BR/>Comparability of groups: no major differences for prognostic variables</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:59:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: coumarin (INR 2.0 to 3.0)<BR/>Monitoring: according to centre, monthly or shorter<BR/>Compliance: stopped in 3 patients, from monthly values 67% within target range<BR/>Control: aspirin 300 mg daily<BR/>Monitoring: with compliance form<BR/>Compliance: stopped in 0 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-28 14:23:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Vascular death, non-fatal ischaemic stroke, non-fatal myocardial infarction, major bleeding complication, all deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:58:48 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: other arterial cause of stroke, (contra) indication for study medication, difficult monitoring<BR/>Follow-up: mean 23.1 months<BR/>Trial stopped early (recruitment too slow, aim was 300 patients)<BR/>No patients were lost</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 12:45:29 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-ESPRIT-2007">
<CHAR_METHODS MODIFIED="2011-03-18 12:45:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment by telephone, computer randomised<BR/>Blinding: outcome assessment only<BR/>Results available for 96.9%<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-17 16:41:06 +0000" MODIFIED_BY="Hazel Fraser">
<P>Europe, Australia, Asia<BR/>1089 patients<BR/>Mean age 61 years<BR/>67% male<BR/>Cerebral ischaemia of non-cardiac origin or transient monocular blindness<BR/>CT in all but 72 (93.3%)<BR/>Time since stroke: less than 6 months<BR/>Comparability of groups: no major differences for prognostic variables</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 11:00:20 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: phenprocoumon or acenocoumarol or warfarin (INR 2.0 to 3.0)<BR/>Monitoring: on regular basis check of INR level<BR/>Compliance: specified in table, stopped in 198 patients (37%), 70% of time within target range<BR/>Control: aspirin 30 mg (57%), 75 mg (15%), 80 mg (6%), 100 mg (12%), 150 mg (3%), 200 mg (6%)<BR/>Monitoring: no monitoring<BR/>Compliance: stopped in 84 (15%)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-17 16:41:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>Vacular death, non-fatal stroke, non-fatal myocardial infarction, major bleeding complication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:58:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: Rankin grade &gt; 3, (contra) indication for study medication<BR/>Follow-up: mean 4.6 years<BR/>Trial stopped early (after 55% of planned patients years) because of new standard therapy of aspirin plus dipyridamole<BR/>34 patients were lost, 7 had incomplete follow-up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-28 14:23:43 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Garde-1983">
<CHAR_METHODS MODIFIED="2012-03-29 11:40:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment: unknown<BR/>Blinding: none<BR/>Results available for all patients randomised: unknown<BR/>Intention-to-treat not defined</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-28 14:23:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Sweden<BR/>241 patients<BR/>Mean age 60.0 years<BR/>64% male<BR/>Carotid symptoms or homonymous hemianopia (104 TIA)<BR/>Time from stroke &lt; 14 days<BR/>LP and CT or radionuclide scan in all<BR/>Comparability of groups: age and history similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:57:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: warfarin (thrombotest 7% to 15%)<BR/>Monitoring: not defined<BR/>Compliance: 77.4% within values, stopped in 12 patients<BR/>Control: acetylsalicylic acid (1000 mg/day)<BR/>Monitoring: 5 hours after intake of acetylsalicylic acid<BR/>Compliance: 97%, stopped in 21 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:55:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ischaemic stroke, TIA, vascular death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:58:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: atrial fibrillation, carotid endarterectomy<BR/>Follow-up: mean 20.5 months in treated group versus 19.6 months in control group<BR/>No lost patients described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-29 11:40:28 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Olsson-1980">
<CHAR_METHODS MODIFIED="2012-03-29 11:40:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment: unknown<BR/>Blinding: none<BR/>Results available for all patients randomised: unknown<BR/>Intention-to-treat analysis specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 12:45:38 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sweden<BR/>135 patients<BR/>Mean age 66 years<BR/>69% male<BR/>TIA or RIND<BR/>Time since TIA/RIND: &lt; 2 to 3 months (all patients + 21 excluded, started with 2 months anticoagulant treatment)<BR/>LP in all<BR/>Comparability of groups: age and history similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 11:01:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: coumadin (thrombotest 7% to 15%)<BR/>Monitoring: not specified<BR/>Compliance: stopped in 17 patients<BR/>Control: acetylsalicylic acid (1000 mg/day) + dipyridamole (150 mg/day)<BR/>Monitoring: regularly (not defined)<BR/>Complicance: stopped in 17 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:57:58 +0000" MODIFIED_BY="Hazel Fraser">
<P>TIA/RIND, cerebral infarction/haemorrhage, lethal myocardial infarction, bleeding complication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 11:02:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: complete cerebral infarction, bleeding complication before randomisation<BR/>Atrial fibrillation is not specified<BR/>Follow-up: mean 12.4 months in treated group versus 12.8 months in control group<BR/>Follow-up discontinued after first (non-fatal) event<BR/>No lost patients described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-18 12:57:38 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-SPIRIT-1997">
<CHAR_METHODS MODIFIED="2012-03-29 11:41:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment by telephone, computer randomised<BR/>Blinding: outcome assessment only<BR/>Results available for all participants<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 12:45:54 +0000" MODIFIED_BY="Hazel Fraser">
<P>Europe (97% Dutch)<BR/>1316 patients<BR/>Mean age 63.3 years<BR/>65% male<BR/>Cerebral ischaemia of non-cardiac origin or transient monocular blindness<BR/>CT in all but 46 patients<BR/>Time since stroke: &lt; 6 months<BR/>Comparability of groups: no major differences for prognostic variables</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 11:02:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: phenprocoumon (INR 3.0 to 4.5)<BR/>Monitoring: every 2.6 weeks (mean)<BR/>Compliance: specified in table, stopped in 143 patients<BR/>Control: aspirin 30 mg (95%), 75 mg (2%), 100 mg (3%)<BR/>Monitoring: no monitoring<BR/>Compliance: stopped in 44 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-18 12:57:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>Vascular death, non-fatal stroke, non-fatal myocardial infarction, major bleeding complication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 11:03:18 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: Rankin grade &gt; 3, (contra) indication for study medication<BR/>Follow-up: mean 14 months<BR/>Termination after first interim analysis<BR/>No patients lost<BR/>Outcomes measured at end of planned follow-up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 11:04:32 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-SWAT-1998">
<CHAR_METHODS MODIFIED="2011-03-18 11:03:24 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment by sealed envelopes (opaque and sequentially numbered)<BR/>Blinding: none<BR/>Results availability for all patients: not assessable<BR/>Intention-to-treat not assessable</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 11:03:37 +0000" MODIFIED_BY="Hazel Fraser">
<P>Canada<BR/>178 patients<BR/>Mean age 68 years<BR/>58% male<BR/>Non-cardiogenic TIA or mild stroke<BR/>CT not in all<BR/>Time since stroke: &lt; 180 days<BR/>Comparability of groups not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 11:04:13 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: warfarin (INR 2.0 to 3.0)<BR/>Monitoring and compliance not described<BR/>Control: acetylsalicylic acid (1300 mg)<BR/>Monitoring and compliance not described<BR/>Rx 2: warfarin (INR 2.0 to 3.0) + acetylsalicylic acid (80 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 11:04:17 +0000" MODIFIED_BY="Hazel Fraser">
<P>Stroke, death, myocardial infarction, haemorrhage, TIA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 11:04:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: cardiac cause of stroke, carotid stenosis &gt; 70%, (contra) indication for warfarin<BR/>Follow-up: not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-28 14:23:45 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-WARSS-2001">
<CHAR_METHODS MODIFIED="2011-03-18 12:45:58 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial<BR/>Concealment by pre-arranged assignment and labelled boxes<BR/>Blinding: double<BR/>Results available for 98.5% patients<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 11:05:01 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>2206 patients<BR/>Mean age 63 years<BR/>59% male<BR/>Ischaemic stroke of non-cardiac origin<BR/>Time since stroke: &lt; 30 days<BR/>Comparibility of groups: no significant differences in any characteristic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-29 11:45:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: warfarin (INR 1.4 to 2.8)<BR/>Monitoring: first month 7 times, thereafter monthly INR measurements compliance: not described, 16.3% below range<BR/>Control: aspirin 325 mg daily<BR/>Monitoring: idem<BR/>Compliance: not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 11:05:20 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death from any cause or recurrent ischaemic stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-28 14:23:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: GOS &lt; 3, TIA, contraindication for study medication<BR/>Follow-up: 2 years<BR/>12 patients lost in treated group, 21 patients in control group<BR/>Outcomes measured at end of planned follow-up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 11:07:32 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-WASID-2005">
<CHAR_METHODS MODIFIED="2010-06-13 16:55:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial<BR/>Concealment computer randomised<BR/>Blinding: double<BR/>Results available for 97.7%<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 11:06:39 +0000" MODIFIED_BY="Hazel Fraser">
<P>North America<BR/>569 patients<BR/>Mean age 64 years<BR/>62% male<BR/>Patients with TIA or ischaemic stroke and an angiographically proven, 50% to 99% symptomatic stenosis of a major intracranial artery, Rankin &#8804; 3<BR/>Time since stroke: &lt; 90 days<BR/>Comparibility of groups: no significant differences in any characteristic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 11:06:59 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: warfarin (INR 2.0 to 3.0)<BR/>Monitoring: at least monthly compliance: stopped in 28.4%, 63% of time within target range<BR/>Control: aspirin 1300 mg daily<BR/>Monitoring: idem<BR/>Compliance: stopped in 16.4%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 11:07:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ischaemic and haemorrhagic stroke and death from vascular causes other than stroke, major bleedings, myocardial infarction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 11:07:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: tandem stenosis extracranial carotid, cardiac embolus, limited survival, (contra) indication for study medication<BR/>Follow-up: 1.8 years<BR/>8 patients lost in treated group, 5 in control group<BR/>Trial stopped earlier because of safety recommendations of the monitoring committee</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CT: computed tomography<BR/>CTA: computed tomography angiography<BR/>GOS: Glasgow Outcome Scale<BR/>INR: International Normalised Ratio<BR/>LP: lumbar puncture<BR/>MCA: middle cerebral artery<BR/>MRA: magnetic resonance angiography<BR/>RIND: reversible ischaemic neurologic deficit<BR/>Rx: treatment<BR/>TCD: transcranial doppler<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-05-14 13:40:58 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-05-14 13:40:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ARCH-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-14 13:40:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>After consideration, the review authors agreed that this trial was not suitable for inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 11:12:00 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Buren-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 11:12:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>No concealed randomisation (depending whether they were born on odd or even dates)<BR/>The intensity of anticoagulation was not specified<BR/>No definition of outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 11:12:03 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Eriksson-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 11:12:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>Non-randomised study (the month of admission determined treatment allocation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 11:12:29 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Norrving-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 11:12:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>The cause of stroke is not described (is atrial fibrillation included or not?)<BR/>The intensity of anticoagulation is not described and could not be obtained<BR/>The method of randomisation is not detailed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 12:46:11 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Olsson-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 12:46:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment allocation according to date of birth, the intensity of anticoagulation is not defined by means of the INR and no maximum aimed anticoagulation level is defined<BR/>Atrial fibrillation is not specified as exclusion criterion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 11:12:50 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ortiz-Castellon-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 11:12:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>No information on the method of randomisation, the duration of treatment and follow-up, or number of outcome events<BR/>A request for this information was returned by mail as undeliverable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-06-13 16:17:46 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-05-18 13:09:08 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-05-12 17:34:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:38:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AVASIS-2006">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:39:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2007">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:40:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garde-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsson-1980">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:41:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPIRIT-1997">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:41:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SWAT-1998">
<DESCRIPTION>
<P>With envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:42:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WARSS-2001">
<DESCRIPTION>
<P>With labelled boxes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:42:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WASID-2005">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-05-12 17:34:05 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:38:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AVASIS-2006">
<DESCRIPTION>
<P>Adequate. However, unclear whether outcome assessment was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:39:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:40:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garde-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:40:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsson-1980">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:41:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPIRIT-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:41:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SWAT-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:42:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WARSS-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 11:42:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WASID-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-06-13 16:50:00 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-05-12 17:34:05 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-AVASIS-2006">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ESPRIT-2007">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:40:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garde-1983">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:40:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olsson-1980">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:41:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SPIRIT-1997">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:41:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SWAT-1998">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:42:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WARSS-2001">
<DESCRIPTION>
<P>Double-blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 11:42:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WASID-2005">
<DESCRIPTION>
<P>Double-blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-05-18 13:09:08 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 11:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AVASIS-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-18 13:09:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESPRIT-2007">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 11:40:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garde-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 11:40:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsson-1980">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-18 13:09:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SPIRIT-1997">
<DESCRIPTION>
<P>Outcome assessment blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 11:41:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SWAT-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 11:42:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WARSS-2001">
<DESCRIPTION>
<P>Double-blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-29 11:42:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WASID-2005">
<DESCRIPTION>
<P>Double-blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-01-31 20:36:58 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-01-31 20:36:19 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Vitamin K antagonists versus antiplatelet therapy</NAME>
<DICH_OUTCOME CHI2="12.962529838776664" CI_END="1.656307139907308" CI_START="1.0956290497603425" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3471073519983159" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="134" I2="92.28545652401463" I2_Q="92.20466488261748" ID="CMP-001.01" LOG_CI_END="0.21914087399387167" LOG_CI_START="0.03966353871825283" LOG_EFFECT_SIZE="0.12940220635606225" METHOD="MH" MODIFIED="2011-03-18 13:02:15 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="3.177905615963095E-4" P_Q="3.41439325690307E-4" P_Z="0.00470968932170639" Q="12.828184868795926" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="2.82624726502005">
<NAME>The composite vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2903052776560777" CI_START="0.7791470835207055" DF="0" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2011-03-18 13:02:15 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.9834978074153713" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.00000000000001" Z="0.02068390601148354">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.2903052776560777" CI_START="0.7791470835207055" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2010-06-13 11:41:13 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.12868457888866022" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.01655972084375182" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.352277230298463" CI_START="1.575819326299508" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2011-03-18 13:02:12 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="1.5492851349470596E-5" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="4.321561986097329">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.352277230298463" CI_START="1.575819326299508" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" ORDER="1" O_E="0.0" SE="0.1925710234727316" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.03708359908133535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.334182181331553" CI_END="1.5937086612422777" CI_START="1.0007648995494351" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2629044652226045" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="119" I2="51.616877733853215" I2_Q="74.05142997107139" ID="CMP-001.02" LOG_CI_END="0.202408932882528" LOG_CI_START="3.320646716550403E-4" LOG_EFFECT_SIZE="0.10137049877709149" METHOD="MH" MODIFIED="2011-03-18 13:02:10 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.06630157796169678" P_Q="0.021199545565112388" P_Z="0.04925179529489772" Q="7.707553818072869" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2531" TOTAL_2="2552" WEIGHT="300.0" Z="1.966405442216474">
<NAME>All death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3015876926993528" CI_START="0.6041858407293877" DF="0" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" MODIFIED="2011-03-18 13:02:10 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.5394412276723357" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.6136581869405714">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="1.3015876926993528" CI_START="0.6041858407293877" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" ORDER="2" O_E="0.0" SE="0.19578376757433918" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.03833128364560287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5944601472146056" CI_END="1.8751822549208503" CI_START="0.9390771555469803" DF="3" EFFECT_SIZE="1.3270044529251757" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="51" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.2730434845756141" LOG_CI_START="-0.027298724185722087" LOG_EFFECT_SIZE="0.12287238019494601" MODIFIED="2011-03-18 13:02:07 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.45846162685929104" P_Z="0.1087860117272357" STUDIES="4" TAU2="0.0" TOTAL_1="777" TOTAL_2="784" WEIGHT="100.0" Z="1.6036736286252478">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.9297257332720512" CI_START="0.9179029534104168" EFFECT_SIZE="1.3309023066485752" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.28549558828720983" LOG_CI_START="-0.037203232770740086" LOG_EFFECT_SIZE="0.1241461777582349" MODIFIED="2010-06-13 11:36:14 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.1895548848743663" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03593105437973427" WEIGHT="85.69233527312541"/>
<DICH_DATA CI_END="5.409665747760656" CI_START="0.22941790390348796" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.733170431763185" LOG_CI_START="-0.6393726925242165" LOG_EFFECT_SIZE="0.04689886961948424" ORDER="3" O_E="0.0" SE="0.8062386254044603" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.6500207210940737" WEIGHT="5.506870051240995"/>
<DICH_DATA CI_END="14.127632349253236" CI_START="0.6184504429640615" EFFECT_SIZE="2.9558823529411766" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1500693845086816" LOG_CI_START="-0.20869509508017642" LOG_EFFECT_SIZE="0.4706871447142526" ORDER="4" O_E="0.0" SE="0.7981449813031446" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="0.6370354111793971" WEIGHT="3.9093171496529093"/>
<DICH_DATA CI_END="4.009949235794223" CI_START="0.009645453222331667" EFFECT_SIZE="0.19666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6031388746765423" LOG_CI_START="-2.0156773608315786" LOG_EFFECT_SIZE="-0.7062692430775183" ORDER="5" O_E="0.0" SE="1.538305620086906" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.3663841807909605" WEIGHT="4.891477525980686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.321929350988984" CI_START="1.3144898007026957" DF="0" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" MODIFIED="2011-03-18 13:02:04 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.004229367160529912" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.860527615964332">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.321929350988984" CI_START="1.3144898007026957" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" ORDER="6" O_E="0.0" SE="0.30364162680585666" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.09219823752930713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0207408405092098" CI_END="2.3424566577388046" CI_START="1.0772377045803918" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.588515858611933" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="40" I2="0.0" I2_Q="26.127679083637908" ID="CMP-001.03" LOG_CI_END="0.36967156392309775" LOG_CI_START="0.03231154582063985" LOG_EFFECT_SIZE="0.20099155487186882" METHOD="MH" MODIFIED="2011-03-18 13:02:02 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.5681130823417797" P_Q="0.24463475057657302" P_Z="0.019522251134597185" Q="1.353686993443993" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1369" TOTAL_2="1391" WEIGHT="200.0" Z="2.3354054280725616">
<NAME>Vascular death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6338899146515888" CI_END="2.155081396243086" CI_START="0.8428989768013373" DF="2" EFFECT_SIZE="1.3477818457810204" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.3334636778710602" LOG_CI_START="-0.07422447335485748" LOG_EFFECT_SIZE="0.12961960225810135" MODIFIED="2011-03-18 13:02:02 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.7283708938390046" P_Z="0.21265631712963096" STUDIES="3" TAU2="0.0" TOTAL_1="718" TOTAL_2="726" WEIGHT="100.0" Z="1.2462945089395319">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="2.1547276890413607" CI_START="0.762785092664753" EFFECT_SIZE="1.2820273631840795" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.3333923925388221" LOG_CI_START="-0.11759780308893258" LOG_EFFECT_SIZE="0.10789729472494479" MODIFIED="2010-06-13 12:55:39 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2649138733492158" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07017936029288434" WEIGHT="83.23252683521083"/>
<DICH_DATA CI_END="5.409665747760656" CI_START="0.22941790390348796" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.733170431763185" LOG_CI_START="-0.6393726925242165" LOG_EFFECT_SIZE="0.04689886961948424" ORDER="7" O_E="0.0" SE="0.8062386254044603" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.6500207210940737" WEIGHT="9.806123629041569"/>
<DICH_DATA CI_END="12.258465062743564" CI_START="0.4949663830773997" EFFECT_SIZE="2.463235294117647" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.088436093631523" LOG_CI_START="-0.30542429629826756" LOG_EFFECT_SIZE="0.39150589866662777" ORDER="8" O_E="0.0" SE="0.8187604927649663" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="0.6703687445127304" WEIGHT="6.961349535747594"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.512487155597061" CI_START="1.1007848603029535" DF="0" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" MODIFIED="2011-03-18 13:02:00 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.025963202024573785" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2267617349336666">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.512487155597061" CI_START="1.1007848603029535" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" ORDER="9" O_E="0.0" SE="0.3599109610264315" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.12953589986696948" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.280181417768788" CI_END="1.3977221095231223" CI_START="0.8794355902108272" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.108695886318331" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="122" I2="43.18377035485098" I2_Q="80.00844614725328" ID="CMP-001.04" LOG_CI_END="0.14542083500257277" LOG_CI_START="-0.05579596273336093" LOG_EFFECT_SIZE="0.04481243613460591" METHOD="MH" MODIFIED="2011-03-18 13:01:57 +0000" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="0.15239362667826906" P_Q="0.025316574474050668" P_Z="0.3826650986709359" Q="5.002112428907601" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1369" TOTAL_2="1391" WEIGHT="200.0" Z="0.8729963091709008">
<NAME>Vascular death or non-fatal stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23595663394912314" CI_END="1.2209691917809697" CI_START="0.7064135216915974" DF="2" EFFECT_SIZE="0.9287137054243025" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="93" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.0867047057071063" LOG_CI_START="-0.150940996378614" LOG_EFFECT_SIZE="-0.03211814533575386" MODIFIED="2011-03-18 13:01:57 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.8887153258280429" P_Z="0.5962619191612504" STUDIES="3" TAU2="0.0" TOTAL_1="718" TOTAL_2="726" WEIGHT="100.0" Z="0.5297836868566139">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.2174438688844504" CI_START="0.6704590083443696" EFFECT_SIZE="0.9034634519709147" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="78" LOG_CI_END="0.08544894689225135" LOG_CI_START="-0.1736277696305052" LOG_EFFECT_SIZE="-0.044089411369126925" MODIFIED="2010-06-13 13:04:01 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.15218294573589708" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.023159648972854996" WEIGHT="84.37584160391003"/>
<DICH_DATA CI_END="2.3796110544455" CI_START="0.42245142592714263" EFFECT_SIZE="1.0026315789473683" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.37650597776575734" LOG_CI_START="-0.37422321964813915" LOG_EFFECT_SIZE="0.0011413790588091003" ORDER="10" O_E="0.0" SE="0.4409820467303836" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.19446516553851823" WEIGHT="10.195717338696772"/>
<DICH_DATA CI_END="3.689012037195892" CI_START="0.37895199674416696" EFFECT_SIZE="1.1823529411764706" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5669100723260782" LOG_CI_START="-0.4214158002416483" LOG_EFFECT_SIZE="0.07274713604221494" ORDER="11" O_E="0.0" SE="0.5805475098382537" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="0.33703541117939717" WEIGHT="5.4284410573932"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6466870259382267" CI_START="1.0801030786283004" DF="0" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" MODIFIED="2011-03-18 13:01:55 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.021619623918429972" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2969850266705834">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.6466870259382267" CI_START="1.0801030786283004" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" ORDER="12" O_E="0.0" SE="0.22863996642152237" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.05227623424523488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.374267756462668" CI_END="1.348893628017374" CI_START="0.8557161797312547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0743696301696448" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="125" I2="86.43933156449847" I2_Q="86.37613643267139" ID="CMP-001.05" LOG_CI_END="0.12997770312887694" LOG_CI_START="-0.06767025636927675" LOG_EFFECT_SIZE="0.031153723379800085" METHOD="MH" MODIFIED="2011-03-18 13:01:54 +0000" MODIFIED_BY="Hazel Fraser" NO="5" P_CHI2="0.00661640642674155" P_Q="0.006743483805131567" P_Z="0.536662350563796" Q="7.340061760439968" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="0.6178680110208982">
<NAME>Vascular death, non-fatal stroke or non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.230759577708872E-31" CI_END="1.1228134403876229" CI_START="0.6469409031342811" DF="0" EFFECT_SIZE="0.8522874756651526" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" I2="100.0" ID="CMP-001.05.01" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.189135389524328" LOG_EFFECT_SIZE="-0.06941389345283562" MODIFIED="2011-03-18 13:01:54 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.0" P_Z="0.25579891791346354" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.00000000000001" Z="1.1363768049892744">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.1228134403876229" CI_START="0.646940903134281" EFFECT_SIZE="0.8522874756651525" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.1891353895243281" LOG_EFFECT_SIZE="-0.06941389345283568" MODIFIED="2010-06-13 13:06:10 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.14064999884671603" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.019782422175581224" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.585515291433895" CI_START="1.1210673440749552" DF="0" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.41254711065023614" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2011-03-18 13:01:50 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.012558604782764023" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.4960467531926507">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.5855152914338944" CI_START="1.1210673440749552" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.4125471106502361" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" ORDER="13" O_E="0.0" SE="0.213178307470672" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.04544499077606038" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8047881257050278" CI_END="1.1541512134746512" CI_START="0.606317344634786" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8365296761388484" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.062262712524583444" LOG_CI_START="-0.21730000792958037" LOG_EFFECT_SIZE="-0.07751864770249846" METHOD="MH" MODIFIED="2011-03-18 13:01:47 +0000" MODIFIED_BY="Hazel Fraser" NO="6" P_CHI2="0.6138936881300157" P_Q="0.5473313429830443" P_Z="0.2770639574734223" Q="0.36212017467987667" RANDOM="NO" SCALE="8.507820826598152" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1369" TOTAL_2="1391" WEIGHT="100.0" Z="1.0869386117027444">
<NAME>Recurrent ischaemic stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4550353622453218" CI_END="1.1382144867202424" CI_START="0.5554684291029482" DF="2" EFFECT_SIZE="0.795136600164218" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="62" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.056224108826887255" LOG_CI_START="-0.25534061981225065" LOG_EFFECT_SIZE="-0.0995582554926817" MODIFIED="2011-03-18 13:01:47 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.48310680977127096" P_Z="0.21035693582260373" STUDIES="3" TAU2="0.0" TOTAL_1="718" TOTAL_2="726" WEIGHT="81.71431737487488" Z="1.2525846297274446">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.1335878784083793" CI_START="0.5200612148420677" EFFECT_SIZE="0.7678118839763447" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="53" LOG_CI_END="0.054455193301067024" LOG_CI_START="-0.28394553385861776" LOG_EFFECT_SIZE="-0.11474517027877539" MODIFIED="2010-06-13 13:13:04 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.19877826224421413" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03951279754082957" WEIGHT="70.23077312542516"/>
<DICH_DATA CI_END="3.754054208487166" CI_START="0.44997747974955454" EFFECT_SIZE="1.2997076023391814" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.574500539536492" LOG_CI_START="-0.34680922103629697" LOG_EFFECT_SIZE="0.1138456592500975" ORDER="14" O_E="0.0" SE="0.5411819139173228" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.2928778639512166" WEIGHT="7.49371378896842"/>
<DICH_DATA CI_END="3.0785388113778964" CI_START="0.03503842994467677" EFFECT_SIZE="0.3284313725490196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48834463314627763" LOG_CI_START="-1.4554553625964222" LOG_EFFECT_SIZE="-0.4835553647250723" ORDER="15" O_E="0.0" SE="1.1417977394644219" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="1.3037020778460637" WEIGHT="3.9898304604813015"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1258039571298935" CI_START="0.49086051909918116" DF="0" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758587" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2011-03-18 13:01:44 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.9546221586897212" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="18.285682625125116" Z="0.05690338393650061">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.1258039571298935" CI_START="0.49086051909918105" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758588" LOG_EFFECT_SIZE="0.009240656734912641" ORDER="16" O_E="0.0" SE="0.3739214959698824" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.13981728514835476" WEIGHT="18.285682625125116"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.7155262186664295" CI_END="1.5012413768990784" CI_START="0.8806974330821928" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1498432184744993" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="93" I2="48.1564849028357" I2_Q="85.13083910330457" ID="CMP-001.07" LOG_CI_END="0.17645052583917054" LOG_CI_START="-0.055173269467915544" LOG_EFFECT_SIZE="0.060638628185627506" METHOD="MH" MODIFIED="2011-03-18 13:01:42 +0000" MODIFIED_BY="Hazel Fraser" NO="7" P_CHI2="0.10257268574219436" P_Q="0.009505365669335242" P_Z="0.3047836717187542" Q="6.725329068315096" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1428" TOTAL_2="1449" WEIGHT="200.0" Z="1.026228994807507">
<NAME>Recurrent ischaemic stroke or intracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0987753488474707" CI_END="1.2445231807375075" CI_START="0.6615901848216036" DF="3" EFFECT_SIZE="0.9073942479203279" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="73" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.09500299027577144" LOG_CI_START="-0.17941094648670122" LOG_EFFECT_SIZE="-0.04220397810546492" MODIFIED="2011-03-18 13:01:42 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.7773697590714368" P_Z="0.5465936648532224" STUDIES="4" TAU2="0.0" TOTAL_1="777" TOTAL_2="784" WEIGHT="100.00000000000001" Z="0.6028722743963807">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.3065215771534402" CI_START="0.6568264783323874" EFFECT_SIZE="0.9263681592039801" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" LOG_CI_END="0.11611658647918395" LOG_CI_START="-0.18254934802951403" LOG_EFFECT_SIZE="-0.03321638077516506" MODIFIED="2010-08-22 10:55:03 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.17543784835062867" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.030778438633898182" WEIGHT="82.61846244471656"/>
<DICH_DATA CI_END="3.079161106976936" CI_START="0.40305594074231743" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4884324125279555" LOG_CI_START="-0.39463467328898705" LOG_EFFECT_SIZE="0.04689886961948424" ORDER="17" O_E="0.0" SE="0.5187179774614455" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.2690683401416928" WEIGHT="9.084858549186627"/>
<DICH_DATA CI_END="3.8069045270712594" CI_START="0.11333845197049652" EFFECT_SIZE="0.6568627450980392" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5805719853286707" LOG_CI_START="-0.945622723450853" LOG_EFFECT_SIZE="-0.18252536906109113" ORDER="18" O_E="0.0" SE="0.8964943267227427" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="0.8037020778460637" WEIGHT="4.1459944835441505"/>
<DICH_DATA CI_END="3.059523432100449" CI_START="0.03509584236216615" EFFECT_SIZE="0.327683615819209" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48565378369477086" LOG_CI_START="-1.4547443292925097" LOG_EFFECT_SIZE="-0.4845452727988694" ORDER="19" O_E="0.0" SE="1.1397994566942975" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="1.2991428014806157" WEIGHT="4.150684522552685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4562787889402675" CI_START="1.2076262334379722" DF="0" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" MODIFIED="2011-03-18 13:01:40 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.007739208693857412" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.6632404651896153">
<NAME>INR 3. 0 - 4.5</NAME>
<DICH_DATA CI_END="3.4562787889402675" CI_START="1.2076262334379722" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" ORDER="20" O_E="0.0" SE="0.268253876563251" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.0719601422912119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" I2_Q="100.0" ID="CMP-001.08" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" METHOD="MH" MODIFIED="2011-03-18 13:01:39 +0000" MODIFIED_BY="Hazel Fraser" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.0015562649609034886" Q="1.7816609378369543E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>Death or dependent at end of follow-up</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2011-03-18 13:01:39 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.0015562649609034886" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.8486711720506848" CI_START="1.3725732884068116" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" ORDER="21" O_E="0.0" SE="0.26302540659304025" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.06918236451343412" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.86176457163512" CI_END="2.995345117926041" CI_START="1.7057758327618204" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2603953886299064" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="67" I2="77.12901909808632" I2_Q="87.55361679878594" ID="CMP-001.09" LOG_CI_END="0.47644686818641485" LOG_CI_START="0.23192195708280028" LOG_EFFECT_SIZE="0.3541844126346076" METHOD="MH" MODIFIED="2011-03-18 13:01:34 +0000" MODIFIED_BY="Hazel Fraser" NO="9" P_CHI2="5.562448568662282E-4" P_Q="3.241009773438108E-4" P_Z="1.3639296239899297E-8" Q="16.068925146101183" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2531" TOTAL_2="2552" WEIGHT="300.0" Z="5.677856620139202">
<NAME>Major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0294043664354917" CI_START="0.7905986953514542" DF="0" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" MODIFIED="2011-03-18 13:01:34 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.32563570148921617" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.9829426023810879">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="2.0294043664354917" CI_START="0.7905986953514542" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="22" O_E="0.0" SE="0.24049092743726877" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.05783588617963767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.923583620214853" CI_END="2.9401903566967036" CI_START="1.2689782524115572" DF="3" EFFECT_SIZE="1.93158940269362" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="31" I2="49.35498184304879" ID="CMP-001.09.02" LOG_CI_END="0.46837544884301946" LOG_CI_START="0.10345417927469898" LOG_EFFECT_SIZE="0.2859148140588592" MODIFIED="2011-03-18 13:01:31 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.1153878612850433" P_Z="0.002131625791923933" STUDIES="4" TAU2="0.0" TOTAL_1="777" TOTAL_2="784" WEIGHT="100.0" Z="3.0712528149687137">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="4.229503623094466" CI_START="1.455741628251214" EFFECT_SIZE="2.4813432835820897" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="18" LOG_CI_END="0.6262894013229263" LOG_CI_START="0.16308430122570522" LOG_EFFECT_SIZE="0.3946868512743158" MODIFIED="2010-06-13 13:25:15 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.27208896869933263" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07403240688786643" WEIGHT="57.48737685108396"/>
<DICH_DATA CI_END="7.202461201322997" CI_START="0.6892500449384026" EFFECT_SIZE="2.2280701754385963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8574809274735596" LOG_CI_START="-0.16162319690662882" LOG_EFFECT_SIZE="0.34792886528346545" ORDER="23" O_E="0.0" SE="0.5986268073076975" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.3583540544274071" WEIGHT="12.040769710185542"/>
<DICH_DATA CI_END="8.518415980403558" CI_START="0.6204781698154183" EFFECT_SIZE="2.299019607843137" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9303588441883911" LOG_CI_START="-0.2072734936100222" LOG_EFFECT_SIZE="0.3615426752891845" ORDER="24" O_E="0.0" SE="0.6682508665936817" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="0.44655922070320664" WEIGHT="9.616185867959096"/>
<DICH_DATA CI_END="1.3127828342733947" CI_START="0.004358348243632464" EFFECT_SIZE="0.07564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11819288932087291" LOG_CI_START="-2.3606780714175453" LOG_EFFECT_SIZE="-1.1212425910483363" ORDER="25" O_E="0.0" SE="1.4561010729469004" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.1202303346371143" WEIGHT="20.8556675707714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.84459626516066" CI_START="3.9060433973423807" DF="0" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" NO="3" P_CHI2="1.0" P_Z="2.6126581556263546E-7" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="5.149439653022548">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="20.84459626516066" CI_START="3.9060433973423807" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" ORDER="26" O_E="0.0" SE="0.42719402323321476" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.18249473348618045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.433048209727753" CI_END="5.964401167119027" CI_START="1.6269024885703272" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.115043996738683" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="11" I2="37.82107844378675" I2_Q="56.48918275871203" ID="CMP-001.10" LOG_CI_END="0.775566846519184" LOG_CI_START="0.21136152346855674" LOG_EFFECT_SIZE="0.49346418499387035" METHOD="MH" MODIFIED="2011-03-18 12:14:15 +0000" MODIFIED_BY="Hazel Fraser" NO="10" P_CHI2="0.16905813213742105" P_Q="0.1004316878402477" P_Z="6.070608528529726E-4" Q="4.596558113144735" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2472" TOTAL_2="2494" WEIGHT="300.0" Z="3.4284399339550733">
<NAME>Fatal intracranial or extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.397652647858285" CI_START="0.44569231745816623" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" NO="1" P_CHI2="1.0" P_Z="0.5645061597471045" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.5761613054715299">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="4.397652647858285" CI_START="0.44569231745816623" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" ORDER="27" O_E="0.0" SE="0.5839896456528686" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.341043906229763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3678481962625788" CI_END="5.752203880896471" CI_START="0.8298837012226203" DF="2" EFFECT_SIZE="2.1848707620510384" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.7598342707647955" LOG_CI_START="-0.08098276480002045" LOG_EFFECT_SIZE="0.33942575298238753" MODIFIED="2010-06-13 13:27:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5046329219056318" P_Z="0.11355404506918873" STUDIES="3" TAU2="0.0" TOTAL_1="718" TOTAL_2="726" WEIGHT="99.99999999999999" Z="1.5824185836672087">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="8.517978259455019" CI_START="0.8746263264776128" EFFECT_SIZE="2.7294776119402986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9303365272837775" LOG_CI_START="-0.0581774544186959" LOG_EFFECT_SIZE="0.4360795364325408" MODIFIED="2010-06-13 13:27:15 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.5806580060751592" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.3371637200191796" WEIGHT="67.6106711334328"/>
<DICH_DATA CI_END="9.017539181230221" CI_START="0.015264891126810612" EFFECT_SIZE="0.3710144927536232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9550880380051068" LOG_CI_START="-1.8163062888559185" LOG_EFFECT_SIZE="-0.43060912542540575" ORDER="28" O_E="0.0" SE="1.6279307462213353" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="2.6501585144927535" WEIGHT="23.908071415515646"/>
<DICH_DATA CI_END="71.31099580520645" CI_START="0.12257605850615069" EFFECT_SIZE="2.9565217391304346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8531565010907625" LOG_CI_START="-0.9115943477134756" LOG_EFFECT_SIZE="0.4707810766886434" ORDER="29" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="2.637468030690537" WEIGHT="8.481257451051535"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.1099536139226" CI_START="2.3177609108362187" DF="0" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" NO="3" P_CHI2="1.0" P_Z="0.005468500714406536" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.7780571023295555">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="130.1099536139226" CI_START="2.3177609108362187" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" ORDER="30" O_E="0.0" SE="1.0275133438077466" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="1.0557836717029765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.323411999169709" CI_END="6.134396574089255" CI_START="1.8757059135342964" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.392097276020212" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="13" I2="52.55725863831247" I2_Q="80.69625732027494" ID="CMP-001.11" LOG_CI_END="0.7877718486551694" LOG_CI_START="0.27316474761385173" LOG_EFFECT_SIZE="0.5304682981345106" METHOD="MH" MODIFIED="2011-03-18 12:14:20 +0000" MODIFIED_BY="Hazel Fraser" NO="11" P_CHI2="0.0968930955079692" P_Q="0.02284386318768261" P_Z="5.328102975688589E-5" Q="5.180342571859451" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1369" TOTAL_2="1391" WEIGHT="200.0" Z="4.040747813934343">
<NAME>Intracranial haemorrhage, fatal or non-fatal</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.089806032582365" CI_END="3.779282130945646" CI_START="0.8770291939833642" DF="2" EFFECT_SIZE="1.8205880261989507" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.5774093140761248" LOG_CI_START="-0.0569859498781375" LOG_EFFECT_SIZE="0.26021168209899365" MODIFIED="2010-06-13 13:29:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5798981402148295" P_Z="0.10786850938857775" STUDIES="3" TAU2="0.0" TOTAL_1="718" TOTAL_2="726" WEIGHT="100.0" Z="1.6078478332000383">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="4.378765223310152" CI_START="0.8999160889578423" EFFECT_SIZE="1.9850746268656716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6413516602059892" LOG_CI_START="-0.04579798367347058" LOG_EFFECT_SIZE="0.29777683826625934" MODIFIED="2010-06-13 13:29:34 +0100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.40363510226038973" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1629212957767553" WEIGHT="82.44607730979622"/>
<DICH_DATA CI_END="9.017539181230221" CI_START="0.015264891126810612" EFFECT_SIZE="0.3710144927536232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9550880380051068" LOG_CI_START="-1.8163062888559185" LOG_EFFECT_SIZE="-0.43060912542540575" ORDER="31" O_E="0.0" SE="1.6279307462213353" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="2.6501585144927535" WEIGHT="12.957367503006026"/>
<DICH_DATA CI_END="71.31099580520645" CI_START="0.12257605850615069" EFFECT_SIZE="2.9565217391304346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8531565010907625" LOG_CI_START="-0.9115943477134756" LOG_EFFECT_SIZE="0.4707810766886434" ORDER="32" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="2.637468030690537" WEIGHT="4.596555187197758"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.15627356689243" CI_START="2.8027777290985583" DF="0" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" NO="2" P_CHI2="1.0" P_Z="2.5179886990746314E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.66042335249295">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="30.15627356689243" CI_START="2.8027777290985583" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" ORDER="33" O_E="0.0" SE="0.6060779757272016" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.3673305126615823" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.393459472691795" CI_END="6.321872544280934" CI_START="2.2630654432593698" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7824345720253203" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="18" I2="11.594641864978309" I2_Q="66.12453783684593" ID="CMP-001.12" LOG_CI_END="0.8008457357500866" LOG_CI_START="0.35469711305126855" LOG_EFFECT_SIZE="0.5777714244006775" METHOD="MH" MODIFIED="2011-08-21 19:46:20 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.334845299780276" P_Q="0.08577208800033442" P_Z="3.846825815095842E-7" Q="2.9519892457369568" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1369" TOTAL_2="1391" WEIGHT="200.0" Z="5.07638542632549">
<NAME>Major extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2938661776900878" CI_END="4.958203442409838" CI_START="1.5497148667869507" DF="2" EFFECT_SIZE="2.771967097073261" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="15" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.6953243425413845" LOG_CI_START="0.1902517993494607" LOG_EFFECT_SIZE="0.4427880709454226" MODIFIED="2010-06-13 13:31:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8633517556702579" P_Z="5.892153869103699E-4" STUDIES="3" TAU2="0.0" TOTAL_1="718" TOTAL_2="726" WEIGHT="100.0" Z="3.4365307856666396">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="6.270869951720418" CI_START="1.413866486670769" EFFECT_SIZE="2.9776119402985075" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.7973277942634943" LOG_CI_START="0.15040840038038694" LOG_EFFECT_SIZE="0.47386809732194063" MODIFIED="2010-06-13 13:31:19 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.38000365426958305" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1444027772582368" WEIGHT="60.65291101807863"/>
<DICH_DATA CI_END="10.928799313245092" CI_START="0.807537599920367" EFFECT_SIZE="2.9707602339181287" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0385724510370216" LOG_CI_START="-0.09283724725349062" LOG_EFFECT_SIZE="0.4728676018917654" ORDER="34" O_E="0.0" SE="0.6645956573441782" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.44168738776074046" WEIGHT="19.055689452821756"/>
<DICH_DATA CI_END="7.5575170540034184" CI_START="0.5138219292568506" EFFECT_SIZE="1.9705882352941178" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8783791358632483" LOG_CI_START="-0.2891873645461056" LOG_EFFECT_SIZE="0.2945958856585713" ORDER="35" O_E="0.0" SE="0.6858343418878429" STUDY_ID="STD-Olsson-1980" TOTAL_1="68" TOTAL_2="67" VAR="0.4703687445127305" WEIGHT="20.291399529099607"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.106273460663985" CI_START="2.6927677333495303" DF="0" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="1.4639866053333341" LOG_CI_START="0.4301988946388021" LOG_EFFECT_SIZE="0.9470927499860682" NO="2" P_CHI2="1.0" P_Z="3.2916266325405593E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.591197033566187">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="29.106273460664" CI_START="2.69276773334953" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" LOG_CI_END="1.4639866053333344" LOG_CI_START="0.43019889463880207" LOG_EFFECT_SIZE="0.9470927499860682" ORDER="36" O_E="0.0" SE="0.6072520185936674" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.36875501408608374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-01-31 20:36:30 +0000" MODIFIED_BY="Hazel Fraser" NO="2">
<NAME>Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials)</NAME>
<DICH_OUTCOME CHI2="12.962529838776664" CI_END="1.656307139907308" CI_START="1.0956290497603425" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3471073519983159" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="134" I2="92.28545652401463" I2_Q="92.20466488261748" ID="CMP-002.01" LOG_CI_END="0.21914087399387167" LOG_CI_START="0.03966353871825283" LOG_EFFECT_SIZE="0.12940220635606225" METHOD="MH" MODIFIED="2011-03-18 12:14:43 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="3.177905615963095E-4" P_Q="3.41439325690307E-4" P_Z="0.00470968932170639" Q="12.828184868795926" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="2.82624726502005">
<NAME>The composite vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2903052776560777" CI_START="0.7791470835207055" DF="0" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2010-06-13 11:43:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9834978074153713" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.00000000000001" Z="0.02068390601148354">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.2903052776560777" CI_START="0.7791470835207055" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2010-06-13 11:43:04 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.12868457888866022" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.01655972084375182" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.352277230298463" CI_START="1.575819326299508" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 11:43:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.5492851349470596E-5" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="4.321561986097329">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.352277230298463" CI_START="1.575819326299508" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 11:43:04 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.1925710234727316" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.03708359908133535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.133856059379031" CI_END="1.5698619580804787" CI_START="0.9744159716864389" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2368098339262044" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="114" I2="67.15516447273687" I2_Q="73.56313281189972" ID="CMP-002.02" LOG_CI_END="0.19586146547951616" LOG_CI_START="-0.011255606116742476" LOG_EFFECT_SIZE="0.09230292968138683" METHOD="MH" MODIFIED="2011-03-18 12:14:47 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.027563171791578966" P_Q="0.022763532174037704" P_Z="0.08064796530567264" Q="7.565192901904187" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2349" TOTAL_2="2358" WEIGHT="300.0" Z="1.7469387380650796">
<NAME>All death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3015876926993528" CI_START="0.6041858407293877" DF="0" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" NO="1" P_CHI2="1.0" P_Z="0.5394412276723357" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.6136581869405714">
<NAME>INR 1.4 - 2.8 concealed randomisation</NAME>
<DICH_DATA CI_END="1.3015876926993528" CI_START="0.6041858407293877" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" ORDER="37" O_E="0.0" SE="0.19578376757433918" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.03833128364560287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5316052822495085" CI_END="1.8298635786002342" CI_START="0.8809518781444706" DF="1" EFFECT_SIZE="1.2696541876889307" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="46" I2="34.70902643197508" ID="CMP-002.02.02" LOG_CI_END="0.26241871308037856" LOG_CI_START="-0.055047814206690755" LOG_EFFECT_SIZE="0.10368544943684388" MODIFIED="2010-06-13 11:38:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21587211882226087" P_Z="0.20045393525392444" STUDIES="2" TAU2="0.0" TOTAL_1="595" TOTAL_2="590" WEIGHT="100.0" Z="1.2802593605926922">
<NAME>INR 2.0 - 3.6 concealed randomisation</NAME>
<DICH_DATA CI_END="1.9297257332720512" CI_START="0.9179029534104168" EFFECT_SIZE="1.3309023066485752" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.28549558828720983" LOG_CI_START="-0.037203232770740086" LOG_EFFECT_SIZE="0.1241461777582349" MODIFIED="2010-06-13 11:37:45 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.1895548848743663" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03593105437973427" WEIGHT="94.6000533927305"/>
<DICH_DATA CI_END="4.009949235794223" CI_START="0.009645453222331667" EFFECT_SIZE="0.19666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6031388746765423" LOG_CI_START="-2.0156773608315786" LOG_EFFECT_SIZE="-0.7062692430775183" ORDER="38" O_E="0.0" SE="1.538305620086906" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.3663841807909605" WEIGHT="5.399946607269501"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.321929350988984" CI_START="1.3144898007026957" DF="0" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" NO="3" P_CHI2="1.0" P_Z="0.004229367160529912" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.860527615964332">
<NAME>INR 3.0 - 4.5 concealed randomisation</NAME>
<DICH_DATA CI_END="4.321929350988984" CI_START="1.3144898007026957" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" ORDER="39" O_E="0.0" SE="0.30364162680585666" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.09219823752930713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5346344523396704" CI_END="2.38731899149853" CI_START="1.0412337501825053" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5766283983234386" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="35" I2="34.837902376333226" I2_Q="34.691217993913504" ID="CMP-002.03" LOG_CI_END="0.3779104529370548" LOG_CI_START="0.01754823673307875" LOG_EFFECT_SIZE="0.1977293448350668" METHOD="MH" MODIFIED="2011-03-18 12:14:51 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.2154186718253589" P_Q="0.21593472574424954" P_Z="0.03148810325476336" Q="1.531187643197517" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="2.1508492130266568">
<NAME>Vascular death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.154727689041361" CI_START="0.7627850926647529" DF="0" EFFECT_SIZE="1.2820273631840795" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.3333923925388222" LOG_CI_START="-0.11759780308893264" LOG_EFFECT_SIZE="0.10789729472494479" MODIFIED="2010-06-13 13:01:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.34833465512980233" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.0" Z="0.9378244305104392">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="2.1547276890413607" CI_START="0.762785092664753" EFFECT_SIZE="1.2820273631840795" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.3333923925388221" LOG_CI_START="-0.11759780308893258" LOG_EFFECT_SIZE="0.10789729472494479" MODIFIED="2010-06-13 13:01:43 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.2649138733492158" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07017936029288434" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.512487155597061" CI_START="1.1007848603029535" DF="0" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" MODIFIED="2010-06-13 13:01:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.025963202024573785" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2267617349336666">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.512487155597061" CI_START="1.1007848603029535" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" MODIFIED="2010-06-13 13:01:43 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.3599109610264315" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.12953589986696948" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.225821254308349" CI_END="1.4255116740978846" CI_START="0.8715111163408003" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1146072269862108" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="107" I2="80.86425173506336" I2_Q="80.79317674448524" ID="CMP-002.04" LOG_CI_END="0.15397077827510508" LOG_CI_START="-0.059727068984649294" LOG_EFFECT_SIZE="0.04712185464522792" METHOD="MH" MODIFIED="2011-03-18 12:19:00 +0000" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="0.02225398433713932" P_Q="0.02250285642954808" P_Z="0.3873839884909268" Q="5.206483064360345" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="0.8643712529037886">
<NAME>Vascular death or non-fatal stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2174438688844504" CI_START="0.6704590083443696" DF="0" EFFECT_SIZE="0.9034634519709147" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="78" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.08544894689225135" LOG_CI_START="-0.1736277696305052" LOG_EFFECT_SIZE="-0.044089411369126925" MODIFIED="2010-06-13 13:04:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5047150708373285" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.0" Z="0.6670893435957935">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.2174438688844504" CI_START="0.6704590083443696" EFFECT_SIZE="0.9034634519709147" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="78" LOG_CI_END="0.08544894689225135" LOG_CI_START="-0.1736277696305052" LOG_EFFECT_SIZE="-0.044089411369126925" MODIFIED="2010-06-13 13:04:25 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.15218294573589708" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.023159648972854996" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6466870259382267" CI_START="1.0801030786283004" DF="0" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" MODIFIED="2010-06-13 13:04:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.021619623918429972" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2969850266705834">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.6466870259382267" CI_START="1.0801030786283004" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" MODIFIED="2010-06-13 13:04:25 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.22863996642152237" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.05227623424523488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.374267756462668" CI_END="1.348893628017374" CI_START="0.8557161797312547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0743696301696448" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="125" I2="86.43933156449847" I2_Q="86.37613643267139" ID="CMP-002.05" LOG_CI_END="0.12997770312887694" LOG_CI_START="-0.06767025636927675" LOG_EFFECT_SIZE="0.031153723379800085" METHOD="MH" MODIFIED="2011-03-18 12:17:49 +0000" MODIFIED_BY="Hazel Fraser" NO="5" P_CHI2="0.00661640642674155" P_Q="0.006743483805131567" P_Z="0.536662350563796" Q="7.340061760439968" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="0.6178680110208982">
<NAME>Vascular death, non-fatal stroke or non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.230759577708872E-31" CI_END="1.1228134403876229" CI_START="0.6469409031342811" DF="0" EFFECT_SIZE="0.8522874756651526" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" I2="100.0" ID="CMP-002.05.01" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.189135389524328" LOG_EFFECT_SIZE="-0.06941389345283562" MODIFIED="2010-06-13 13:06:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.25579891791346354" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.00000000000001" Z="1.1363768049892744">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.1228134403876229" CI_START="0.646940903134281" EFFECT_SIZE="0.8522874756651525" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.1891353895243281" LOG_EFFECT_SIZE="-0.06941389345283568" MODIFIED="2010-06-13 13:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.14064999884671603" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.019782422175581224" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.585515291433895" CI_START="1.1210673440749552" DF="0" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.41254711065023614" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2010-06-13 13:06:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.012558604782764023" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.4960467531926507">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.5855152914338944" CI_START="1.1210673440749552" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.4125471106502361" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2010-06-13 13:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.213178307470672" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.04544499077606038" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45480476173008555" CI_END="1.1564068704444537" CI_START="0.5817679381920176" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8202197514870959" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.06311066323664408" LOG_CI_START="-0.2352502168290243" LOG_EFFECT_SIZE="-0.0860697767961901" METHOD="MH" MODIFIED="2011-03-18 12:15:01 +0000" MODIFIED_BY="Hazel Fraser" NO="6" P_CHI2="0.5000620659307725" P_Q="0.5002114251868897" P_Z="0.25813811029431677" Q="0.45448788928576334" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="99.99999999999999" Z="1.130802822681076">
<NAME>Recurrent ischaemic stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.133587878408379" CI_START="0.5200612148420677" DF="0" EFFECT_SIZE="0.7678118839763447" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="53" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.05445519330106694" LOG_CI_START="-0.28394553385861776" LOG_EFFECT_SIZE="-0.11474517027877539" MODIFIED="2010-06-13 13:14:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1837912003244505" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="79.34205287584456" Z="1.329172091525627">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.1335878784083793" CI_START="0.5200612148420677" EFFECT_SIZE="0.7678118839763447" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="53" LOG_CI_END="0.054455193301067024" LOG_CI_START="-0.28394553385861776" LOG_EFFECT_SIZE="-0.11474517027877539" MODIFIED="2010-06-13 13:14:34 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.19877826224421413" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03951279754082957" WEIGHT="79.34205287584456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1258039571298935" CI_START="0.49086051909918116" DF="0" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758587" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2010-06-13 13:14:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9546221586897212" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="20.657947124155427" Z="0.05690338393650061">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.1258039571298935" CI_START="0.49086051909918105" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758588" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2010-06-13 13:14:34 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.3739214959698824" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.13981728514835476" WEIGHT="20.657947124155427"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.336896395279375" CI_END="1.5490882875516305" CI_START="0.8846502443859022" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1706414191194026" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="83" I2="72.74051734890494" I2_Q="84.93931449707706" ID="CMP-002.07" LOG_CI_END="0.19007617031171287" LOG_CI_START="-0.05322839817931798" LOG_EFFECT_SIZE="0.06842388606619744" METHOD="MH" MODIFIED="2011-03-18 12:42:43 +0000" MODIFIED_BY="Hazel Fraser" NO="7" P_CHI2="0.02551610639177948" P_Q="0.00997252913504898" P_Z="0.27029185039816106" Q="6.639804010288396" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1246" TOTAL_2="1255" WEIGHT="200.0" Z="1.1023907459178086">
<NAME>Recurrent ischaemic stroke or intracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8138645741899536" CI_END="1.2597420132090076" CI_START="0.6397486746399355" DF="1" EFFECT_SIZE="0.8977295156887216" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="63" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.10028161360033924" LOG_CI_START="-0.19399060516279146" LOG_EFFECT_SIZE="-0.04685449578122611" MODIFIED="2010-08-22 10:55:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36698020795932595" P_Z="0.5325374669061256" STUDIES="2" TAU2="0.0" TOTAL_1="595" TOTAL_2="590" WEIGHT="100.00000000000001" Z="0.6241372334158839">
<NAME>INR 2.0 - 3. 6 concealed randomisation</NAME>
<DICH_DATA CI_END="1.3065215771534402" CI_START="0.6568264783323874" EFFECT_SIZE="0.9263681592039801" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" LOG_CI_END="0.11611658647918395" LOG_CI_START="-0.18254934802951403" LOG_EFFECT_SIZE="-0.03321638077516506" MODIFIED="2010-08-22 10:55:18 +0100" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.17543784835062867" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.030778438633898182" WEIGHT="95.21640506144611"/>
<DICH_DATA CI_END="3.059523432100449" CI_START="0.03509584236216615" EFFECT_SIZE="0.327683615819209" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48565378369477086" LOG_CI_START="-1.4547443292925097" LOG_EFFECT_SIZE="-0.4845452727988694" ORDER="40" O_E="0.0" SE="1.1397994566942975" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="1.2991428014806157" WEIGHT="4.7835949385538985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4562787889402675" CI_START="1.2076262334379722" DF="0" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" MODIFIED="2011-03-18 12:42:43 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.007739208693857412" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.6632404651896153">
<NAME>INR 3.0 - 4.5 concealed randomisation</NAME>
<DICH_DATA CI_END="3.4562787889402675" CI_START="1.2076262334379722" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" ORDER="41" O_E="0.0" SE="0.268253876563251" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.0719601422912119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" I2_Q="100.0" ID="CMP-002.08" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" METHOD="MH" MODIFIED="2011-03-18 12:42:31 +0000" MODIFIED_BY="Hazel Fraser" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.0015562649609034886" Q="1.7816609378369543E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>Death or dependent at end of follow-up</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2011-03-18 12:42:31 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.0015562649609034886" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.8486711720506848" CI_START="1.3725732884068116" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 13:24:30 +0100" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.26302540659304025" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.06918236451343412" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.860769357116165" CI_END="3.0432904446269675" CI_START="1.6790395471987178" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.260487781462366" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="60" I2="86.27678673612905" I2_Q="87.60395525357961" ID="CMP-002.09" LOG_CI_END="0.4833434024006959" LOG_CI_START="0.22506092539826877" LOG_EFFECT_SIZE="0.35420216389948234" METHOD="MH" MODIFIED="2011-03-18 12:15:12 +0000" MODIFIED_BY="Hazel Fraser" NO="9" P_CHI2="6.97304772248053E-5" P_Q="3.1369755713794856E-4" P_Z="7.6289232273264E-8" Q="16.134178610298576" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2349" TOTAL_2="2358" WEIGHT="300.0" Z="5.375691704262345">
<NAME>Major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0294043664354917" CI_START="0.7905986953514542" DF="0" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" NO="1" P_CHI2="1.0" P_Z="0.32563570148921617" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.9829426023810879">
<NAME>INR 1.4 - 2.8 concealed randomisation</NAME>
<DICH_DATA CI_END="2.0294043664354917" CI_START="0.7905986953514542" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="42" O_E="0.0" SE="0.24049092743726877" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.05783588617963767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.0094419238031715" CI_END="2.9741940460509824" CI_START="1.1394666935424038" DF="1" EFFECT_SIZE="1.840922338287853" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="24" I2="83.35951969118733" ID="CMP-002.09.02" LOG_CI_END="0.47336929988868964" LOG_CI_START="0.056701635332852524" LOG_EFFECT_SIZE="0.26503546761077107" MODIFIED="2010-06-13 13:25:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.014229580527699626" P_Z="0.012652554534881535" STUDIES="2" TAU2="0.0" TOTAL_1="595" TOTAL_2="590" WEIGHT="100.0" Z="2.493401889952664">
<NAME>INR 2.0 - 3.6 concealed randomisation</NAME>
<DICH_DATA CI_END="4.229503623094466" CI_START="1.455741628251214" EFFECT_SIZE="2.4813432835820897" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="18" LOG_CI_END="0.6262894013229263" LOG_CI_START="0.16308430122570522" LOG_EFFECT_SIZE="0.3946868512743158" MODIFIED="2010-06-13 13:25:59 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.27208896869933263" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07403240688786643" WEIGHT="73.37904376236713"/>
<DICH_DATA CI_END="1.3127828342733947" CI_START="0.004358348243632464" EFFECT_SIZE="0.07564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11819288932087291" LOG_CI_START="-2.3606780714175453" LOG_EFFECT_SIZE="-1.1212425910483363" ORDER="43" O_E="0.0" SE="1.4561010729469004" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.1202303346371143" WEIGHT="26.620956237632875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.84459626516066" CI_START="3.9060433973423807" DF="0" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" NO="3" P_CHI2="1.0" P_Z="2.6126581556263546E-7" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="5.149439653022548">
<NAME>INR 3.0 - 4.5 concealed randomisation</NAME>
<DICH_DATA CI_END="20.84459626516066" CI_START="3.9060433973423807" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" ORDER="44" O_E="0.0" SE="0.42719402323321476" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.18249473348618045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.08879478197844" CI_END="7.066322824249404" CI_START="1.7459198710589026" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.512439812178153" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="10" I2="60.697963158529404" I2_Q="55.98446023121293" ID="CMP-002.10" LOG_CI_END="0.8491934742518924" LOG_CI_START="0.24202430789445958" LOG_EFFECT_SIZE="0.545608891073176" METHOD="MH" MODIFIED="2011-03-18 12:15:15 +0000" MODIFIED_BY="Hazel Fraser" NO="10" P_CHI2="0.07852044121723512" P_Q="0.10311364339589801" P_Z="4.2751254430021054E-4" Q="4.543849764210477" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2290" TOTAL_2="2300" WEIGHT="300.0" Z="3.52249038785588">
<NAME>Fatal intracranial or extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.397652647858285" CI_START="0.44569231745816623" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" NO="1" P_CHI2="1.0" P_Z="0.5645061597471045" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.5761613054715299">
<NAME>INR 1.4 - 2.8 concealed randomisation</NAME>
<DICH_DATA CI_END="4.397652647858285" CI_START="0.44569231745816623" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" ORDER="45" O_E="0.0" SE="0.5839896456528686" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.341043906229763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.517978259455019" CI_START="0.8746263264776128" DF="0" EFFECT_SIZE="2.7294776119402986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.9303365272837775" LOG_CI_START="-0.0581774544186959" LOG_EFFECT_SIZE="0.4360795364325408" MODIFIED="2010-06-13 13:28:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08376208650419592" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.0" Z="1.7292627147886983">
<NAME>INR 2.0 - 3.6 concealed randomisation</NAME>
<DICH_DATA CI_END="8.517978259455019" CI_START="0.8746263264776128" EFFECT_SIZE="2.7294776119402986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9303365272837775" LOG_CI_START="-0.0581774544186959" LOG_EFFECT_SIZE="0.4360795364325408" MODIFIED="2010-06-13 13:28:15 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.5806580060751592" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.3371637200191796" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.1099536139226" CI_START="2.3177609108362187" DF="0" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" NO="3" P_CHI2="1.0" P_Z="0.005468500714406536" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.7780571023295555">
<NAME>INR 3.0 - 4.5 concealed randomisation</NAME>
<DICH_DATA CI_END="130.1099536139226" CI_START="2.3177609108362187" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" ORDER="46" O_E="0.0" SE="1.0275133438077466" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="1.0557836717029765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.686747319574149" CI_END="7.077138788069689" CI_START="2.005892486347502" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.767755236188712" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="12" I2="78.66324058428516" I2_Q="77.43239817861985" ID="CMP-002.11" LOG_CI_END="0.8498577125335888" LOG_CI_START="0.3023076515970002" LOG_EFFECT_SIZE="0.5760826820652944" METHOD="MH" MODIFIED="2011-03-18 12:15:19 +0000" MODIFIED_BY="Hazel Fraser" NO="11" P_CHI2="0.030396212562469604" P_Q="0.03528915526252974" P_Z="3.7203540093357905E-5" Q="4.431130998831331" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="4.124193893920419">
<NAME>Intracranial haemorrhage, fatal or non-fatal</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.378765223310153" CI_START="0.8999160889578421" DF="0" EFFECT_SIZE="1.9850746268656716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.6413516602059893" LOG_CI_START="-0.045797983673470634" LOG_EFFECT_SIZE="0.29777683826625934" MODIFIED="2010-06-13 13:30:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08937499457845731" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.0" Z="1.6987038664156184">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="4.378765223310152" CI_START="0.8999160889578423" EFFECT_SIZE="1.9850746268656716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6413516602059892" LOG_CI_START="-0.04579798367347058" LOG_EFFECT_SIZE="0.29777683826625934" MODIFIED="2010-06-13 13:29:51 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.40363510226038973" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1629212957767553" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.15627356689243" CI_START="2.8027777290985583" DF="0" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" MODIFIED="2010-06-13 13:29:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.5179886990746314E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.66042335249295">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="30.15627356689243" CI_START="2.8027777290985583" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" MODIFIED="2010-06-13 13:29:51 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.6060779757272016" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.3673305126615823" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.393186444741601" CI_END="8.235685665558957" CI_START="2.383585226839049" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.430627346698936" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="12" I2="58.21470566168225" I2_Q="56.77999352968647" ID="CMP-002.12" LOG_CI_END="0.91569976238524" LOG_CI_START="0.37723068505860424" LOG_EFFECT_SIZE="0.646465223721922" METHOD="MH" MODIFIED="2011-03-18 12:15:23 +0000" MODIFIED_BY="Hazel Fraser" NO="12" P_CHI2="0.12186518996514817" P_Q="0.12823503834533911" P_Z="2.52482793215133E-6" Q="2.3137432908226625" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="4.706114460808689">
<NAME>Major extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiplatelet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.270869951720418" CI_START="1.413866486670769" DF="0" EFFECT_SIZE="2.9776119402985075" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="0.7973277942634943" LOG_CI_START="0.15040840038038694" LOG_EFFECT_SIZE="0.47386809732194063" MODIFIED="2010-06-13 13:31:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.004087290905286058" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.0" Z="2.871345063868481">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="6.270869951720418" CI_START="1.413866486670769" EFFECT_SIZE="2.9776119402985075" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.7973277942634943" LOG_CI_START="0.15040840038038694" LOG_EFFECT_SIZE="0.47386809732194063" MODIFIED="2010-06-13 13:31:35 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.38000365426958305" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1444027772582368" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.106273460663985" CI_START="2.6927677333495303" DF="0" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="1.4639866053333341" LOG_CI_START="0.4301988946388021" LOG_EFFECT_SIZE="0.9470927499860682" MODIFIED="2010-06-13 13:31:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.2916266325405593E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.591197033566187">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="29.106273460664" CI_START="2.69276773334953" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" LOG_CI_END="1.4639866053333344" LOG_CI_START="0.43019889463880207" LOG_EFFECT_SIZE="0.9470927499860682" MODIFIED="2010-06-13 13:31:35 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.6072520185936674" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.36875501408608374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-01-31 20:36:45 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Vitamin K antagonists versus aspirin only</NAME>
<DICH_OUTCOME CHI2="12.962529838776664" CI_END="1.656307139907308" CI_START="1.0956290497603425" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3471073519983159" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="134" I2="92.28545652401463" I2_Q="92.20466488261748" ID="CMP-003.01" LOG_CI_END="0.21914087399387167" LOG_CI_START="0.03966353871825283" LOG_EFFECT_SIZE="0.12940220635606225" METHOD="MH" MODIFIED="2011-09-18 11:13:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.177905615963095E-4" P_Q="3.41439325690307E-4" P_Z="0.00470968932170639" Q="12.828184868795926" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="2.82624726502005">
<NAME>The composite vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2903052776560777" CI_START="0.7791470835207055" DF="0" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2010-06-13 11:43:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9834978074153713" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.00000000000001" Z="0.02068390601148354">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.2903052776560777" CI_START="0.7791470835207055" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2010-06-13 11:43:39 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.12868457888866022" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.01655972084375182" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.352277230298463" CI_START="1.575819326299508" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 11:43:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.5492851349470596E-5" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="4.321561986097329">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.352277230298463" CI_START="1.575819326299508" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 11:43:39 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.1925710234727316" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.03708359908133535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.148841467368548" CI_END="1.5619115459007833" CI_START="0.9746795085112914" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2338408235654577" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="117" I2="56.27861719686671" I2_Q="73.51754707303512" ID="CMP-003.02" LOG_CI_END="0.19365643529356524" LOG_CI_START="-0.011138164369355545" LOG_EFFECT_SIZE="0.09125913546210486" METHOD="MH" MODIFIED="2011-03-18 12:15:43 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.05748502420644741" P_Q="0.02291223287341404" P_Z="0.08067709440759914" Q="7.552170508962055" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2463" TOTAL_2="2485" WEIGHT="300.0" Z="1.7467708529461974">
<NAME>All death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3015876926993528" CI_START="0.6041858407293877" DF="0" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" NO="1" P_CHI2="1.0" P_Z="0.5394412276723357" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.6136581869405714">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="1.3015876926993528" CI_START="0.6041858407293877" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" ORDER="47" O_E="0.0" SE="0.19578376757433918" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.03833128364560287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.563926489511577" CI_END="1.800001887083594" CI_START="0.8830294921409434" DF="2" EFFECT_SIZE="1.260735797938714" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="49" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.2552729604086184" LOG_CI_START="-0.054024791258016645" LOG_EFFECT_SIZE="0.10062408457530087" MODIFIED="2010-06-13 11:38:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45750708036972443" P_Z="0.20221255138081018" STUDIES="3" TAU2="0.0" TOTAL_1="709" TOTAL_2="717" WEIGHT="99.99999999999999" Z="1.275273296893977">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.9297257332720512" CI_START="0.9179029534104168" EFFECT_SIZE="1.3309023066485752" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.28549558828720983" LOG_CI_START="-0.037203232770740086" LOG_EFFECT_SIZE="0.1241461777582349" MODIFIED="2010-06-13 11:38:47 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.1895548848743663" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03593105437973427" WEIGHT="89.17860996636249"/>
<DICH_DATA CI_END="5.409665747760656" CI_START="0.22941790390348796" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.733170431763185" LOG_CI_START="-0.6393726925242165" LOG_EFFECT_SIZE="0.04689886961948424" ORDER="48" O_E="0.0" SE="0.8062386254044603" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.6500207210940737" WEIGHT="5.730909478307556"/>
<DICH_DATA CI_END="4.009949235794223" CI_START="0.009645453222331667" EFFECT_SIZE="0.19666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6031388746765423" LOG_CI_START="-2.0156773608315786" LOG_EFFECT_SIZE="-0.7062692430775183" ORDER="49" O_E="0.0" SE="1.538305620086906" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.3663841807909605" WEIGHT="5.090480555329946"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.321929350988984" CI_START="1.3144898007026957" DF="0" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" NO="3" P_CHI2="1.0" P_Z="0.004229367160529912" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.860527615964332">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.321929350988984" CI_START="1.3144898007026957" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" ORDER="50" O_E="0.0" SE="0.30364162680585666" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.09219823752930713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6957985373009417" CI_END="2.302372291616319" CI_START="1.0326182435983287" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.541905195489756" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="38" I2="0.0" I2_Q="39.99229963848313" ID="CMP-003.03" LOG_CI_END="0.36217555001567747" LOG_CI_START="0.013939793599150685" LOG_EFFECT_SIZE="0.18805767180741412" METHOD="MH" MODIFIED="2011-03-18 12:15:48 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.42831405157223956" P_Q="0.19673440126513864" P_Z="0.034270223748738504" Q="1.6664527951837713" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1301" TOTAL_2="1324" WEIGHT="200.0" Z="2.116877758630375">
<NAME>Vascular death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.02739224731621909" CI_END="2.070332397979291" CI_START="0.7721022096669488" DF="1" EFFECT_SIZE="1.264321248427346" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="27" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.31604007831632897" LOG_CI_START="-0.11232520464335144" LOG_EFFECT_SIZE="0.10185743683648871" MODIFIED="2010-06-13 13:02:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8685457263982874" P_Z="0.35129145140721685" STUDIES="2" TAU2="0.0" TOTAL_1="650" TOTAL_2="659" WEIGHT="100.0" Z="0.9320872428210855">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="2.1547276890413607" CI_START="0.762785092664753" EFFECT_SIZE="1.2820273631840795" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.3333923925388221" LOG_CI_START="-0.11759780308893258" LOG_EFFECT_SIZE="0.10789729472494479" MODIFIED="2010-06-13 13:02:56 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.2649138733492158" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07017936029288434" WEIGHT="89.46016136292808"/>
<DICH_DATA CI_END="5.409665747760656" CI_START="0.22941790390348796" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.733170431763185" LOG_CI_START="-0.6393726925242165" LOG_EFFECT_SIZE="0.04689886961948424" ORDER="51" O_E="0.0" SE="0.8062386254044603" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.6500207210940737" WEIGHT="10.539838637071922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.512487155597061" CI_START="1.1007848603029535" DF="0" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" NO="2" P_CHI2="1.0" P_Z="0.025963202024573785" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2267617349336666">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.512487155597061" CI_START="1.1007848603029535" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" ORDER="52" O_E="0.0" SE="0.3599109610264315" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.12953589986696948" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.261077027235304" CI_END="1.4006292044593378" CI_START="0.8725733303887956" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1055096967349014" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="117" I2="61.98497019438242" I2_Q="80.70209051298448" ID="CMP-003.04" LOG_CI_END="0.146323177561956" LOG_CI_START="-0.05919806506222167" LOG_EFFECT_SIZE="0.043562556249867164" METHOD="MH" MODIFIED="2011-03-18 12:31:05 +0000" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="0.07203978891786189" P_Q="0.022823286199600057" P_Z="0.4060453001199733" Q="5.181908437661831" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1301" TOTAL_2="1324" WEIGHT="200.0" Z="0.8308731519336932">
<NAME>Vascular death or non-fatal stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.049863918765883815" CI_END="1.211942627956651" CI_START="0.6895366486479696" DF="1" EFFECT_SIZE="0.9141547232470235" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="88" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.08348206128935205" LOG_CI_START="-0.1614426462646337" LOG_EFFECT_SIZE="-0.03898029248764082" MODIFIED="2010-06-13 13:05:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.823300235705859" P_Z="0.5327162884643704" STUDIES="2" TAU2="0.0" TOTAL_1="650" TOTAL_2="659" WEIGHT="100.0" Z="0.6238649431950294">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.2174438688844504" CI_START="0.6704590083443696" EFFECT_SIZE="0.9034634519709147" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="78" LOG_CI_END="0.08544894689225135" LOG_CI_START="-0.1736277696305052" LOG_EFFECT_SIZE="-0.044089411369126925" MODIFIED="2010-06-13 13:05:12 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.15218294573589708" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.023159648972854996" WEIGHT="89.21904486645472"/>
<DICH_DATA CI_END="2.3796110544455" CI_START="0.42245142592714263" EFFECT_SIZE="1.0026315789473683" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.37650597776575734" LOG_CI_START="-0.37422321964813915" LOG_EFFECT_SIZE="0.0011413790588091003" ORDER="53" O_E="0.0" SE="0.4409820467303836" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.19446516553851823" WEIGHT="10.780955133545284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6466870259382267" CI_START="1.0801030786283004" DF="0" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" NO="2" P_CHI2="1.0" P_Z="0.021619623918429972" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2969850266705834">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.6466870259382267" CI_START="1.0801030786283004" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" ORDER="54" O_E="0.0" SE="0.22863996642152237" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.05227623424523488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.374267756462668" CI_END="1.348893628017374" CI_START="0.8557161797312547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0743696301696448" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="125" I2="86.43933156449847" I2_Q="86.37613643267139" ID="CMP-003.05" LOG_CI_END="0.12997770312887694" LOG_CI_START="-0.06767025636927675" LOG_EFFECT_SIZE="0.031153723379800085" METHOD="MH" MODIFIED="2011-09-18 11:13:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.00661640642674155" P_Q="0.006743483805131567" P_Z="0.536662350563796" Q="7.340061760439968" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1187" TOTAL_2="1197" WEIGHT="200.0" Z="0.6178680110208982">
<NAME>Vascular death, non-fatal stroke or non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.230759577708872E-31" CI_END="1.1228134403876229" CI_START="0.6469409031342811" DF="0" EFFECT_SIZE="0.8522874756651526" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" I2="100.0" ID="CMP-003.05.01" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.189135389524328" LOG_EFFECT_SIZE="-0.06941389345283562" MODIFIED="2010-06-13 13:06:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.25579891791346354" STUDIES="1" TAU2="0.0" TOTAL_1="536" TOTAL_2="532" WEIGHT="100.00000000000001" Z="1.1363768049892744">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.1228134403876229" CI_START="0.646940903134281" EFFECT_SIZE="0.8522874756651525" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.1891353895243281" LOG_EFFECT_SIZE="-0.06941389345283568" MODIFIED="2010-06-13 13:06:50 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.14064999884671603" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.019782422175581224" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.585515291433895" CI_START="1.1210673440749552" DF="0" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.41254711065023614" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2010-06-13 13:06:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.012558604782764023" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.4960467531926507">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.5855152914338944" CI_START="1.1210673440749552" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.4125471106502361" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2010-06-13 13:06:50 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.213178307470672" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.04544499077606038" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1185173551299603" CI_END="1.1882427518163634" CI_START="0.6190266068856601" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8576443778241439" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.07490517381404378" LOG_CI_START="-0.2082906838146364" LOG_EFFECT_SIZE="-0.06669275500029632" METHOD="MH" MODIFIED="2011-03-18 12:15:59 +0000" MODIFIED_BY="Hazel Fraser" NO="6" P_CHI2="0.5716328155402313" P_Q="0.5969206680446358" P_Z="0.3559317387688924" Q="0.2796654044963174" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1301" TOTAL_2="1324" WEIGHT="200.0" Z="0.923144843465369">
<NAME>Recurrent ischaemic stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8336143704613795" CI_END="1.1791722782816234" CI_START="0.5689710940762104" DF="1" EFFECT_SIZE="0.8190939758527301" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="59" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.07157726060076444" LOG_CI_START="-0.2449097968774745" LOG_EFFECT_SIZE="-0.08666626813835503" MODIFIED="2010-06-13 13:15:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36122954364810744" P_Z="0.2830799095962363" STUDIES="2" TAU2="0.0" TOTAL_1="650" TOTAL_2="659" WEIGHT="100.00000000000001" Z="1.0734262916097068">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.1335878784083793" CI_START="0.5200612148420677" EFFECT_SIZE="0.7678118839763447" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="53" LOG_CI_END="0.054455193301067024" LOG_CI_START="-0.28394553385861776" LOG_EFFECT_SIZE="-0.11474517027877539" MODIFIED="2010-06-13 13:15:18 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.19877826224421413" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03951279754082957" WEIGHT="90.35861916049436"/>
<DICH_DATA CI_END="3.754054208487166" CI_START="0.44997747974955454" EFFECT_SIZE="1.2997076023391814" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.574500539536492" LOG_CI_START="-0.34680922103629697" LOG_EFFECT_SIZE="0.1138456592500975" ORDER="55" O_E="0.0" SE="0.5411819139173228" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.2928778639512166" WEIGHT="9.641380839505652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1258039571298935" CI_START="0.49086051909918116" DF="0" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758587" LOG_EFFECT_SIZE="0.009240656734912641" NO="2" P_CHI2="1.0" P_Z="0.9546221586897212" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="0.05690338393650061">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.1258039571298935" CI_START="0.49086051909918105" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758588" LOG_EFFECT_SIZE="0.009240656734912641" ORDER="56" O_E="0.0" SE="0.3739214959698824" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.13981728514835476" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.339310157291668" CI_END="1.5281010479378188" CI_START="0.8904056884566115" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1664604003652859" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="90" I2="59.12422372531192" I2_Q="84.54743740210938" ID="CMP-003.07" LOG_CI_END="0.184152073553025" LOG_CI_START="-0.05041207412547582" LOG_EFFECT_SIZE="0.06686999971377458" METHOD="MH" MODIFIED="2011-03-18 12:16:03 +0000" MODIFIED_BY="Hazel Fraser" NO="7" P_CHI2="0.06183439835299187" P_Q="0.010962326495381758" P_Z="0.2637803496029182" Q="6.471418534402231" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1360" TOTAL_2="1382" WEIGHT="200.0" Z="1.1175006272897228">
<NAME>Recurrent ischaemic stroke or intracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9586401091018278" CI_END="1.266137617915468" CI_START="0.6659207632916068" DF="2" EFFECT_SIZE="0.9182305423772862" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="70" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.10248091220039336" LOG_CI_START="-0.1765774436712198" LOG_EFFECT_SIZE="-0.03704826573541323" MODIFIED="2010-08-22 10:55:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6192043190101487" P_Z="0.6027734137426399" STUDIES="3" TAU2="0.0" TOTAL_1="709" TOTAL_2="717" WEIGHT="100.0" Z="0.5204163573907573">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="1.3065215771534402" CI_START="0.6568264783323874" EFFECT_SIZE="0.9263681592039801" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" LOG_CI_END="0.11611658647918395" LOG_CI_START="-0.18254934802951403" LOG_EFFECT_SIZE="-0.03321638077516506" MODIFIED="2010-08-22 10:55:40 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.17543784835062867" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.030778438633898182" WEIGHT="86.19197705883342"/>
<DICH_DATA CI_END="3.079161106976936" CI_START="0.40305594074231743" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4884324125279555" LOG_CI_START="-0.39463467328898705" LOG_EFFECT_SIZE="0.04689886961948424" ORDER="57" O_E="0.0" SE="0.5187179774614455" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.2690683401416928" WEIGHT="9.477807943693048"/>
<DICH_DATA CI_END="3.059523432100449" CI_START="0.03509584236216615" EFFECT_SIZE="0.327683615819209" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48565378369477086" LOG_CI_START="-1.4547443292925097" LOG_EFFECT_SIZE="-0.4845452727988694" ORDER="58" O_E="0.0" SE="1.1397994566942975" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="1.2991428014806157" WEIGHT="4.330214997473538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4562787889402675" CI_START="1.2076262334379722" DF="0" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" NO="2" P_CHI2="1.0" P_Z="0.007739208693857412" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.6632404651896153">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.4562787889402675" CI_START="1.2076262334379722" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" ORDER="59" O_E="0.0" SE="0.268253876563251" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.0719601422912119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" I2_Q="100.0" ID="CMP-003.08" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" METHOD="MH" MODIFIED="2011-09-18 11:14:21 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.0015562649609034886" Q="1.7816609378369543E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>Death or dependent at end of follow-up</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2011-03-18 12:42:19 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.0015562649609034886" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.8486711720506848" CI_START="1.3725732884068116" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 13:24:26 +0100" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.26302540659304025" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.06918236451343412" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.85663277034914" CI_END="3.0131661524287443" CI_START="1.6929663560120933" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2585811743517814" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="64" I2="81.69891930733984" I2_Q="87.5725783543569" ID="CMP-003.09" LOG_CI_END="0.47902308026061863" LOG_CI_START="0.22864832754574513" LOG_EFFECT_SIZE="0.3538357039031819" METHOD="MH" MODIFIED="2011-03-18 12:16:10 +0000" MODIFIED_BY="Hazel Fraser" NO="9" P_CHI2="2.1402900601552588E-4" P_Q="3.201522336797602E-4" P_Z="3.029249151010374E-8" Q="16.09344284782657" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2463" TOTAL_2="2485" WEIGHT="300.0" Z="5.539737761693397">
<NAME>Major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0294043664354917" CI_START="0.7905986953514542" DF="0" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" NO="1" P_CHI2="1.0" P_Z="0.32563570148921617" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.9829426023810879">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="2.0294043664354917" CI_START="0.7905986953514542" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="60" O_E="0.0" SE="0.24049092743726877" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.05783588617963767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.9548300875674" CI_END="2.949624924674329" CI_START="1.2142380134013535" DF="2" EFFECT_SIZE="1.8924974792098601" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="28" I2="66.41381919232867" ID="CMP-003.09.02" LOG_CI_END="0.46976679445254527" LOG_CI_START="0.08430382493952014" LOG_EFFECT_SIZE="0.27703530969603274" MODIFIED="2010-06-13 13:26:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05092441324610919" P_Z="0.004843175654524189" STUDIES="3" TAU2="0.0" TOTAL_1="709" TOTAL_2="717" WEIGHT="99.99999999999999" Z="2.817283487106932">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="4.229503623094466" CI_START="1.455741628251214" EFFECT_SIZE="2.4813432835820897" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="18" LOG_CI_END="0.6262894013229263" LOG_CI_START="0.16308430122570522" LOG_EFFECT_SIZE="0.3946868512743158" MODIFIED="2010-06-13 13:26:29 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.27208896869933263" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07403240688786643" WEIGHT="63.60361908062561"/>
<DICH_DATA CI_END="7.202461201322997" CI_START="0.6892500449384026" EFFECT_SIZE="2.2280701754385963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8574809274735596" LOG_CI_START="-0.16162319690662882" LOG_EFFECT_SIZE="0.34792886528346545" ORDER="61" O_E="0.0" SE="0.5986268073076975" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.3583540544274071" WEIGHT="13.321820754980852"/>
<DICH_DATA CI_END="1.3127828342733947" CI_START="0.004358348243632464" EFFECT_SIZE="0.07564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11819288932087291" LOG_CI_START="-2.3606780714175453" LOG_EFFECT_SIZE="-1.1212425910483363" ORDER="62" O_E="0.0" SE="1.4561010729469004" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.1202303346371143" WEIGHT="23.074560164393528"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.84459626516066" CI_START="3.9060433973423807" DF="0" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" NO="3" P_CHI2="1.0" P_Z="2.6126581556263546E-7" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="5.149439653022548">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="20.84459626516066" CI_START="3.9060433973423807" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" ORDER="63" O_E="0.0" SE="0.42719402323321476" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.18249473348618045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.07005973539013" CI_END="6.898988788007164" CI_START="1.7612383794570738" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4857945769769993" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="10" I2="40.82909952600082" I2_Q="56.00603026538209" ID="CMP-003.10" LOG_CI_END="0.8387854391471198" LOG_CI_START="0.2458181406784811" LOG_EFFECT_SIZE="0.5423017899128004" METHOD="MH" MODIFIED="2011-03-18 12:16:14 +0000" MODIFIED_BY="Hazel Fraser" NO="10" P_CHI2="0.1667385275433969" P_Q="0.10299884856234387" P_Z="3.3708650628237817E-4" Q="4.546077592143822" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2358" TOTAL_2="2367" WEIGHT="300.0" Z="3.584993572919302">
<NAME>Fatal intracranial or extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.397652647858285" CI_START="0.44569231745816623" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" NO="1" P_CHI2="1.0" P_Z="0.5645061597471045" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.5761613054715299">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="4.397652647858285" CI_START="0.44569231745816623" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" ORDER="64" O_E="0.0" SE="0.5839896456528686" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.341043906229763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0021464249911960012" CI_END="8.043847842460844" CI_START="0.9434334912449694" DF="1" EFFECT_SIZE="2.7547841028030033" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="0.9054638468818614" LOG_CI_START="-0.025288710658994795" LOG_EFFECT_SIZE="0.44008756811143335" MODIFIED="2010-06-13 13:28:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9630476174681828" P_Z="0.06381661866676672" STUDIES="2" TAU2="0.0" TOTAL_1="604" TOTAL_2="599" WEIGHT="99.99999999999999" Z="1.8534588523101956">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="8.517978259455019" CI_START="0.8746263264776128" EFFECT_SIZE="2.7294776119402986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9303365272837775" LOG_CI_START="-0.0581774544186959" LOG_EFFECT_SIZE="0.4360795364325408" MODIFIED="2010-06-13 13:28:47 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.5806580060751592" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.3371637200191796" WEIGHT="88.85393285618348"/>
<DICH_DATA CI_END="71.31099580520645" CI_START="0.12257605850615069" EFFECT_SIZE="2.9565217391304346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8531565010907625" LOG_CI_START="-0.9115943477134756" LOG_EFFECT_SIZE="0.4707810766886434" ORDER="65" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-Garde-1983" TOTAL_1="68" TOTAL_2="67" VAR="2.637468030690537" WEIGHT="11.146067143816513"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.1099536139226" CI_START="2.3177609108362187" DF="0" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-003.10.03" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" NO="3" P_CHI2="1.0" P_Z="0.005468500714406536" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.7780571023295555">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="130.1099536139226" CI_START="2.3177609108362187" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" ORDER="66" O_E="0.0" SE="1.0275133438077466" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="1.0557836717029765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.3300136048473705" CI_END="6.229528197116705" CI_START="1.864905261585731" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4084424466315424" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="13" I2="68.40449128784734" I2_Q="81.10332649878413" ID="CMP-003.11" LOG_CI_END="0.7944551559452329" LOG_CI_START="0.27065677425966395" LOG_EFFECT_SIZE="0.5325559651024484" METHOD="MH" MODIFIED="2011-03-18 12:16:21 +0000" MODIFIED_BY="Hazel Fraser" NO="11" P_CHI2="0.042213900761486345" P_Q="0.02142443882925571" P_Z="6.734761415368755E-5" Q="5.29193669952363" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1301" TOTAL_2="1324" WEIGHT="200.0" Z="3.985466728606069">
<NAME>Intracranial haemorrhage, fatal or non-fatal</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0025128421187381" CI_END="3.744242197879857" CI_START="0.8328137445620944" DF="1" EFFECT_SIZE="1.765858534923942" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.2506543570481787" ID="CMP-003.11.01" LOG_CI_END="0.5733639334957424" LOG_CI_START="-0.07945211594442649" LOG_EFFECT_SIZE="0.24695590877565804" MODIFIED="2010-06-13 13:30:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3167034947213635" P_Z="0.13810568118105043" STUDIES="2" TAU2="0.0" TOTAL_1="650" TOTAL_2="659" WEIGHT="100.0" Z="1.4828823138914264">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="4.378765223310152" CI_START="0.8999160889578423" EFFECT_SIZE="1.9850746268656716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6413516602059892" LOG_CI_START="-0.04579798367347058" LOG_EFFECT_SIZE="0.29777683826625934" MODIFIED="2010-06-13 13:30:34 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.40363510226038973" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1629212957767553" WEIGHT="86.4183441924654"/>
<DICH_DATA CI_END="9.017539181230221" CI_START="0.015264891126810612" EFFECT_SIZE="0.3710144927536232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9550880380051068" LOG_CI_START="-1.8163062888559185" LOG_EFFECT_SIZE="-0.43060912542540575" ORDER="67" O_E="0.0" SE="1.6279307462213353" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="2.6501585144927535" WEIGHT="13.581655807534602"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.15627356689243" CI_START="2.8027777290985583" DF="0" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" NO="2" P_CHI2="1.0" P_Z="2.5179886990746314E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.66042335249295">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="30.15627356689243" CI_START="2.8027777290985583" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" ORDER="68" O_E="0.0" SE="0.6060779757272016" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.3673305126615823" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5736378721500364" CI_END="7.261883083528458" CI_START="2.3732587424775016" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.151424757216899" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="15" I2="22.288989385706195" I2_Q="59.814340599190686" ID="CMP-003.12" LOG_CI_END="0.8610492524827974" LOG_CI_START="0.37534508937808314" LOG_EFFECT_SIZE="0.6181971709304404" METHOD="MH" MODIFIED="2011-03-18 12:16:26 +0000" MODIFIED_BY="Hazel Fraser" NO="12" P_CHI2="0.27614795529637615" P_Q="0.11468489783106106" P_Z="6.062134204514125E-7" Q="2.488449897079107" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1301" TOTAL_2="1324" WEIGHT="200.0" Z="4.989227115630027">
<NAME>Major extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.057943628242129E-6" CI_END="5.681602500153628" CI_START="1.5587892317205316" DF="1" EFFECT_SIZE="2.9759739239710963" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="12" I2="0.0" ID="CMP-003.12.01" LOG_CI_END="0.7544708460661514" LOG_CI_START="0.19278739697919395" LOG_EFFECT_SIZE="0.4736291215226727" MODIFIED="2010-06-13 13:32:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9975986569174878" P_Z="9.48387912111306E-4" STUDIES="2" TAU2="0.0" TOTAL_1="650" TOTAL_2="659" WEIGHT="100.0" Z="3.3054063520040384">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="6.270869951720418" CI_START="1.413866486670769" EFFECT_SIZE="2.9776119402985075" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.7973277942634943" LOG_CI_START="0.15040840038038694" LOG_EFFECT_SIZE="0.47386809732194063" MODIFIED="2010-06-13 13:32:16 +0100" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.38000365426958305" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1444027772582368" WEIGHT="76.0933081998115"/>
<DICH_DATA CI_END="10.928799313245092" CI_START="0.807537599920367" EFFECT_SIZE="2.9707602339181287" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0385724510370216" LOG_CI_START="-0.09283724725349062" LOG_EFFECT_SIZE="0.4728676018917654" ORDER="69" O_E="0.0" SE="0.6645956573441782" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.44168738776074046" WEIGHT="23.906691800188504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.106273460663985" CI_START="2.6927677333495303" DF="0" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" I2="0.0" ID="CMP-003.12.02" LOG_CI_END="1.4639866053333341" LOG_CI_START="0.4301988946388021" LOG_EFFECT_SIZE="0.9470927499860682" NO="2" P_CHI2="1.0" P_Z="3.2916266325405593E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.591197033566187">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="29.106273460664" CI_START="2.69276773334953" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" LOG_CI_END="1.4639866053333344" LOG_CI_START="0.43019889463880207" LOG_EFFECT_SIZE="0.9470927499860682" ORDER="70" O_E="0.0" SE="0.6072520185936674" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.36875501408608374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-01-31 20:36:58 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Vitamin K antagonists versus aspirin, including intracranial artery stenosis</NAME>
<DICH_OUTCOME CHI2="13.990446925432693" CI_END="1.5306414695142647" CI_START="1.1117911167995633" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3045127783241486" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="211" I2="78.55679653416635" I2_Q="91.56281067393915" ID="CMP-004.01" LOG_CI_END="0.18487347544922805" LOG_CI_START="0.04602319970762877" LOG_EFFECT_SIZE="0.11544833757842841" METHOD="MH" MODIFIED="2011-09-18 11:15:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0029181993364353342" P_Q="5.75907572171519E-4" P_Z="0.0011170319611223888" Q="11.852288260394904" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1490" TOTAL_2="1491" WEIGHT="200.0" Z="3.259260127791744">
<NAME>The composite vascular death, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0603717890698015" CI_END="1.3193203070123787" CI_START="0.9248511530139757" DF="2" EFFECT_SIZE="1.1046152756209515" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="175" I2="2.9301405401720033" ID="CMP-004.01.01" LOG_CI_END="0.1203502471613983" LOG_CI_START="-0.033928157667784696" LOG_EFFECT_SIZE="0.04321104474680679" MODIFIED="2010-06-13 20:06:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3569407470835112" P_Z="0.2722427341080933" STUDIES="3" TAU2="0.0" TOTAL_1="839" TOTAL_2="826" WEIGHT="100.0" Z="1.0979124593861478">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="95.60761657277001" CI_START="0.26148544327503137" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9804924916878397" LOG_CI_START="-0.5825524830158021" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2010-06-13 20:01:24 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="1.5055453054181618" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.266666666666666" WEIGHT="0.2823503357648275"/>
<DICH_DATA CI_END="1.2903052776560777" CI_START="0.7791470835207055" EFFECT_SIZE="1.0026652452025586" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="98" LOG_CI_END="0.1106924736453147" LOG_CI_START="-0.10838055063064823" LOG_EFFECT_SIZE="0.0011559615073332146" MODIFIED="2010-06-13 19:59:51 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.12868457888866022" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.01655972084375182" WEIGHT="55.54793422117924"/>
<DICH_DATA CI_END="1.5522252048980452" CI_START="0.9399974202460638" EFFECT_SIZE="1.20792702107581" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="77" LOG_CI_END="0.19095473119351558" LOG_CI_START="-0.026873338287999794" LOG_EFFECT_SIZE="0.0820406964527579" MODIFIED="2010-06-13 20:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.1279532862797761" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.016372043469794335" WEIGHT="44.16971544305593"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.352277230298463" CI_START="1.575819326299508" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 19:59:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.5492851349470596E-5" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="4.321561986097329">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.352277230298463" CI_START="1.575819326299508" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" LOG_CI_END="0.5253399272047284" LOG_CI_START="0.19750642248782166" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 19:59:51 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.1925710234727316" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.03708359908133535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.208234427924477" CI_END="1.6639052296828107" CI_START="1.07204695644148" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3355839686401298" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="130" I2="50.852844156761" I2_Q="76.09159452399012" ID="CMP-004.02" LOG_CI_END="0.22112858673962296" LOG_CI_START="0.03021380818959226" LOG_EFFECT_SIZE="0.12567119746460764" METHOD="MH" MODIFIED="2011-03-18 12:16:45 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.057481380847245966" P_Q="0.015258355260214795" P_Z="0.00987075717281501" Q="8.365258829188068" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2766" TOTAL_2="2779" WEIGHT="300.0" Z="2.580324297525292">
<NAME>All death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3015876926993528" CI_START="0.6041858407293877" DF="0" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5394412276723357" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.6136581869405714">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="1.3015876926993528" CI_START="0.6041858407293877" EFFECT_SIZE="0.8867924528301887" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" LOG_CI_END="0.1144734334306246" LOG_CI_START="-0.21882945676076773" LOG_EFFECT_SIZE="-0.05217801166507157" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.19578376757433918" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.03833128364560287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.826987495000961" CI_END="1.9958546715120429" CI_START="1.078107078754611" DF="4" EFFECT_SIZE="1.4668827661141133" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="62" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.3001289148781033" LOG_CI_START="0.03266189758799337" LOG_EFFECT_SIZE="0.16639540623304833" MODIFIED="2010-06-13 20:08:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4299267248876184" P_Z="0.014742305276548157" STUDIES="5" TAU2="0.0" TOTAL_1="1012" TOTAL_2="1011" WEIGHT="100.0" Z="2.438648374023242">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="19.617776589893595" CI_START="0.20389670468878027" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.292649784417128" LOG_CI_START="-0.6905897930891655" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-06-13 20:07:48 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="1.164964745021435" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="1.3571428571428572" WEIGHT="1.5945458021728642"/>
<DICH_DATA CI_END="1.9297257332720512" CI_START="0.9179029534104168" EFFECT_SIZE="1.3309023066485752" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.28549558828720983" LOG_CI_START="-0.037203232770740086" LOG_EFFECT_SIZE="0.1241461777582349" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.1895548848743663" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03593105437973427" WEIGHT="70.42278688847347"/>
<DICH_DATA CI_END="5.409665747760656" CI_START="0.22941790390348796" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.733170431763185" LOG_CI_START="-0.6393726925242165" LOG_EFFECT_SIZE="0.04689886961948424" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.8062386254044603" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.6500207210940737" WEIGHT="4.52559887421676"/>
<DICH_DATA CI_END="4.009949235794223" CI_START="0.009645453222331667" EFFECT_SIZE="0.19666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6031388746765423" LOG_CI_START="-2.0156773608315786" LOG_EFFECT_SIZE="-0.7062692430775183" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="1.538305620086906" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.3663841807909605" WEIGHT="4.019863366822347"/>
<DICH_DATA CI_END="4.356360597414337" CI_START="1.173140765861101" EFFECT_SIZE="2.260668973471742" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" LOG_CI_END="0.6391238212640756" LOG_CI_START="0.06935012649645597" LOG_EFFECT_SIZE="0.35423697388026576" MODIFIED="2010-06-13 20:08:32 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.3346878887317761" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.11201598286373372" WEIGHT="19.43720506831456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.321929350988984" CI_START="1.3144898007026957" DF="0" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.004229367160529912" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.860527615964332">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.321929350988984" CI_START="1.3144898007026957" EFFECT_SIZE="2.3835125448028673" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6356776633509216" LOG_CI_START="0.11875722070809243" LOG_EFFECT_SIZE="0.377217442029507" MODIFIED="2010-06-13 20:00:01 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.30364162680585666" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.09219823752930713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.019101452807239" CI_END="2.2998271109120556" CI_START="1.1309880530761536" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.612785474445433" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="47" I2="0.0" I2_Q="11.822355892532425" ID="CMP-004.03" LOG_CI_END="0.3616951892353985" LOG_CI_START="0.05345801738300986" LOG_EFFECT_SIZE="0.20757660330920416" METHOD="MH" MODIFIED="2011-03-18 12:16:48 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.732245541097309" P_Q="0.2869079896890121" P_Z="0.008295429384510949" Q="1.1340742998091873" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1604" TOTAL_2="1618" WEIGHT="200.0" Z="2.639802747178271">
<NAME>Vascular death</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8560701877932109" CI_END="2.1603197608589935" CI_START="0.9458899164414871" DF="3" EFFECT_SIZE="1.429484060102038" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.33451803823361453" LOG_CI_START="-0.024159404257733875" LOG_EFFECT_SIZE="0.15517931698794035" MODIFIED="2010-06-13 20:09:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8360140901623971" P_Z="0.08989918506286662" STUDIES="4" TAU2="0.0" TOTAL_1="953" TOTAL_2="953" WEIGHT="100.00000000000001" Z="1.6959297486304783">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-13 20:09:23 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="1.3672253205410676"/>
<DICH_DATA CI_END="2.1547276890413607" CI_START="0.762785092664753" EFFECT_SIZE="1.2820273631840795" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.3333923925388221" LOG_CI_START="-0.11759780308893258" LOG_EFFECT_SIZE="0.10789729472494479" MODIFIED="2010-06-13 20:00:08 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.2649138733492158" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07017936029288434" WEIGHT="65.87260870202357"/>
<DICH_DATA CI_END="5.409665747760656" CI_START="0.22941790390348796" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.733170431763185" LOG_CI_START="-0.6393726925242165" LOG_EFFECT_SIZE="0.04689886961948424" MODIFIED="2010-06-13 20:00:08 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.8062386254044603" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.6500207210940737" WEIGHT="7.760847462656351"/>
<DICH_DATA CI_END="4.03665966444691" CI_START="0.8296808496034117" EFFECT_SIZE="1.8300653594771241" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6060221350721002" LOG_CI_START="-0.08108893402285947" LOG_EFFECT_SIZE="0.2624666005246204" MODIFIED="2010-06-13 20:09:41 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.40361244324102613" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.16290300433899052" WEIGHT="24.999318514779027"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.512487155597061" CI_START="1.1007848603029535" DF="0" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" MODIFIED="2010-06-13 20:00:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.025963202024573785" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2267617349336666">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="4.512487155597061" CI_START="1.1007848603029535" EFFECT_SIZE="2.228739002932551" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.654415978733934" LOG_CI_START="0.04170244784265325" LOG_EFFECT_SIZE="0.3480592132882936" MODIFIED="2010-06-13 20:00:08 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.3599109610264315" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.12953589986696948" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.870835488014013" CI_END="1.2970570379841282" CI_START="0.8900930016440348" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.074477264646774" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="178" I2="31.866597042849165" I2_Q="80.380825309629" ID="CMP-004.04" LOG_CI_END="0.11295907457066463" LOG_CI_START="-0.05056461359030897" LOG_EFFECT_SIZE="0.031197230490177825" METHOD="MH" MODIFIED="2011-03-18 12:18:14 +0000" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="0.2090043400207967" P_Q="0.023966545145433282" P_Z="0.4545517292083636" Q="5.097054365343899" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1604" TOTAL_2="1618" WEIGHT="200.0" Z="0.7478482031050022">
<NAME>Vascular death or non-fatal stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7482944528255233" CI_END="1.1786918744267825" CI_START="0.7766248179740507" DF="3" EFFECT_SIZE="0.9567660959838578" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="149" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.07140028963669104" LOG_CI_START="-0.10978873516910649" LOG_EFFECT_SIZE="-0.019194222766207737" MODIFIED="2010-06-13 20:11:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8617900445781239" P_Z="0.6779539393341288" STUDIES="4" TAU2="0.0" TOTAL_1="953" TOTAL_2="953" WEIGHT="100.00000000000001" Z="0.41525677808937805">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-13 20:10:17 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.332850552779965"/>
<DICH_DATA CI_END="1.2174438688844504" CI_START="0.6704590083443696" EFFECT_SIZE="0.9034634519709147" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="78" LOG_CI_END="0.08544894689225135" LOG_CI_START="-0.1736277696305052" LOG_EFFECT_SIZE="-0.044089411369126925" MODIFIED="2010-06-13 20:00:16 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.15218294573589708" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.023159648972854996" WEIGHT="52.11916071395047"/>
<DICH_DATA CI_END="2.3796110544455" CI_START="0.42245142592714263" EFFECT_SIZE="1.0026315789473683" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.37650597776575734" LOG_CI_START="-0.37422321964813915" LOG_EFFECT_SIZE="0.0011413790588091003" MODIFIED="2010-06-13 20:00:16 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.4409820467303836" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.19446516553851823" WEIGHT="6.297919172932118"/>
<DICH_DATA CI_END="1.366118229160981" CI_START="0.7329148471175148" EFFECT_SIZE="1.0006239718645413" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="61" LOG_CI_END="0.13548828649800088" LOG_CI_START="-0.13494648044102886" LOG_EFFECT_SIZE="2.709030284860128E-4" MODIFIED="2010-06-13 20:11:11 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.15885472077367224" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.025234822312081375" WEIGHT="41.25006956033746"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6466870259382267" CI_START="1.0801030786283004" DF="0" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" MODIFIED="2010-06-13 20:00:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.021619623918429972" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.2969850266705834">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.6466870259382267" CI_START="1.0801030786283004" EFFECT_SIZE="1.6907675194660734" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="29" LOG_CI_END="0.4227025884701365" LOG_CI_START="0.033465203952951064" LOG_EFFECT_SIZE="0.22808389621154376" MODIFIED="2010-06-13 20:00:16 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.22863996642152237" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.05227623424523488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.567995436190005" CI_END="1.2616126204280553" CI_START="0.8842382404997292" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0562036374106825" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="195" I2="64.9859757472743" I2_Q="84.92824497680098" ID="CMP-004.05" LOG_CI_END="0.10092602476825398" LOG_CI_START="-0.053430707164934886" LOG_EFFECT_SIZE="0.02374765880165955" METHOD="MH" MODIFIED="2011-09-18 11:15:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.03562183990430756" P_Q="0.009999865481385761" P_Z="0.5464569648306218" Q="6.634927375483228" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1490" TOTAL_2="1491" WEIGHT="200.0" Z="0.6030777587147217">
<NAME>Vascular death, non-fatal stroke or non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8574843105342613" CI_END="1.1300182103220378" CI_START="0.7612765341877612" DF="2" EFFECT_SIZE="0.927500052141787" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="162" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.05308544222558802" LOG_CI_START="-0.11845755682147019" LOG_EFFECT_SIZE="-0.032686057297941065" MODIFIED="2010-06-13 20:12:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3950503666701123" P_Z="0.45511856809343965" STUDIES="3" TAU2="0.0" TOTAL_1="839" TOTAL_2="826" WEIGHT="100.0" Z="0.7469088853110584">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="95.60761657277001" CI_START="0.26148544327503137" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9804924916878397" LOG_CI_START="-0.5825524830158021" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2010-06-13 20:11:42 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="1.5055453054181618" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.266666666666666" WEIGHT="0.30496772619112167"/>
<DICH_DATA CI_END="1.1228134403876229" CI_START="0.646940903134281" EFFECT_SIZE="0.8522874756651525" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="92" LOG_CI_END="0.05030760261865674" LOG_CI_START="-0.1891353895243281" LOG_EFFECT_SIZE="-0.06941389345283568" MODIFIED="2010-06-13 20:00:22 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.14064999884671603" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.019782422175581224" WEIGHT="56.32422664395727"/>
<DICH_DATA CI_END="1.3251487722237791" CI_START="0.7494189170513026" EFFECT_SIZE="0.9965397923875432" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="70" LOG_CI_END="0.1222646385210005" LOG_CI_START="-0.12527534851563452" LOG_EFFECT_SIZE="-0.0015053549973170295" MODIFIED="2010-06-13 20:12:02 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.14540621372801732" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.02114296699071785" WEIGHT="43.37080562985161"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.585515291433895" CI_START="1.1210673440749552" DF="0" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.41254711065023614" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2010-06-13 20:00:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.012558604782764023" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.4960467531926507">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.5855152914338944" CI_START="1.1210673440749552" EFFECT_SIZE="1.7025089605734767" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.4125471106502361" LOG_CI_START="0.04963170205230192" LOG_EFFECT_SIZE="0.231089406351269" MODIFIED="2010-06-13 20:00:22 +0100" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.213178307470672" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.04544499077606038" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1298324769498873" CI_END="1.0734744266555567" CI_START="0.6677794828865643" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8466665208474933" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="130" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.03079170271295894" LOG_CI_START="-0.17536692850721355" LOG_EFFECT_SIZE="-0.0722876128971273" METHOD="MH" MODIFIED="2011-03-18 12:16:59 +0000" MODIFIED_BY="Hazel Fraser" NO="6" P_CHI2="0.7698777598049582" P_Q="0.5907544496152628" P_Z="0.16929072839561438" Q="0.2891677096131487" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1604" TOTAL_2="1618" WEIGHT="200.0" Z="1.3744864036803834">
<NAME>Recurrent ischaemic stroke</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8388631400841956" CI_END="1.0613927816813566" CI_START="0.6427008089335577" DF="2" EFFECT_SIZE="0.8259285679662902" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="116" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.025876129754064666" LOG_CI_START="-0.1919911534657331" LOG_EFFECT_SIZE="-0.08305751185583424" MODIFIED="2010-06-13 20:12:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6574204274584252" P_Z="0.13507278527245106" STUDIES="4" TAU2="0.0" TOTAL_1="953" TOTAL_2="953" WEIGHT="100.0" Z="1.4943935544348024">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-13 20:12:29 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.0" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1335878784083793" CI_START="0.5200612148420677" EFFECT_SIZE="0.7678118839763447" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="53" LOG_CI_END="0.054455193301067024" LOG_CI_START="-0.28394553385861776" LOG_EFFECT_SIZE="-0.11474517027877539" MODIFIED="2010-06-13 20:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.19877826224421413" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.03951279754082957" WEIGHT="45.555854804377304"/>
<DICH_DATA CI_END="3.754054208487166" CI_START="0.44997747974955454" EFFECT_SIZE="1.2997076023391814" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.574500539536492" LOG_CI_START="-0.34680922103629697" LOG_EFFECT_SIZE="0.1138456592500975" MODIFIED="2010-06-13 20:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.5411819139173228" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.2928778639512166" WEIGHT="4.86086827929589"/>
<DICH_DATA CI_END="1.1755966528727115" CI_START="0.5900712906760023" EFFECT_SIZE="0.83287804285801" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="57" LOG_CI_END="0.07025834089072383" LOG_CI_START="-0.22909551500733666" LOG_EFFECT_SIZE="-0.0794185870583064" MODIFIED="2010-06-13 20:12:51 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.17584193678000595" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.030920386730543606" WEIGHT="49.58327691632681"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1258039571298935" CI_START="0.49086051909918116" DF="0" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758587" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2010-06-13 20:00:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9546221586897212" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="0.05690338393650061">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="2.1258039571298935" CI_START="0.49086051909918105" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32752321114568406" LOG_CI_START="-0.3090418976758588" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2010-06-13 20:00:28 +0100" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.3739214959698824" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.13981728514835476" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.617928447903275" CI_END="1.2935927278210164" CI_START="0.8495235181596917" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0483021726602986" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="148" I2="48.01375340767887" I2_Q="87.33659378353782" ID="CMP-004.07" LOG_CI_END="0.11179756543569679" LOG_CI_START="-0.07082459364532039" LOG_EFFECT_SIZE="0.02048648589518821" METHOD="MH" MODIFIED="2011-03-18 12:17:03 +0000" MODIFIED_BY="Hazel Fraser" NO="7" P_CHI2="0.08681392631281215" P_Q="0.004952335404986852" P_Z="0.6601282820921075" Q="7.896769501873983" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1663" TOTAL_2="1676" WEIGHT="199.99999999999997" Z="0.43973606189316405">
<NAME>Recurrent ischaemic stroke or intracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.653008779687861" CI_END="1.130462797694517" CI_START="0.71027174192044" DF="4" EFFECT_SIZE="0.8960668393009187" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="128" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.05325627475582956" LOG_CI_START="-0.14857546334025729" LOG_EFFECT_SIZE="-0.04765959429221387" MODIFIED="2010-08-22 10:55:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7992348912164351" P_Z="0.35463659539814263" STUDIES="5" TAU2="0.0" TOTAL_1="1012" TOTAL_2="1011" WEIGHT="99.99999999999997" Z="0.9256332944629287">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-13 20:13:26 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.3867270161262924"/>
<DICH_DATA CI_END="1.3065215771534402" CI_START="0.6568264783323874" EFFECT_SIZE="0.9263681592039801" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" LOG_CI_END="0.11611658647918395" LOG_CI_START="-0.18254934802951403" LOG_EFFECT_SIZE="-0.03321638077516506" MODIFIED="2010-08-22 10:55:56 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.17543784835062867" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.030778438633898182" WEIGHT="46.58105183004331"/>
<DICH_DATA CI_END="3.079161106976936" CI_START="0.40305594074231743" EFFECT_SIZE="1.1140350877192982" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4884324125279555" LOG_CI_START="-0.39463467328898705" LOG_EFFECT_SIZE="0.04689886961948424" MODIFIED="2010-06-13 20:00:34 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.5187179774614455" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.2690683401416928" WEIGHT="5.122127118154046"/>
<DICH_DATA CI_END="3.059523432100449" CI_START="0.03509584236216615" EFFECT_SIZE="0.327683615819209" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48565378369477086" LOG_CI_START="-1.4547443292925097" LOG_EFFECT_SIZE="-0.4845452727988694" MODIFIED="2010-06-13 20:00:34 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.1397994566942975" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="1.2991428014806157" WEIGHT="2.3401942514308973"/>
<DICH_DATA CI_END="1.1950494913428122" CI_START="0.6073217725037103" EFFECT_SIZE="0.8519269776876268" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="58" LOG_CI_END="0.07738589136952105" LOG_CI_START="-0.21658114912818013" LOG_EFFECT_SIZE="-0.06959762887932953" MODIFIED="2010-06-13 20:14:21 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.1726776947486687" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.02981758626371441" WEIGHT="45.569899784245436"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4562787889402675" CI_START="1.2076262334379722" DF="0" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" MODIFIED="2010-06-13 20:00:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.007739208693857412" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.6632404651896153">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.4562787889402675" CI_START="1.2076262334379722" EFFECT_SIZE="2.043010752688172" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" LOG_CI_END="0.5386087661029005" LOG_CI_START="0.0819325386948871" LOG_EFFECT_SIZE="0.31027065239889384" MODIFIED="2010-06-13 20:00:34 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.268253876563251" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.0719601422912119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" I2_Q="100.0" ID="CMP-004.08" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" METHOD="MH" MODIFIED="2011-09-18 11:15:57 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.0015562649609034886" Q="1.7816609378369543E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>Death or dependent at end of follow-up</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8486711720506848" CI_START="1.3725732884068116" DF="0" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2011-03-18 12:42:05 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.0015562649609034886" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.16398185803863">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="3.8486711720506848" CI_START="1.3725732884068116" EFFECT_SIZE="2.2983870967741935" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" LOG_CI_END="0.585310806842986" LOG_CI_START="0.1375355428495643" LOG_EFFECT_SIZE="0.3614231748462751" MODIFIED="2010-06-13 20:00:42 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.26302540659304025" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.06918236451343412" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.09995011127097" CI_END="3.0115520670452645" CI_START="1.7623130866655339" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.303757282989792" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="73" I2="72.85061744578327" I2_Q="87.53545193362555" ID="CMP-004.09" LOG_CI_END="0.47879037613518033" LOG_CI_START="0.24608306623966944" LOG_EFFECT_SIZE="0.36243672118742487" METHOD="MH" MODIFIED="2011-03-18 12:17:10 +0000" MODIFIED_BY="Hazel Fraser" NO="9" P_CHI2="0.001161396868356146" P_Q="3.279180137139015E-4" P_Z="1.0266879559591296E-9" Q="16.045507541467863" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2766" TOTAL_2="2779" WEIGHT="300.0" Z="6.105205036499296">
<NAME>Major bleeding complication</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0294043664354917" CI_START="0.7905986953514542" DF="0" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32563570148921617" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.9829426023810879">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="2.0294043664354917" CI_START="0.7905986953514542" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.30736859046092285" LOG_CI_START="-0.10204390666662744" LOG_EFFECT_SIZE="0.1026623418971477" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.24049092743726877" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.05783588617963767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.007273235341356" CI_END="3.025585728659448" CI_START="1.420487409473046" DF="4" EFFECT_SIZE="2.073115152094084" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="37" I2="33.41404921508111" ID="CMP-004.09.02" LOG_CI_END="0.4808094629885806" LOG_CI_START="0.1524373886956226" LOG_EFFECT_SIZE="0.3166234258421016" MODIFIED="2010-06-13 20:15:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19860588798935863" P_Z="1.570306915964251E-4" STUDIES="5" TAU2="0.0" TOTAL_1="1012" TOTAL_2="1011" WEIGHT="100.0" Z="3.7796789672106175">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-13 20:15:09 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="1.314107935878131"/>
<DICH_DATA CI_END="4.229503623094466" CI_START="1.455741628251214" EFFECT_SIZE="2.4813432835820897" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="18" LOG_CI_END="0.6262894013229263" LOG_CI_START="0.16308430122570522" LOG_EFFECT_SIZE="0.3946868512743158" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.27208896869933263" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.07403240688786643" WEIGHT="47.485068784090664"/>
<DICH_DATA CI_END="7.202461201322997" CI_START="0.6892500449384026" EFFECT_SIZE="2.2280701754385963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8574809274735596" LOG_CI_START="-0.16162319690662882" LOG_EFFECT_SIZE="0.34792886528346545" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.5986268073076975" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.3583540544274071" WEIGHT="9.945779564488426"/>
<DICH_DATA CI_END="1.3127828342733947" CI_START="0.004358348243632464" EFFECT_SIZE="0.07564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11819288932087291" LOG_CI_START="-2.3606780714175453" LOG_EFFECT_SIZE="-1.1212425910483363" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.4561010729469004" STUDY_ID="STD-SWAT-1998" TOTAL_1="59" TOTAL_2="58" VAR="2.1202303346371143" WEIGHT="17.226961176217515"/>
<DICH_DATA CI_END="5.459962892380696" CI_START="1.2225542805763625" EFFECT_SIZE="2.5836216839677046" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.7371896911133337" LOG_CI_START="0.08726815060257131" LOG_EFFECT_SIZE="0.4122289208579525" MODIFIED="2010-06-13 20:15:38 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.3817671300595331" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.14574614159389246" WEIGHT="24.02808253932526"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.84459626516066" CI_START="3.9060433973423807" DF="0" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" I2="0.0" ID="CMP-004.09.03" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.6126581556263546E-7" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="5.149439653022548">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="20.84459626516066" CI_START="3.9060433973423807" EFFECT_SIZE="9.023297491039427" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="6" LOG_CI_END="1.3189934877803335" LOG_CI_START="0.5917370641237827" LOG_EFFECT_SIZE="0.9553652759520581" MODIFIED="2010-06-13 20:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.42719402323321476" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.18249473348618045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.114102694258566" CI_END="6.331261132047319" CI_START="1.756510847635892" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3348056701488042" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="11" I2="2.2311381112206727" I2_Q="55.9458740901024" ID="CMP-004.10" LOG_CI_END="0.8014902263106692" LOG_CI_START="0.2446508361968531" LOG_EFFECT_SIZE="0.5230705312537612" METHOD="MH" MODIFIED="2011-03-18 12:17:16 +0000" MODIFIED_BY="Hazel Fraser" NO="10" P_CHI2="0.4021145978867068" P_Q="0.10331903537925047" P_Z="2.3122206812881845E-4" Q="4.539869895706322" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2661" TOTAL_2="2661" WEIGHT="300.0" Z="3.682208625442454">
<NAME>Fatal intracranial or extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.397652647858285" CI_START="0.44569231745816623" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2010-06-13 20:00:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5645061597471045" STUDIES="1" TAU2="0.0" TOTAL_1="1103" TOTAL_2="1103" WEIGHT="100.0" Z="0.5761613054715299">
<NAME>INR 1.4 - 2.8</NAME>
<DICH_DATA CI_END="4.397652647858285" CI_START="0.44569231745816623" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6432209232794567" LOG_CI_START="-0.3509648519229806" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2010-06-13 20:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.5839896456528686" STUDY_ID="STD-WARSS-2001" TOTAL_1="1103" TOTAL_2="1103" VAR="0.341043906229763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07864845560446522" CI_END="6.695502778306768" CI_START="1.0390141301740017" DF="3" EFFECT_SIZE="2.6375598562459235" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-004.10.02" LOG_CI_END="0.8257831945886159" LOG_CI_START="0.01662145382750373" LOG_EFFECT_SIZE="0.42120232420805975" MODIFIED="2010-06-13 20:17:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9942703225272214" P_Z="0.04130199721618097" STUDIES="4" TAU2="0.0" TOTAL_1="907" TOTAL_2="893" WEIGHT="99.99999999999999" Z="2.040485465553133">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-13 20:16:23 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="8.285761830947042"/>
<DICH_DATA CI_END="8.517978259455019" CI_START="0.8746263264776128" EFFECT_SIZE="2.7294776119402986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9303365272837775" LOG_CI_START="-0.0581774544186959" LOG_EFFECT_SIZE="0.4360795364325408" MODIFIED="2010-06-13 20:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.5806580060751592" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.3371637200191796" WEIGHT="66.53435717434628"/>
<DICH_DATA CI_END="71.31099580520645" CI_START="0.12257605850615069" EFFECT_SIZE="2.9565217391304346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8531565010907625" LOG_CI_START="-0.9115943477134756" LOG_EFFECT_SIZE="0.4707810766886434" MODIFIED="2010-06-13 20:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-Garde-1983" TOTAL_1="68" TOTAL_2="67" VAR="2.637468030690537" WEIGHT="8.346241844311619"/>
<DICH_DATA CI_END="21.249491106289312" CI_START="0.17669808171027246" EFFECT_SIZE="1.9377162629757785" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.327348533803891" LOG_CI_START="-0.752768165304586" LOG_EFFECT_SIZE="0.2872901842496525" MODIFIED="2010-06-13 20:17:25 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="1.2218708458000438" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="1.4929683638161146" WEIGHT="16.833639150395044"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.1099536139226" CI_START="2.3177609108362187" DF="0" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-004.10.03" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" MODIFIED="2010-06-13 20:00:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.005468500714406536" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="2.7780571023295555">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="130.1099536139226" CI_START="2.3177609108362187" EFFECT_SIZE="17.365591397849464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.1143105220361975" LOG_CI_START="0.36506863419017593" LOG_EFFECT_SIZE="1.2396895781131867" MODIFIED="2010-06-13 20:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="1.0275133438077466" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="1.0557836717029765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.434208667351391" CI_END="5.848249145044294" CI_START="1.8561797949262888" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.294753693180442" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="14" I2="37.832292877026326" I2_Q="81.01302337124591" ID="CMP-004.11" LOG_CI_END="0.7670258660040276" LOG_CI_START="0.2686200409359259" LOG_EFFECT_SIZE="0.5178229534699768" METHOD="MH" MODIFIED="2011-03-18 12:17:21 +0000" MODIFIED_BY="Hazel Fraser" NO="11" P_CHI2="0.16898331867418936" P_Q="0.021736388109445448" P_Z="4.648277024195177E-5" Q="5.266767951278714" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1604" TOTAL_2="1618" WEIGHT="200.0" Z="4.072642365408301">
<NAME>Intracranial haemorrhage, fatal or non-fatal</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.099922555494922" CI_END="3.6807754135575244" CI_START="0.9118236950784561" DF="3" EFFECT_SIZE="1.8319984274949457" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="0.5659393193134777" LOG_CI_START="-0.0400891262071955" LOG_EFFECT_SIZE="0.2629250965531411" MODIFIED="2010-06-13 20:18:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7770928109098103" P_Z="0.08900712827571193" STUDIES="4" TAU2="0.0" TOTAL_1="953" TOTAL_2="953" WEIGHT="100.0" Z="1.7006585208492293">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-13 20:17:51 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="4.1773613470964595"/>
<DICH_DATA CI_END="4.378765223310152" CI_START="0.8999160889578423" EFFECT_SIZE="1.9850746268656716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6413516602059892" LOG_CI_START="-0.04579798367347058" LOG_EFFECT_SIZE="0.29777683826625934" MODIFIED="2010-06-13 20:01:02 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.40363510226038973" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1629212957767553" WEIGHT="75.47412411383266"/>
<DICH_DATA CI_END="9.017539181230221" CI_START="0.015264891126810612" EFFECT_SIZE="0.3710144927536232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9550880380051068" LOG_CI_START="-1.8163062888559185" LOG_EFFECT_SIZE="-0.43060912542540575" MODIFIED="2010-06-13 20:01:02 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="1.6279307462213353" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="2.6501585144927535" WEIGHT="11.861643331261552"/>
<DICH_DATA CI_END="21.249491106289312" CI_START="0.17669808171027246" EFFECT_SIZE="1.9377162629757785" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.327348533803891" LOG_CI_START="-0.752768165304586" LOG_EFFECT_SIZE="0.2872901842496525" MODIFIED="2010-06-13 20:18:05 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="1.2218708458000438" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="1.4929683638161146" WEIGHT="8.486871207809328"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.15627356689243" CI_START="2.8027777290985583" DF="0" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-004.11.02" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" MODIFIED="2010-06-13 20:01:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.5179886990746314E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.66042335249295">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="30.15627356689243" CI_START="2.8027777290985583" EFFECT_SIZE="9.193548387096774" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.4793776744217673" LOG_CI_START="0.44758865792670754" LOG_EFFECT_SIZE="0.9634831661742376" MODIFIED="2010-06-13 20:01:02 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.6060779757272016" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.3673305126615823" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2446423697665447" CI_END="5.651468800130947" CI_START="2.2708215007158783" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5823842426465533" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="23" I2="7.539887047217072" I2_Q="67.21848454860613" ID="CMP-004.12" LOG_CI_END="0.7521613343489263" LOG_CI_START="0.35618299758352195" LOG_EFFECT_SIZE="0.5541721659662241" METHOD="MH" MODIFIED="2011-03-18 12:17:25 +0000" MODIFIED_BY="Hazel Fraser" NO="12" P_CHI2="0.3554220642766923" P_Q="0.08071254268977446" P_Z="4.1126722319386246E-8" Q="3.0504996069590797" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1604" TOTAL_2="1618" WEIGHT="200.0" Z="5.485943980677115">
<NAME>Major extracranial haemorrhage</NAME>
<GROUP_LABEL_1>Anticoagulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0899907263737527" CI_END="4.625971163807924" CI_START="1.6949411431388968" DF="2" EFFECT_SIZE="2.800133720469824" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="20" I2="0.0" ID="CMP-004.12.01" LOG_CI_END="0.6652029212495314" LOG_CI_START="0.22915462191738953" LOG_EFFECT_SIZE="0.44717877158346053" MODIFIED="2010-06-13 20:19:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9560019161054566" P_Z="5.82013080454094E-5" STUDIES="4" TAU2="0.0" TOTAL_1="953" TOTAL_2="953" WEIGHT="99.99999999999999" Z="4.019987181680729">
<NAME>INR 2.0 - 3.6</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-13 20:18:31 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.0" STUDY_ID="STD-AVASIS-2006" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.270869951720418" CI_START="1.413866486670769" EFFECT_SIZE="2.9776119402985075" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.7973277942634943" LOG_CI_START="0.15040840038038694" LOG_EFFECT_SIZE="0.47386809732194063" MODIFIED="2010-06-13 20:01:07 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.38000365426958305" STUDY_ID="STD-ESPRIT-2007" TOTAL_1="536" TOTAL_2="532" VAR="0.1444027772582368" WEIGHT="45.172108092644244"/>
<DICH_DATA CI_END="10.928799313245092" CI_START="0.807537599920367" EFFECT_SIZE="2.9707602339181287" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0385724510370216" LOG_CI_START="-0.09283724725349062" LOG_EFFECT_SIZE="0.4728676018917654" MODIFIED="2010-06-13 20:01:07 +0100" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.6645956573441782" STUDY_ID="STD-Garde-1983" TOTAL_1="114" TOTAL_2="127" VAR="0.44168738776074046" WEIGHT="14.19199259020154"/>
<DICH_DATA CI_END="5.646302154482371" CI_START="1.1455521836767912" EFFECT_SIZE="2.5432525951557095" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="8" LOG_CI_END="0.751764115134523" LOG_CI_START="0.059014877520771156" LOG_EFFECT_SIZE="0.4053894963276471" MODIFIED="2010-06-13 20:19:12 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.4069243313383488" STUDY_ID="STD-WASID-2005" TOTAL_1="289" TOTAL_2="280" VAR="0.1655874114351623" WEIGHT="40.63589931715421"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.106273460663985" CI_START="2.6927677333495303" DF="0" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" I2="0.0" ID="CMP-004.12.02" LOG_CI_END="1.4639866053333341" LOG_CI_START="0.4301988946388021" LOG_EFFECT_SIZE="0.9470927499860682" MODIFIED="2010-06-13 20:01:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.2916266325405593E-4" STUDIES="1" TAU2="0.0" TOTAL_1="651" TOTAL_2="665" WEIGHT="100.0" Z="3.591197033566187">
<NAME>INR 3.0 - 4.5</NAME>
<DICH_DATA CI_END="29.106273460664" CI_START="2.69276773334953" EFFECT_SIZE="8.853046594982079" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" LOG_CI_END="1.4639866053333344" LOG_CI_START="0.43019889463880207" LOG_EFFECT_SIZE="0.9470927499860682" MODIFIED="2010-06-13 20:01:07 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.6072520185936674" STUDY_ID="STD-SPIRIT-1997" TOTAL_1="651" TOTAL_2="665" VAR="0.36875501408608374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2011-03-18 10:53:18 +0000" MODIFIED_BY="Hazel Fraser">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-03-18 10:53:18 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2011-03-18 10:53:14 +0000" MODIFIED_BY="Hazel Fraser">Feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-03-18 10:53:18 +0000" MODIFIED_BY="Hazel Fraser">
<P>Feedback received for this review, and other reviews and protocols of anticoagulants, is available on the Cochrane Editorial Unit website at <A HREF="http://www.editorial-unit.cochrane.org/anticoagulants-feedback">http://www.editorial-unit.cochrane.org/anticoagulants-feedback</A>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY/>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2012-03-28 16:18:59 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-03-28 16:18:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-03-28 16:18:08 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-28 16:14:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>#1.MeSH descriptor anticoagulants explode all trees <BR/>#2.MeSH descriptor pipecolic acids explode all trees with qualifiers: AE,TU <BR/>#3.MeSH descriptor vitamin k explode all trees with qualifiers: AI <BR/>#4.MeSH descriptor thrombin this term only with qualifiers: AI <BR/>#5.MeSH descriptor factor xa this term only with qualifiers: AI <BR/>#6.MeSH descriptor blood coagulation factors explode all trees with qualifiers: AI <BR/>#7.MeSH descriptor blood coagulation explode all trees with qualifiers: DE <BR/>#8.MeSH descriptor antithrombins explode all trees <BR/>#9.MeSH descriptor hirudin therapy this term only <BR/>#10.(anticoagul* in Title, Abstract or Keywords or antithromb* in Title, Abstract or Keywords) <BR/>#11.(Vitamin next K next antagonist* in Title, Abstract or Keywords or VKA in Title, Abstract or Keywords or VKAs in Title, Abstract or Keywords) <BR/>#12.(direct* in Title, Abstract or Keywords near/5 thrombin in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) <BR/>#13.DTI* in Title, Abstract or Keywords <BR/>#14.( (factor next Xa in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) or (factor next 10a in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) or (fXa in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) or (autoprothrombin in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) or (thrombokinase in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) ) <BR/>#15.(activated in Title, Abstract or Keywords near/5 factor next Xa in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) <BR/>#16.(activated in Title, Abstract or Keywords near/5 factor next 10a in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) <BR/>#17.(acenocoumarol* in Title, Abstract or Keywords or dicoumarol* in Title, Abstract or Keywords or ethyl next biscoumacetate* in Title, Abstract or Keywords or phenprocoumon* in Title, Abstract or Keywords or warfarin* in Title, Abstract or Keywords or ancrod* in Title, Abstract or Keywords or citric next acid* in Title, Abstract or Keywords or coumarin* in Title, Abstract or Keywords or chromonar* in Title, Abstract or Keywords or coumestro* in Title, Abstract or Keywords or esculi* in Title, Abstract or Keywords or ochratoxin* in Title, Abstract or Keywords or umbelliferone* in Title, Abstract or Keywords or dermatan next sulfate* in Title, Abstract or Keywords or dextran* in Title, Abstract or Keywords or edetic next acid* in Title, Abstract or Keywords or enoxaparin* in Title, Abstract or Keywords or gabexate* in Title, Abstract or Keywords or heparin* in Title, Abstract or Keywords or lmwh* in Title, Abstract or Keywords or nadroparin* in Title, Abstract or Keywords or pentosan next sulfuric next polyester* in Title, Abstract or Keywords or phenindione* in Title, Abstract or Keywords or protein next c in Title, Abstract or Keywords or protein next s in Title, Abstract or Keywords or tedelparin* in Title, Abstract or Keywords) <BR/>#18.(tinzaparin in Title, Abstract or Keywords or parnaparin in Title, Abstract or Keywords or dalteparin in Title, Abstract or Keywords or reviparin in Title, Abstract or Keywords or danaparoid in Title, Abstract or Keywords or lomoparan in Title, Abstract or Keywords or org next 10172 in Title, Abstract or Keywords or mesoglycan in Title, Abstract or Keywords or polysaccharide next sulphate* in Title, Abstract or Keywords or sp54 in Title, Abstract or Keywords or sp-54 in Title, Abstract or Keywords or md805 in Title, Abstract or Keywords or md-805 in Title, Abstract or Keywords or cy222 in Title, Abstract or Keywords or cy-222 in Title, Abstract or Keywords or cy216 in Title, Abstract or Keywords or cy-216 in Title, Abstract or Keywords) <BR/>#19.(Marevan in Title, Abstract or Keywords or Fragmin* in Title, Abstract or Keywords or Fraxiparin* in Title, Abstract or Keywords or Klexane in Title, Abstract or Keywords) <BR/>#20.(argatroban in Title, Abstract or Keywords or MD805 in Title, Abstract or Keywords or MD-805 in Title, Abstract or Keywords or dabigatran in Title, Abstract or Keywords or ximelagatran in Title, Abstract or Keywords or melagatran in Title, Abstract or Keywords or efegatran in Title, Abstract or Keywords or flovagatran in Title, Abstract or Keywords or inogatran in Title, Abstract or Keywords or napsagatran in Title, Abstract or Keywords or bivalirudin in Title, Abstract or Keywords or lepirudin in Title, Abstract or Keywords or hirudin* in Title, Abstract or Keywords or desirudin in Title, Abstract or Keywords or desulfatohirudin in Title, Abstract or Keywords or hirugen in Title, Abstract or Keywords or hirulog in Title, Abstract or Keywords or AZD0837 in Title, Abstract or Keywords or bothrojaracin in Title, Abstract or Keywords or odiparcil in Title, Abstract or Keywords) <BR/>#21.(xabans in Title, Abstract or Keywords or antistasin in Title, Abstract or Keywords or apixaban in Title, Abstract or Keywords or betrixaban in Title, Abstract or Keywords or du next 176b in Title, Abstract or Keywords or eribaxaban in Title, Abstract or Keywords or fondaparinux in Title, Abstract or Keywords or idraparinux in Title, Abstract or Keywords or otamixaban in Title, Abstract or Keywords or razaxaban in Title, Abstract or Keywords or rivaroxaban in Title, Abstract or Keywords or yagin in Title, Abstract or Keywords or ym next 150 in Title, Abstract or Keywords or ym150 in Title, Abstract or Keywords or LY517717 in Title, Abstract or Keywords) <BR/>#22.(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21) <BR/>#23.MeSH descriptor platelet aggregation inhibitors explode all trees <BR/>#24.MeSH descriptor Platelet Glycoprotein GPIIb-IIIa Complex explode all trees with qualifiers: AI,DE <BR/>#25.MeSH descriptor platelet activation explode all trees with qualifiers: DE <BR/>#26.MeSH descriptor blood platelets explode all trees with qualifiers: DE <BR/>#27.(antiplatelet* in Title, Abstract or Keywords or anti-platelet* in Title, Abstract or Keywords or antiaggreg* in Title, Abstract or Keywords or anti-aggreg* in Title, Abstract or Keywords or (platelet* in Title, Abstract or Keywords near/5 inhibit* in Title, Abstract or Keywords) or (thrombocyt* in Title, Abstract or Keywords near/5 inhibit* in Title, Abstract or Keywords) ) <BR/>#28.(alprostadil* in Title, Abstract or Keywords or aspirin* in Title, Abstract or Keywords or acetylsalicylic next acid in Title, Abstract or Keywords or (acetyl next salicylic in Title, Abstract or Keywords and acid* in Title, Abstract or Keywords) or (acetyl-salicylic in Title, Abstract or Keywords and acid in Title, Abstract or Keywords) or epoprostenol* in Title, Abstract or Keywords or ketanserin* in Title, Abstract or Keywords or ketorolac next tromethamine* in Title, Abstract or Keywords or milrinone* in Title, Abstract or Keywords or mopidamol* in Title, Abstract or Keywords or procainamide* in Title, Abstract or Keywords or thiophen* in Title, Abstract or Keywords or trapidil* in Title, Abstract or Keywords or picotamide* in Title, Abstract or Keywords or ligustrazine* in Title, Abstract or Keywords or levamisol* in Title, Abstract or Keywords or suloctidil* in Title, Abstract or Keywords or ozagrel* in Title, Abstract or Keywords or oky046 in Title, Abstract or Keywords or oky-046 in Title, Abstract or Keywords or defibrotide* in Title, Abstract or Keywords or cilostazol in Title, Abstract or Keywords or satigrel in Title, Abstract or Keywords or sarpolgrelate in Title, Abstract or Keywords or kbt3022 in Title, Abstract or Keywords or kbt-3022 in Title, Abstract or Keywords or isbogrel in Title, Abstract or Keywords or cv4151 in Title, Abstract or Keywords or cv-4151 in Title, Abstract or Keywords) <BR/>#29.( (glycoprotein next iib* in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) or (glycoprotein next iib* in Title, Abstract or Keywords near/5 antag* in Title, Abstract or Keywords) or (gp next iib* in Title, Abstract or Keywords near/5 inhib* in Title, Abstract or Keywords) or (gp next iib* in Title, Abstract or Keywords near/5 antag* in Title, Abstract or Keywords) or GR144053 in Title, Abstract or Keywords or GR-144053 in Title, Abstract or Keywords or triflusal in Title, Abstract or Keywords) <BR/>#30.(Argatroban in Title, Abstract or Keywords or Beraprost in Title, Abstract or Keywords or Cicaprost in Title, Abstract or Keywords or Cilostazol in Title, Abstract or Keywords or Clopidogrel in Title, Abstract or Keywords or Dipyridamole in Title, Abstract or Keywords or Iloprost in Title, Abstract or Keywords or Indobufen in Title, Abstract or Keywords or Lepirudin in Title, Abstract or Keywords or Pentosan next Polysulfate in Title, Abstract or Keywords or Pentoxifylline in Title, Abstract or Keywords or Piracetam in Title, Abstract or Keywords or Prostacyclin in Title, Abstract or Keywords or Sulfinpyrazone in Title, Abstract or Keywords or Sulphinpyrazone in Title, Abstract or Keywords or Ticlopidine in Title, Abstract or Keywords or Triflusal in Title, Abstract or Keywords or Abciximab in Title, Abstract or Keywords or Disintegrin in Title, Abstract or Keywords or Echistatin in Title, Abstract or Keywords or Eptifibatide in Title, Abstract or Keywords or Lamifiban in Title, Abstract or Keywords or Orbofiban in Title, Abstract or Keywords or Roxifiban in Title, Abstract or Keywords or Sibrafiban in Title, Abstract or Keywords or Tirofiban in Title, Abstract or Keywords or Xemilofiban in Title, Abstract or Keywords or terutroban in Title, Abstract or Keywords or picotamide in Title, Abstract or Keywords or prasugrel in Title, Abstract or Keywords)<BR/>#31.(Dispril in Title, Abstract or Keywords or Albyl* in Title, Abstract or Keywords or Ticlid* in Title, Abstract or Keywords or Persantin* in Title, Abstract or Keywords or Plavix in Title, Abstract or Keywords or ReoPro in Title, Abstract or Keywords or Integrilin* in Title, Abstract or Keywords or Aggrastat in Title, Abstract or Keywords) <BR/>#32.(#23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31) <BR/>#33.MeSH descriptor Cerebrovascular Disorders this term only<BR/>#34.MeSH descriptor Basal Ganglia Cerebrovascular Disease this term only <BR/>#35.MeSH descriptor brain ischemia explode all trees <BR/>#36.MeSH descriptor Carotid Artery Diseases this term only <BR/>#37.MeSH descriptor carotid artery thrombosis this term only<BR/>#38.MeSH descriptor intracranial arterial diseases this term only <BR/>#39.MeSH descriptor cerebral arterial diseases this term only <BR/>#40.MeSH descriptor Intracranial Embolism and Thrombosis explode all trees <BR/>#41.MeSH descriptor stroke explode all trees <BR/>#42.(ischaemi* in Title, Abstract or Keywords or ischemi* in Title, Abstract or Keywords) <BR/>#43.(stroke* in Title, Abstract or Keywords or apoplex* in Title, Abstract or Keywords or (cerebral in Title, Abstract or Keywords and vasc* in Title, Abstract or Keywords) or cerebrovasc* in Title, Abstract or Keywords or cva in Title, Abstract or Keywords or attack* in Title, Abstract or Keywords) <BR/>#44.(#42 and #43) <BR/>#45.(brain in Title, Abstract or Keywords or cerebr* in Title, Abstract or Keywords or cerebell* in Title, Abstract or Keywords or vertebrobasil* in Title, Abstract or Keywords or hemispher* in Title, Abstract or Keywords or intracran* in Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords or infratentorial in Title, Abstract or Keywords or supratentorial in Title, Abstract or Keywords or (middle in Title, Abstract or Keywords and cerebr* in Title, Abstract or Keywords) or mca* in Title, Abstract or Keywords or (anterior in Title, Abstract or Keywords and circulation in Title, Abstract or Keywords) )<BR/>#46.(ischemi* in Title, Abstract or Keywords or ischaemi* in Title, Abstract or Keywords or infarct* in Title, Abstract or Keywords or thrombo* in Title, Abstract or Keywords or emboli* in Title, Abstract or Keywords or occlus* in Title, Abstract or Keywords or hypoxi* in Title, Abstract or Keywords) <BR/>#47.(#45 and #46) <BR/>#48.(TIA in Title, Abstract or Keywords or TIAs in Title, Abstract or Keywords) <BR/>#49.(#33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #44 or #47 or #48) <BR/>#50.(#22 and #32 and #49)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-03-28 16:18:20 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-03-28 16:18:20 +0100" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-28 16:16:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp stroke/<BR/>2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. tia$1.tw.<BR/>5. 1 or 2 or 3 or 4<BR/>6. exp platelet aggregation inhibitors/<BR/>7. exp platelet glycoprotein gpiib-iiia complex/ai, de<BR/>8. exp Platelet activation/de<BR/>9. exp Blood platelets/de<BR/>10. (antiplatelet$ or anti-platelet$ or antiaggreg$ or anti-aggreg$ or (platelet$ adj5 inhibit$) or (thrombocyt$ adj5 inhibit$)).tw.<BR/>11. (alprostadil$ or aspirin$ or acetylsalicylic acid or acetyl salicylic acid$ or acetyl?salicylic acid or epoprostenol$ or ketanserin$ or ketorolac tromethamine$ or milrinone$ or mopidamol$ or procainamide$ or thiophen$ or trapidil$ or picotamide$ or ligustrazine$ or levamisol$ or suloctidil$ or ozagrel$ or oky046 or oky-046 or defibrotide$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or isbogrel or cv4151 or cv-4151 or ((glycoprotein iib$ or gp iib$) adj5 (antagonist$ or inhibitor$)) or GR144053 or GR-144053 or triflusal).tw,nm.<BR/>12. (Argatroban or Beraprost or Cicaprost or Cilostazol or Clopidogrel or Dipyridamole or Iloprost or Indobufen or Lepirudin or Pentosan Polysulfate or Pentoxifylline or Piracetam or Prostacyclin or Sulfinpyrazone or Sulphinpyrazone or Ticlopidine or Triflusal or Abciximab or Disintegrin or Echistatin or Eptifibatide or Lamifiban or Orbofiban or Roxifiban or Sibrafiban or Tirofiban or Xemilofiban or terutroban or picotamide or prasugrel).tw,nm.<BR/>13. (Dispril or Albyl$ or Ticlid$ or Persantin$ or Plavix or ReoPro or Integrilin$ or Aggrastat).tw,nm.<BR/>14. or/6-13<BR/>15. exp anticoagulants/<BR/>16. exp Pipecolic acids/ae, tu or exp Vitamin K/ai or thrombin/ai or factor Xa/ai<BR/>17. exp Blood coagulation factors/ai, de or exp Blood coagulation/de<BR/>18. exp antithrombins/ or hirudin therapy/<BR/>19. (anticoagul$ or antithromb$).tw.<BR/>20. (Vitamin K antagonist$ or VKA or VKAs).tw.<BR/>21. (direct$ adj5 thrombin adj5 inhib$).tw.<BR/>22. DTI$1.tw.<BR/>23. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$).tw.<BR/>24. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.<BR/>25. (acenocoumarol$ or dicoumarol$ or ethyl biscoumacetate$ or phenprocoumon$ or warfarin$ or ancrod$ or citric acid$ or coumarin$ or chromonar$ or coumestro$ or esculi$ or ochratoxin$ or umbelliferone$ or dermatan sulfate$ or dextran$ or edetic acid$ or enoxaparin$ or gabexate$ or heparin$ or lmwh$ or nadroparin$ or pentosan sulfuric polyester$ or phenindione$ or protein c or protein s or tedelparin$).tw,nm.<BR/>26. (tinzaparin or parnaparin or dalteparin or reviparin or danaparoid or lomoparan or org 10172 or mesoglycan or polysaccharide sulphate$ or sp54 or sp-54 or md805 or md-805 or cy222 or cy-222 or cy216 or cy-216).tw,nm.<BR/>27. (Marevan or Fragmin$ or Fraxiparin$ or Klexane).tw,nm.<BR/>28. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil).tw,nm.<BR/>29. (xabans or antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym 150 or ym150 or LY517717).tw,nm.<BR/>30. or/15-29<BR/>31. 5 and 14 and 30<BR/>32. Randomized Controlled Trials as Topic/<BR/>33. random allocation/<BR/>34. Controlled Clinical Trials as Topic/<BR/>35. control groups/<BR/>36. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/<BR/>37. double-blind method/<BR/>38. single-blind method/<BR/>39. Placebos/<BR/>40. placebo effect/<BR/>41. Drug Evaluation/<BR/>42. Research Design/<BR/>43. randomized controlled trial.pt.<BR/>44. controlled clinical trial.pt.<BR/>45. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.<BR/>46. random$.tw.<BR/>47. (controlled adj5 (trial$ or stud$)).tw.<BR/>48. (clinical$ adj5 trial$).tw.<BR/>49. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>50. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>51. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>52. (coin adj5 (flip or flipped or toss$)).tw.<BR/>53. placebo$.tw.<BR/>54. controls.tw.<BR/>55. trial.ti.<BR/>56. or/32-55<BR/>57. 31 and 56<BR/>58. exp animals/ not humans.sh.<BR/>59. 57 not 58<BR/>60. (atrial fibrillation or coronary or myocardial).ti<BR/>61. 59 not 60</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-03-28 16:18:59 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-03-28 16:18:33 +0100" MODIFIED_BY="[Empty name]">EMBASE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-28 16:17:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>1. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insufficiency/ or carotid artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/<BR/>2. stroke patient/ or stroke unit/<BR/>3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>4. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>5. tia$1.tw.<BR/>6. 1 or 2 or 3 or 4 or 5<BR/>7. exp antithrombocytic agent/<BR/>8. fibrinogen receptor/dt [Drug Therapy]<BR/>9. (antiplatelet$ or anti-platelet$ or antiaggreg$ or anti-aggreg$ or (platelet$ adj5 inhibit$) or (thrombocyt$ adj5 inhibit$)).tw.<BR/>10. (alprostadil$ or aspirin$ or acetylsalicylic acid or acetyl salicylic acid$ or acetyl?salicylic acid or epoprostenol$ or ketanserin$ or ketorolac tromethamine$ or milrinone$ or mopidamol$ or procainamide$ or thiophen$ or trapidil$ or picotamide$ or ligustrazine$ or levamisol$ or suloctidil$ or ozagrel$ or oky046 or oky-046 or defibrotide$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or isbogrel or cv4151 or cv-4151 or ((glycoprotein iib$ or gp iib$) adj5 (antagonist$ or inhibitor$)) or GR144053 or GR-144053 or triflusal).tw.<BR/>11. (Argatroban or Beraprost or Cicaprost or Cilostazol or Clopidogrel or Dipyridamole or Iloprost or Indobufen or Lepirudin or Pentosan Polysulfate or Pentoxifylline or Piracetam or Prostacyclin or Sulfinpyrazone or Sulphinpyrazone or Ticlopidine or Triflusal or Abciximab or Disintegrin or Echistatin or Eptifibatide or Lamifiban or Orbofiban or Roxifiban or Sibrafiban or Tirofiban or Xemilofiban or terutroban or picotamide or prasugrel).tw.<BR/>12. (Dispril or Albyl$ or Ticlid$ or Persantin$ or Plavix or ReoPro or Integrilin$ or Aggrastat).tw.<BR/>13. or/7-12<BR/>14. anticoagulant agent/ or antivitamin k/ or exp blood clotting inhibitor/ or exp coumarin anticoagulant/ or defibrotide/ or dextran sulfate/ or fluindione/ or glycosaminoglycan polysulfate/ or exp heparin derivative/ or lupus anticoagulant/ or phenindione/<BR/>15. (anticoagul$ or antithromb$).tw.<BR/>16. (Vitamin K antagonist$ or VKA or VKAs).tw.<BR/>17. (direct$ adj5 thrombin adj5 inhib$).tw.<BR/>18. DTI$1.tw.<BR/>19. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$).tw.<BR/>20. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.<BR/>21. (acenocoumarol$ or dicoumarol$ or ethyl biscoumacetate$ or phenprocoumon$ or warfarin$ or ancrod$ or citric acid$ or coumarin$ or chromonar$ or coumestro$ or esculi$ or ochratoxin$ or umbelliferone$ or dermatan sulfate$ or dextran$ or edetic acid$ or enoxaparin$ or gabexate$ or heparin$ or lmwh$ or nadroparin$ or pentosan sulfuric polyester$ or phenindione$ or protein c or protein s or tedelparin$).tw.<BR/>22. (tinzaparin or parnaparin or dalteparin or reviparin or danaparoid or lomoparan or org 10172 or mesoglycan or polysaccharide sulphate$ or sp54 or sp-54 or md805 or md-805 or cy222 or cy-222 or cy216 or cy-216).tw.<BR/>23. (Marevan or Fragmin$ or Fraxiparin$ or Klexane).tw.<BR/>24. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil).tw.<BR/>25. (xabans or antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym 150 or ym150 or LY517717).tw.<BR/>26. or/14-25<BR/>27. 6 and 13 and 26<BR/>28. Randomized Controlled Trial/<BR/>29. Randomization/<BR/>30. Controlled Study/<BR/>31. control group/<BR/>32. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical trial/<BR/>33. Double Blind Procedure/<BR/>34. Single Blind Procedure/ or triple blind procedure/<BR/>35. placebo/<BR/>36. drug comparison/ or drug dose comparison/<BR/>37. "types of study"/<BR/>38. random$.tw.<BR/>39. (controlled adj5 (trial$ or stud$)).tw.<BR/>40. (clinical$ adj5 trial$).tw.<BR/>41. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>42. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>43. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>44. (coin adj5 (flip or flipped or toss$)).tw.<BR/>45. placebo$.tw.<BR/>46. controls.tw.<BR/>47. trial.ti.<BR/>48. or/28-47<BR/>49. 27 and 48<BR/>50. limit 49 to human<BR/>51. (atrial fibrillation or coronary or myocardial).ti.<BR/>52. 50 not 51</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>